# **CAMBRIDGE**

# Cancer Incidence by Sex, 1990 - 1995

# **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|                      | <b>Exp</b>          | <u>Obs</u> | <u>SIR</u>               |                     | Exp                | <u>Obs</u> | SIR    |  |
|----------------------|---------------------|------------|--------------------------|---------------------|--------------------|------------|--------|--|
| Bladder, Urina       | ry                  |            | $\underline{\mathbf{M}}$ | <u>lelanoma of</u>  | <u>Skin</u>        |            |        |  |
| Male                 | 52.63               | 52         | 99                       | Male                | 32.13              | 29         | 90     |  |
| Female               | 23.03               | 26         | 113                      | Female              | 30.05              | 12         | 40 ^-  |  |
| Total                | 75.66               | 78         | 103                      | Total               | 62.19              | 41         | 66 ~-  |  |
| <b>Brain and Cen</b> | <u>tral Nervous</u> | System     | $\underline{\mathbf{M}}$ | <u>lultiple Mye</u> | <u>loma</u>        |            |        |  |
| Male                 | 22.27               | 20         | 90                       | Male                | 9.56               | 10         | 105    |  |
| Female               | 21.63               | 19         | 88                       | Female              | 10.15              | 12         | 118    |  |
| Total                | 43.91               | 39         | 89                       | Total               | 19.70              | 22         | 112    |  |
| <b>Breast</b>        |                     |            | No                       | <u>on-Hodgkin</u>   | <u>'s Lymphoma</u> | _          |        |  |
| Male                 | 2.92                | 4          | NC*                      | Male                | 46.91              | 35         | 75     |  |
| Female               | 386.35              | 390        | 101                      | Female              | 43.03              | 32         | 74     |  |
| Total                | 389.26              | 394        | 101                      | Total               | 89.94              | 67         | 74 #-  |  |
| <u>Cervix Uteri</u>  |                     |            | Oral Cavity and Pharynx  |                     |                    |            |        |  |
|                      |                     |            |                          | Male                | 39.32              | 51         | 130    |  |
| Female               | 29.79               | 19         | 64 #-                    | Female              | 19.21              | 23         | 120    |  |
|                      |                     |            |                          | Total               | 58.53              | 74         | 126    |  |
| Colon / Rectun       | <u>1</u>            |            | <u>O</u>                 | <u>vary</u>         |                    |            |        |  |
| Male                 | 139.54              | 135        | 97                       |                     |                    |            |        |  |
| Female               | 154.03              | 159        | 103                      | Female              | 48.16              | 39         | 81     |  |
| Total                | 293.57              | 294        | 100                      |                     |                    |            |        |  |
| <b>Esophagus</b>     |                     |            | <u>Pa</u>                | ancreas             |                    |            |        |  |
| Male                 | 18.31               | 20         | 109                      | Male                | 19.82              | 22         | 111    |  |
| Female               | 7.54                | 4          | NC*                      | Female              | 23.95              | 13         | 54 #-  |  |
| Total                | 25.85               | 24         | 93                       | Total               | 43.77              | 35         | 80     |  |
| <b>Hodgkin's Dis</b> | ease                |            | <u>P</u> 1               | <u>rostate</u>      |                    |            |        |  |
| Male                 | 13.23               | 11         | 83                       | Male                | 300.44             | 346        | 115 #+ |  |
| Female               | 10.74               | 6          | 56                       |                     |                    |            |        |  |
| Total                | 23.97               | 17         | 71                       |                     |                    |            |        |  |
| Kidney and Re        | <u>enal Pelvis</u>  |            | <u>St</u>                | <u>omach</u>        |                    |            |        |  |
| Male                 | 32.68               | 17         | 52 ~-                    | Male                | 23.67              | 29         | 123    |  |
| Female               | 21.85               | 23         | 105                      | Female              | 17.18              | 13         | 76     |  |
| Total                | 54.53               | 40         | 73 #-                    | Total               | 40.85              | 42         | 103    |  |
| <u>Larynx</u>        |                     |            | <u>T</u>                 | <u>estis</u>        |                    |            |        |  |
| Male                 | 19.99               | 12         | 60                       | Male                | 22.94              | 18         | 78     |  |
| Female               | 6.09                | 8          | 131                      |                     |                    |            |        |  |
| Total                | 26.09               | 20         | 77                       |                     |                    |            |        |  |
| <u>Leukemia</u>      |                     |            | <u>T</u> ]               | <u>hyroid</u>       |                    |            |        |  |

| Male                  | 23.64         | 17           | 72        | Male                          | 7.51    | 3    | NC*   |  |  |
|-----------------------|---------------|--------------|-----------|-------------------------------|---------|------|-------|--|--|
| Female                | 20.12         | 14           | 70        | Female                        | 21.54   | 15   | 70    |  |  |
| Total                 | 43.76         | 31           | 71        | Total                         | 29.05   | 18   | 62 #- |  |  |
| <b>Liver and Intr</b> | ahepatic Bile | <b>Ducts</b> | <u>Ut</u> | Uteri, Corpus and Uterus, NOS |         |      |       |  |  |
| Male                  | 9.10          | 13           | 143       |                               |         |      |       |  |  |
| Female                | 4.67          | 3            | NC*       | Female                        | 69.18   | 61   | 88    |  |  |
| Total                 | 13.77         | 16           | 116       |                               |         |      |       |  |  |
| <b>Lung and Bron</b>  | <u>nchus</u>  |              | <u>Al</u> | l Sites / Ty                  | pes     |      |       |  |  |
| Male                  | 172.60        | 133          | 77 ~-     | Male                          | 1092.85 | 1051 | 96    |  |  |
| Female                | 137.82        | 121          | 88        | Female                        | 1193.57 | 1078 | 90 ^- |  |  |
| Total                 | 310.43        | 254          | 82 ~-     | Total                         | 2286.43 | 2129 | 93 ^- |  |  |
|                       |               |              |           |                               |         |      |       |  |  |

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases

#### **CANTON**

#### Cancer Incidence by Sex, 1990 - 1995

#### **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|                      | $\mathbf{Exp}$ | <u>Obs</u>    | <u>SIR</u>               |                     | <b>Exp</b>  | <u>Obs</u> | <u>SIR</u> |
|----------------------|----------------|---------------|--------------------------|---------------------|-------------|------------|------------|
| Bladder, Urina       | <u>ry</u>      |               | $\underline{\mathbf{M}}$ | <u>lelanoma of</u>  | <u>Skin</u> |            |            |
| Male                 | 14.39          | 17            | 118                      | Male                | 7.62        | 8          | 105        |
| Female               | 5.61           | 6             | 107                      | Female              | 6.37        | 7          | 110        |
| Total                | 20.00          | 23            | 115                      | Total               | 13.99       | 15         | 107        |
| <b>Brain and Cen</b> | tral Nervous S | <u>System</u> | $\underline{\mathbf{M}}$ | <u>lultiple Mye</u> | <u>loma</u> |            |            |
| Male                 | 5.08           | 7             | 138                      | Male                | 2.62        | 2          | NC*        |
| Female               | 4.86           | 5             | 103                      | Female              | 2.51        | 5          | 200        |
| Total                | 9.94           | 12            | 121                      | Total               | 5.12        | 7          | 137        |
| <b>Breast</b>        |                |               | N                        | on-Hodgkin'         | s Lymphom   | <u>a</u>   |            |
| Male                 | 0.78           | 1             | NC*                      | Male                | 10.87       | 13         | 120        |
| Female               | 90.56          | 99            | 109                      | Female              | 9.98        | 6          | 60         |
| Total                | 91.33          | 100           | 109                      | Total               | 20.84       | 19         | 91         |
| Cervix Uteri         |                |               | <u>o</u>                 | ral Cavity aı       | nd Pharynx  |            |            |

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} <= 0.05$  level

<sup>~</sup> indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

|                  |                                       |       |            | Male                | 10.26      | 7     | 68     |
|------------------|---------------------------------------|-------|------------|---------------------|------------|-------|--------|
| Female           | 5.76                                  | 5     | 87         | Female              | 4.61       | 8     | 174    |
|                  |                                       |       |            | Total               | 14.87      | 15    | 101    |
| Colon / Rectur   | <u>m_</u>                             |       | <u>O</u>   | <u>vary</u>         |            |       |        |
| Male             | 38.31                                 | 40    | 104        |                     |            |       |        |
| Female           | 37.31                                 | 49    | 131        | Female              | 10.96      | 13    | 119    |
| Total            | 75.62                                 | 89    | 118        |                     |            |       |        |
| <b>Esophagus</b> |                                       |       | <u>Pa</u>  | <u>ancreas</u>      |            |       |        |
| Male             | 5.10                                  | 2     | NC*        | Male                | 5.41       | 11    | 203 #+ |
| Female           | 1.86                                  | 0     | NC*        | Female              | 5.88       | 6     | 102    |
| Total            | 6.95                                  | 2     | NC*        | Total               | 11.29      | 17    | 151    |
| Hodgkin's Di     | sease_                                |       | <u>P</u> 1 | <u>rostate</u>      |            |       |        |
| Male             | 2.27                                  | 2     | NC*        | Male                | 86.66      | 115   | 133 ~+ |
| Female           | 1.87                                  | 2     | NC*        |                     |            |       |        |
| Total            | 4.14                                  | 4     | NC*        |                     |            |       |        |
| Kidney and R     | enal Pelvis                           |       | St         | <u>omach</u>        |            |       |        |
| Male             | 8.73                                  | 13    | 149        | Male                | 6.31       | 4     | NC*    |
| Female           | 5.30                                  | 8     | 151        | Female              | 4.09       | 6     | 147    |
| Total            | 14.04                                 | 21    | 150        | Total               | 10.41      | 10    | 96     |
| <u>Larynx</u>    |                                       |       |            | <u>estis</u>        |            |       |        |
| Male             | 5.58                                  | 0     | NC*        | Male                | 3.29       | 4     | NC*    |
| Female           | 1.56                                  | 1     | NC*        |                     |            |       |        |
| Total            | 7.14                                  | 1     | NC*        |                     |            |       |        |
| <u>Leukemia</u>  |                                       |       | <u>T</u>   | <u>hyroid</u>       |            |       |        |
| Male             | 5.81                                  | 12    | 206 #+     | Male                | 1.44       | 1     | NC*    |
| Female           | 4.54                                  | 3     | NC*        | Female              | 3.99       | 3     | NC*    |
| Total            | 10.36                                 | 15    | 145        | Total               | 5.44       | 4     | NC*    |
| Liver and Inti   | _                                     | Ducts |            | <u>teri, Corpus</u> | and Uterus | , NOS |        |
| Male             | 2.44                                  | 1     | NC*        |                     |            |       |        |
| Female           | 1.13                                  | 2     | NC*        | Female              | 17.03      | 29    | 170 #+ |
| Total            | 3.56                                  | 3     | NC*        |                     |            |       |        |
| Lung and Bro     | · · · · · · · · · · · · · · · · · · · |       |            | ll Sites / Ty       |            |       |        |
| Male             | 48.69                                 | 43    | 88         | Male                | 292.02     | 331   | 113 #+ |
| Female           | 34.49                                 | 44    | 128        | Female              | 280.81     | 335   | 119 ~+ |
| Total            | 83.18                                 | 87    | 105        | Total               | 572.82     | 666   | 116 ^+ |
|                  |                                       |       |            |                     |            |       |        |

**Obs** = observed case count

SIR = standardized incidence ratio [ (Obs / Exp) X 100]

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} \le 0.05$  level

# **CARLISLE**

# Cancer Incidence by Sex, 1990 - 1995

# **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|                        | Exp            | <u>Obs</u>              | SIR                      |                     | Exp         | <u>Obs</u> | SIR    |  |
|------------------------|----------------|-------------------------|--------------------------|---------------------|-------------|------------|--------|--|
| <u>Bladder, Urinaı</u> | <u>ry</u>      |                         | $\underline{\mathbf{M}}$ | <u>lelanoma of</u>  | <u>Skin</u> |            |        |  |
| Male                   | 2.77           | 2                       | NC*                      | Male                | 1.68        | 4          | NC*    |  |
| Female                 | 0.80           | 0                       | NC*                      | Female              | 1.25        | 4          | NC*    |  |
| Total                  | 3.57           | 2                       | NC*                      | Total               | 2.93        | 8          | 273 #+ |  |
| <b>Brain and Cent</b>  | tral Nervous S | <u>System</u>           | $\underline{\mathbf{M}}$ | <u>[ultiple Mye</u> | <u>loma</u> |            |        |  |
| Male                   | 1.15           | 0                       | NC*                      | Male                | 0.52        | 1          | NC*    |  |
| Female                 | 0.93           | 2                       | NC*                      | Female              | 0.38        | 0          | NC*    |  |
| Total                  | 2.08           | 2                       | NC*                      | Total               | 0.90        | 1          | NC*    |  |
| <b>Breast</b>          |                |                         | <u>N</u>                 | <u>on-Hodgkin'</u>  | s Lymphoma  | <u>L</u>   |        |  |
| Male                   | 0.16           | 0                       | NC*                      | Male                | 2.27        | 0          | NC*    |  |
| Female                 | 17.14          | 33                      | 193 ^+                   | Female              | 1.59        | 2          | NC*    |  |
| Total                  | 17.30          | 33                      | 191 ~+                   | Total               | 3.86        | 2          | NC*    |  |
| Cervix Uteri           |                | Oral Cavity and Pharynx |                          |                     |             |            |        |  |
|                        |                |                         |                          | Male                | 2.44        | 1          | NC*    |  |
| Female                 | 1.20           | 1                       | NC*                      | Female              | 0.83        | 3          | NC*    |  |
|                        |                |                         |                          | Total               | 3.27        | 4          | NC*    |  |
| Colon / Rectum         | <u>L</u>       |                         | <u>O</u>                 | <u>vary</u>         |             |            |        |  |
| Male                   | 7.36           | 7                       | 95                       |                     |             |            |        |  |
| Female                 | 5.02           | 12                      | 239 #+                   | Female              | 2.15        | 3          | NC*    |  |
| Total                  | 12.38          | 19                      | 154                      |                     |             |            |        |  |
| <b>Esophagus</b>       |                |                         | <u>Pa</u>                | ancreas             |             |            |        |  |
| Male                   | 1.13           | 0                       | NC*                      | Male                | 1.11        | 2          | NC*    |  |
| Female                 | 0.25           | 0                       | NC*                      | Female              | 0.84        | 1          | NC*    |  |
| Total                  | 1.38           | 0                       | NC*                      | Total               | 1.95        | 3          | NC*    |  |
| Hodgkin's Disc         | ease_          |                         | <u>P</u> 1               | rostate             |             |            |        |  |
| Male                   | 0.49           | 0                       | NC*                      | Male                | 16.10       | 20         | 124    |  |
| Female                 | 0.38           | 1                       | NC*                      |                     |             |            |        |  |
| Total                  | 0.86           | 1                       | NC*                      |                     |             |            |        |  |
| Kidney and Re          | nal Pelvis     |                         | St                       | omach_              |             |            |        |  |
| Male                   | 1.93           | 1                       | NC*                      | Male                | 1.23        | 1          | NC*    |  |
| Female                 | 0.92           | 0                       | NC*                      | Female              | 0.54        | 0          | NC*    |  |
| Total                  | 2.85           | 1                       | NC*                      | Total               | 1.77        | 1          | NC*    |  |
| <u>Larynx</u>          |                |                         | <u>T</u>                 | <u>estis</u>        |             |            |        |  |

<sup>~</sup> indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

| Male                                     | 1.29          | 0      | NC*        | Male          | 0.66        | 0   | NC*    |
|--|---------------|--------|------------|---------------|-------------|-----|--------|
| Female                                   | 0.31          | 0      | NC*        |               |             |     |        |
| Total                                    | 1.60          | 0      | NC*        |               |             |     |        |
| <b>Leukemia</b>                          |               |        | <u>T</u>   | <u>nyroid</u> |             |     |        |
| Male                                     | 1.23          | 0      | NC*        | Male          | 0.33        | 0   | NC*    |
| Female                                   | 0.77          | 2      | NC*        | Female        | 0.84        | 1   | NC*    |
| Total                                    | 2.00          | 2      | NC*        | Total         | 1.17        | 1   | NC*    |
| <b>Liver and Intrahepatic Bile Ducts</b> |               |        | <u>U1</u>  | teri, Corpus  | and Uterus, | NOS |        |
| Male                                     | 0.52          | 0      | NC*        |               |             |     |        |
| Female                                   | 0.17          | 0      | NC*        | Female        | 3.28        | 5   | 153    |
| Total                                    | 0.69          | 0      | NC*        |               |             |     |        |
| <b>Lung and Bron</b>                     | nchus_        |        | <u>A</u> l | ll Sites / Ty | pes         |     |        |
| 3.7.1                                    |               | _      | 50         | Molo          | 50.70       | 49  | 83     |
| Male                                     | 10.17         | 6      | 59         | Male          | 58.70       | 49  | 65     |
| Male<br>Female                           | 10.17<br>6.06 | 6<br>2 | 59<br>NC*  | Female        | 48.83       | 74  | 152 ^+ |
|  |               |        |            |               |             |     |        |

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

#### **CARVER**

#### Cancer Incidence by Sex, 1990 - 1995

#### **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|                       | <b>Exp</b>       | <u>Obs</u>       | <u>SIR</u> |              | <b>Exp</b>      | <u>Obs</u> | <u>SIR</u> |  |  |  |
|-----------------------|------------------|------------------|------------|--------------|-----------------|------------|------------|--|--|--|
| Bladder, Urina        | <u>ry</u>        | Melanoma of Skin |            |              |                 |            |            |  |  |  |
| Male                  | 8.18             | 13               | 159        | Male         | 4.13            | 1          | NC*        |  |  |  |
| Female                | 2.82             | 4                | NC*        | Female       | 3.35            | 2          | NC*        |  |  |  |
| Total                 | 11.00            | 17               | 155        | Total        | 7.49            | 3          | NC*        |  |  |  |
| <b>Brain and Cent</b> | Multiple Myeloma |                  |            |              |                 |            |            |  |  |  |
| Male                  | 2.82             | 4                | NC*        | Male         | 1.48            | 1          | NC*        |  |  |  |
| Female                | 2.64             | 2                | NC*        | Female       | 1.28            | 1          | NC*        |  |  |  |
| Total                 | 5.47             | 6                | 110        | Total        | 2.75            | 2          | NC*        |  |  |  |
| <b>Breast</b>         |                  |                  | <u>N</u>   | on-Hodgkin's | <u>Lymphoma</u> | <u>1</u>   |            |  |  |  |

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} \le 0.05$  level

 $<sup>\</sup>sim$  indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

| Male                  | 0.43          | 0            | NC*        | Male                | 6.08       | 6     | 99     |
|-----------------------|---------------|--------------|------------|---------------------|------------|-------|--------|
| Female                | 46.58         | 45           | 97         | Female              | 5.18       | 6     | 116    |
| Total                 | 47.01         | 45           | 96         | Total               | 11.26      | 12    | 107    |
| Cervix Uteri          |               |              | <u>O</u> 1 | ral Cavity a        | nd Pharynx |       |        |
|                       |               |              |            | Male                | 5.31       | 11    | 207 #+ |
| Female                | 3.13          | 1            | NC*        | Female              | 2.35       | 0     | NC*    |
|                       |               |              |            | Total               | 7.66       | 11    | 144    |
| Colon / Rectun        | <u>n</u>      |              | <u>O</u>   | <u>vary</u>         |            |       |        |
| Male                  | 21.70         | 14           | 65         |                     |            |       |        |
| Female                | 18.78         | 17           | 91         | Female              | 5.71       | 2     | NC*    |
| Total                 | 40.48         | 31           | 77         |                     |            |       |        |
| <b>Esophagus</b>      |               |              | <u>Pa</u>  | <u>ancreas</u>      |            |       |        |
| Male                  | 2.71          | 5            | 184        | Male                | 2.96       | 2     | NC*    |
| Female                | 0.94          | 0            | NC*        | Female              | 3.01       | 2     | NC*    |
| Total                 | 3.65          | 5            | 137        | Total               | 5.97       | 4     | NC*    |
| <b>Hodgkin's Dis</b>  | sease         |              | <u>Pr</u>  | <u>rostate</u>      |            |       |        |
| Male                  | 1.34          | 4            | NC*        | Male                | 48.42      | 52    | 107    |
| Female                | 1.12          | 0            | NC*        |                     |            |       |        |
| Total                 | 2.46          | 4            | NC*        |                     |            |       |        |
| Kidney and Ro         | enal Pelvis   |              | <u>St</u>  | <u>omach</u>        |            |       |        |
| Male                  | 4.69          | 9            | 192        | Male                | 3.58       | 0     | NC*    |
| Female                | 2.80          | 4            | NC*        | Female              | 2.02       | 2     | NC*    |
| Total                 | 7.49          | 13           | 173        | Total               | 5.60       | 2     | NC*    |
| <u>Larynx</u>         |               |              | <u>Te</u>  | <u>estis</u>        |            |       |        |
| Male                  | 2.89          | 4            | NC*        | Male                | 1.94       | 3     | NC*    |
| Female                | 0.79          | 1            | NC*        |                     |            |       |        |
| Total                 | 3.68          | 5            | 136        |                     |            |       |        |
| <u>Leukemia</u>       |               |              | <u>Tł</u>  | <u>nyroid</u>       |            |       |        |
| Male                  | 3.34          | 5            | 150        | Male                | 0.79       | 0     | NC*    |
| Female                | 2.44          | 6            | 246        | Female              | 2.22       | 3     | NC*    |
| Total                 | 5.79          | 11           | 190        | Total               | 3.02       | 3     | NC*    |
| <b>Liver and Intr</b> | ahepatic Bile | <u>Ducts</u> | <u>U1</u>  | <u>teri, Corpus</u> | and Uterus | , NOS |        |
| Male                  | 1.33          | 3            | NC*        |                     |            |       |        |
| Female                | 0.59          | 0            | NC*        | Female              | 8.76       | 8     | 91     |
| Total                 | 1.92          | 3            | NC*        |                     |            |       |        |
| <b>Lung and Bron</b>  |               |              |            | ll Sites / Ty       |            |       |        |
| Male                  | 26.31         | 22           | 84         | Male                | 162.00     | 173   | 107    |
| Female                | 18.27         | 22           | 120        | Female              | 145.31     | 139   | 96     |
| Total                 | 44.58         | 44           | 99         | Total               | 307.31     | 312   | 102    |
|                       |               |              |            |                     |            |       |        |

 $\mathbf{Exp} = \text{expected case count}$ , based on the Massachusetts average age-specific incidence rates for this cancer  $\mathbf{Obs} = \text{observed case count}$ 

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

- \* = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the  $\mathbf{p} <= 0.05$  level
- ~ indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level
- ^ indicates statistical significance at the  $\mathbf{p} <= 0.001$  level, as well as at the  $\mathbf{p} <= 0.05$  and  $\mathbf{p} <= 0.01$  levels

#### **CHARLEMONT**

#### Cancer Incidence by Sex, 1990 - 1995

#### **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|                         | <b>Exp</b>   | <u>Obs</u>              | <u>SIR</u>             |                | Exp         | <u>Obs</u> | <u>SIR</u> |  |  |
|-------------------------|--------------|-------------------------|------------------------|----------------|-------------|------------|------------|--|--|
| <b>Bladder, Urinary</b> | <del>-</del> |                         | <u>M</u>               | elanoma of S   | <u>Skin</u> |            |            |  |  |
| Male                    | 1.00         | 1                       | NC*                    | Male           | 0.54        | 0          | NC*        |  |  |
| Female                  | 0.28         | 0                       | NC*                    | Female         | 0.36        | 0          | NC*        |  |  |
| Total                   | 1.27         | 1                       | NC*                    | Total          | 0.90        | 0          | NC*        |  |  |
| <b>Brain and Centra</b> | al Nervous   | <u>System</u>           | <u>M</u>               | ultiple Myel   | <u>oma</u>  |            |            |  |  |
| Male                    | 0.35         | 0                       | NC*                    | Male           | 0.18        | 1          | NC*        |  |  |
| Female                  | 0.28         | 0                       | NC*                    | Female         | 0.13        | 0          | NC*        |  |  |
| Total                   | 0.63         | 0                       | NC*                    | Total          | 0.31        | 1          | NC*        |  |  |
| <b>Breast</b>           |              |                         | Non-Hodgkin's Lymphoma |                |             |            |            |  |  |
| Male                    | 0.05         | 0                       | NC*                    | Male           | 0.75        | 1          | NC*        |  |  |
| Female                  | 5.03         | 9                       | 179                    | Female         | 0.52        | 0          | NC*        |  |  |
| Total                   | 5.08         | 9                       | 177                    | Total          | 1.27        | 1          | NC*        |  |  |
| <u>Cervix Uteri</u>     |              | Oral Cavity and Pharynx |                        |                |             |            |            |  |  |
|                         |              |                         |                        | Male           | 0.73        | 0          | NC*        |  |  |
| Female                  | 0.34         | 0                       | NC*                    | Female         | 0.25        | 0          | NC*        |  |  |
|                         |              |                         |                        | Total          | 0.98        | 0          | NC*        |  |  |
| Colon / Rectum          |              |                         | <u>O</u>               | <u>vary</u>    |             |            |            |  |  |
| Male                    | 2.65         | 6                       | 226                    |                |             |            |            |  |  |
| Female                  | 1.79         | 1                       | NC*                    | Female         | 0.62        | 0          | NC*        |  |  |
| Total                   | 4.44         | 7                       | 158                    |                |             |            |            |  |  |
| <b>Esophagus</b>        |              |                         | <u>Pa</u>              | ancreas_       |             |            |            |  |  |
| Male                    | 0.36         | 1                       | NC*                    | Male           | 0.38        | 0          | NC*        |  |  |
| Female                  | 0.09         | 0                       | NC*                    | Female         | 0.29        | 0          | NC*        |  |  |
| Total                   | 0.45         | 1                       | NC*                    | Total          | 0.67        | 0          | NC*        |  |  |
| <b>Hodgkin's Disea</b>  | <u>se</u>    |                         | <u>P</u> 1             | <u>rostate</u> |             |            |            |  |  |
| Male                    | 0.16         | 0                       | NC*                    | Male           | 5.93        | 4          | NC*        |  |  |
| Female                  | 0.11         | 0                       | NC*                    |                |             |            |            |  |  |
| Total                   | 0.27         | 0                       | NC*                    |                |             |            |            |  |  |
|                         |              |                         |                        |                |             |            |            |  |  |

| Kidney and Re          |                                   | <b>Stomach</b> |           |                              |            |    |     |
|------------------------|-----------------------------------|----------------|-----------|------------------------------|------------|----|-----|
| Male                   | 0.61                              | 1              | NC*       | Male                         | 0.44       | 0  | NC* |
| Female                 | 0.29                              | 1              | NC*       | Female                       | 0.19       | 0  | NC* |
| Total                  | 0.90                              | 2              | NC*       | Total                        | 0.63       | 0  | NC* |
| <u>Larynx</u>          |                                   |                | <u>Te</u> | <u>estis</u>                 |            |    |     |
| Male                   | 0.40                              | 1              | NC*       | Male                         | 0.22       | 0  | NC* |
| Female                 | 0.09                              | 0              | NC*       |                              |            |    |     |
| Total                  | 0.49                              | 1              | NC*       |                              |            |    |     |
| <u>Leukemia</u>        |                                   |                | <u>T</u>  | <u>ıyroid</u>                |            |    |     |
| Male                   | 0.40                              | 2              | NC*       | Male                         | 0.10       | 0  | NC* |
| Female                 | 0.24                              | 0              | NC*       | Female                       | 0.24       | 0  | NC* |
| Total                  | 0.65                              | 2              | NC*       | Total                        | 0.34       | 0  | NC* |
| <b>Liver and Intra</b> | <u>hepatic Bile D</u>             | <u>Oucts</u>   | <u>U1</u> | teri, Corpus and Uterus, NOS |            |    |     |
| Male                   | 0.17                              | 0              | NC*       |                              |            |    |     |
| Female                 | 0.06                              | 0              | NC*       | Female                       | 0.96       | 3  | NC* |
| Total                  | 0.23                              | 0              | NC*       |                              |            |    |     |
| <b>Lung and Bron</b>   | <u>Lung and Bronchus</u> <u>A</u> |                |           |                              | <u>oes</u> |    |     |
| Male                   | 3.38                              | 3              | NC*       | Male                         | 20.21      | 23 | 114 |
| Female                 | 1.91                              | 3              | NC*       | Female                       | 15.11      | 17 | 113 |
| Total                  | 5.29                              | 6              | 113       | Total                        | 35.32      | 40 | 113 |
|                        |                                   |                |           |                              |            |    |     |

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

#### **CHARLTON**

# Cancer Incidence by Sex, 1990 - 1995

# **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|                  | <b>Exp</b> | <u>Obs</u> | <u>SIR</u>               |                      | <b>Exp</b>  | <u>Obs</u> | <u>SIR</u> |
|------------------|------------|------------|--------------------------|----------------------|-------------|------------|------------|
| Bladder, Urinary |            |            | $\underline{\mathbf{M}}$ | <u>lelanoma of S</u> | <u>Skin</u> |            |            |
| Male             | 5.84       | 8          | 137                      | Male                 | 3.35        | 4          | NC*        |
| Female           | 1.72       | 1          | NC*                      | Female               | 2.51        | 2          | NC*        |
| Total            | 7.56       | 9          | 119                      | Total                | 5.86        | 6          | 102        |

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} <= 0.05$  level

 $<sup>\</sup>sim$  indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

| Brain and Central Nervous System |            |              |            | Multiple Myeloma    |              |              |       |  |
|----------------------------------|------------|--------------|------------|---------------------|--------------|--------------|-------|--|
| Male                             | 2.37       | 3            | NC*        | Male                | 1.06         | 0            | NC*   |  |
| Female                           | 1.88       | 0            | NC*        | Female              | 0.77         | 2            | NC*   |  |
| Total                            | 4.25       | 3            | NC*        | Total               | 1.83         | 2            | NC*   |  |
| <b>Breast</b>                    |            |              | <u>N</u>   | on-Hodgkin          | 's Lymphom   | <u>ıa</u>    |       |  |
| Male                             | 0.32       | 1            | NC*        | Male                | 4.83         | 6            | 124   |  |
| Female                           | 31.37      | 33           | 105        | Female              | 3.35         | 7            | 209   |  |
| Total                            | 31.69      | 34           | 107        | Total               | 8.18         | 13           | 159   |  |
| Cervix Uteri                     |            |              | <u>O</u>   | ral Cavity a        | nd Pharynx   |              |       |  |
|                                  |            |              |            | Male                | 4.30         | 2            | NC*   |  |
| Female                           | 2.53       | 4            | NC*        | Female              | 1.55         | 0            | NC*   |  |
|                                  |            |              |            | Total               | 5.85         | 2            | NC*   |  |
| Colon / Rectum                   | _          |              | <u>O</u>   | <u>vary</u>         |              |              |       |  |
| Male                             | 15.40      | 17           | 110        |                     |              |              |       |  |
| Female                           | 11.34      | 15           | 132        | Female              | 4.01         | 5            | 125   |  |
| Total                            | 26.74      | 32           | 120        |                     |              |              |       |  |
| <b>Esophagus</b>                 |            |              | <u>Pa</u>  | ancreas             |              |              |       |  |
| Male                             | 2.06       | 1            | NC*        | Male                | 2.16         | 0            | NC*   |  |
| Female                           | 0.55       | 0            | NC*        | Female              | 1.77         | 1            | NC*   |  |
| Total                            | 2.61       | 1            | NC*        | Total               | 3.94         | 1            | NC*   |  |
| <b>Hodgkin's Dise</b>            | ease_      |              | <u>P</u> 1 | <u>rostate</u>      |              |              |       |  |
| Male                             | 1.24       | 2            | NC*        | Male                | 32.62        | 14           | 43 ^- |  |
| Female                           | 0.96       | 0            | NC*        |                     |              |              |       |  |
| Total                            | 2.21       | 2            | NC*        |                     |              |              |       |  |
| Kidney and Rea                   | nal Pelvis |              | <u>St</u>  | omach_              |              |              |       |  |
| Male                             | 3.58       | 2            | NC*        | Male                | 2.62         | 3            | NC*   |  |
| Female                           | 1.75       | 1            | NC*        | Female              | 1.27         | 2            | NC*   |  |
| Total                            | 5.33       | 3            | NC*        | Total               | 3.89         | 5            | 129   |  |
| <u>Larynx</u>                    |            |              | <u>T</u>   | <u>estis</u>        |              |              |       |  |
| Male                             | 2.23       | 2            | NC*        | Male                | 1.91         | 0            | NC*   |  |
| Female                           | 0.50       | 1            | NC*        |                     |              |              |       |  |
| Total                            | 2.73       | 3            | NC*        |                     |              |              |       |  |
| <u>Leukemia</u>                  |            |              | _          | <u>hyroid</u>       |              |              |       |  |
| Male                             | 2.64       | 0            | NC*        | Male                | 0.71         | 0            | NC*   |  |
| Female                           | 1.74       | 1            | NC*        | Female              | 1.87         | 2            | NC*   |  |
| Total                            | 4.38       | 1            | NC*        | Total               | 2.58         | 2            | NC*   |  |
| <b>Liver and Intra</b>           | _          | <u>Ducts</u> |            | <u>teri, Corpus</u> | s and Uterus | <u>, NOS</u> |       |  |
| Male                             | 1.00       | 0            | NC*        |                     |              |              |       |  |
| Female                           | 0.36       | 2            | NC*        | Female              | 5.60         | 8            | 143   |  |
| Total                            | 1.36       | 2            | NC*        |                     |              |              |       |  |
| Lung and Brone                   |            |              |            | ll Sites / Ty       |              |              |       |  |
| Male                             | 18.95      | 8            | 42 ~-      | Male                | 118.12       | 82           | 69 ^- |  |
| Female                           | 10.70      | 6            | 56         | Female              | 94.99        | 99           | 104   |  |
| Total                            | 29.65      | 14           | 47 ~-      | Total               | 213.11       | 181          | 85 #- |  |

9 of 84

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

- \* = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the  $\mathbf{p} \le 0.05$  level
- ~ indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level
- ^ indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

#### **CHATHAM**

#### Cancer Incidence by Sex, 1990 - 1995

#### **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|                      | $\mathbf{Exp}$ | <u>Obs</u>             | <u>SIR</u> |                      | <b>Exp</b>  | <u>Obs</u> | <u>SIR</u> |
|----------------------|----------------|------------------------|------------|----------------------|-------------|------------|------------|
| Bladder, Urina       | <u>ry</u>      |                        | <u>M</u>   | elanoma of           | <u>Skin</u> |            |            |
| Male                 | 11.67          | 7                      | 60         | Male                 | 4.65        | 3          | NC*        |
| Female               | 4.16           | 4                      | NC*        | Female               | 3.33        | 9          | 270 #+     |
| Total                | 15.83          | 11                     | 70         | Total                | 7.99        | 12         | 150        |
| <b>Brain and Cen</b> | tral Nervous   | <u>System</u>          | <u>M</u>   | <u>ultiple Mye</u>   | <u>loma</u> |            |            |
| Male                 | 2.69           | 5                      | 186        | Male                 | 2.04        | 1          | NC*        |
| Female               | 2.67           | 4                      | NC*        | Female               | 1.81        | 1          | NC*        |
| Total                | 5.36           | 9                      | 168        | Total                | 3.84        | 2          | NC*        |
| <b>Breast</b>        |                | Non-Hodgkin's Lymphoma |            |                      |             |            |            |
| Male                 | 0.57           | 1                      | NC*        | Male                 | 6.87        | 11         | 160        |
| Female               | 53.68          | 75                     | 140 ~+     | Female               | 6.72        | 12         | 179        |
| Total                | 54.25          | 76                     | 140 ~+     | Total                | 13.58       | 23         | 169 #+     |
| <u>Cervix Uteri</u>  |                |                        | <u>O</u> 1 | <u>ral Cavity aı</u> | nd Pharynx  |            |            |
|                      |                |                        |            | Male                 | 6.05        | 4          | NC*        |
| Female               | 2.53           | 1                      | NC*        | Female               | 2.87        | 3          | NC*        |
|                      |                |                        |            | Total                | 8.92        | 7          | 79         |
| Colon / Rectun       | <u>1</u>       |                        | <u>O</u>   | <u>vary</u>          |             |            |            |
| Male                 | 30.68          | 13                     | 42 ^-      |                      |             |            |            |
| Female               | 28.60          | 19                     | 66         | Female               | 6.10        | 4          | NC*        |
| Total                | 59.28          | 32                     | 54 ^-      |                      |             |            |            |
| <b>Esophagus</b>     |                |                        | <u>Pa</u>  | <u>ancreas</u>       |             |            |            |
| Male                 | 3.47           | 4                      | NC*        | Male                 | 3.91        | 7          | 179        |
| Female               | 1.42           | 3                      | NC*        | Female               | 4.40        | 1          | NC*        |
| Total                | 4.89           | 7                      | 143        | Total                | 8.32        | 8          | 96         |
|                      |                |                        |            |                      |             |            |            |

| Hodgkin's Disc         | <u>ease</u>  |              | <b>Prostate</b> |                     |             |      |        |
|------------------------|--------------|--------------|-----------------|---------------------|-------------|------|--------|
| Male                   | 0.86         | 0            | NC*             | Male                | 68.73       | 97   | 141 ~+ |
| Female                 | 0.72         | 1            | NC*             |                     |             |      |        |
| Total                  | 1.58         | 1            | NC*             |                     |             |      |        |
| Kidney and Re          | nal Pelvis   |              | <u>St</u>       | <u>omach</u>        |             |      |        |
| Male                   | 5.60         | 4            | NC*             | Male                | 5.05        | 0    | NC*    |
| Female                 | 3.43         | 1            | NC*             | Female              | 3.14        | 2    | NC*    |
| Total                  | 9.03         | 5            | 55              | Total               | 8.19        | 2    | NC*    |
| <u>Larynx</u>          |              |              | <u>Te</u>       | <u>estis</u>        |             |      |        |
| Male                   | 3.52         | 3            | NC*             | Male                | 0.91        | 0    | NC*    |
| Female                 | 0.91         | 0            | NC*             |                     |             |      |        |
| Total                  | 4.43         | 3            | NC*             |                     |             |      |        |
| <u>Leukemia</u>        |              |              | <u>Tł</u>       | <u> </u>            |             |      |        |
| Male                   | 3.74         | 7            | 187             | Male                | 0.62        | 0    | NC*    |
| Female                 | 2.79         | 1            | NC*             | Female              | 1.63        | 4    | NC*    |
| Total                  | 6.53         | 8            | 122             | Total               | 2.25        | 4    | NC*    |
| <b>Liver and Intra</b> | hepatic Bile | <u>Ducts</u> | <u>U1</u>       | <u>teri, Corpus</u> | and Uterus, | NOS_ |        |
| Male                   | 1.65         | 2            | NC*             |                     |             |      |        |
| Female                 | 0.79         | 1            | NC*             | Female              | 10.26       | 5    | 49     |
| Total                  | 2.44         | 3            | NC*             |                     |             |      |        |
| <b>Lung and Bron</b>   | <u>chus</u>  |              | <u>A</u> l      | ll Sites / Ty       | pes         |      |        |
| Male                   | 34.24        | 27           | 79              | Male                | 211.40      | 213  | 101    |
| Female                 | 22.79        | 24           | 105             | Female              | 178.84      | 187  | 105    |
| Total                  | 57.03        | 51           | 89              | Total               | 390.24      | 400  | 103    |
|                        |              |              |                 |                     |             |      |        |

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

#### **CHELMSFORD**

Cancer Incidence by Sex, 1990 - 1995

**Expected and Observed Case Counts, with Standardized Incidence Ratios** 

<u>Exp</u> <u>Obs</u> <u>SIR</u> <u>Exp</u> <u>Obs</u> <u>SIR</u>

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases  $\mu$  indicates statistical significance at the  $\mu$  <= 0.05 level

<sup>~</sup> indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

| Bladder, Urina         | <u>ry</u>     | Melanoma of Skin       |            |                     |              |     |     |  |  |
|------------------------|---------------|------------------------|------------|---------------------|--------------|-----|-----|--|--|
| Male                   | 21.60         | 21                     | 97         | Male                | 12.45        | 17  | 137 |  |  |
| Female                 | 8.35          | 6                      | 72         | Female              | 10.56        | 12  | 114 |  |  |
| Total                  | 29.95         | 27                     | 90         | Total               | 23.01        | 29  | 126 |  |  |
| <b>Brain and Cen</b>   | tral Nervous  | <u>System</u>          | <u>M</u>   | ultiple Mye         | <u>eloma</u> |     |     |  |  |
| Male                   | 8.52          | 14                     | 164        | Male                | 3.98         | 4   | NC* |  |  |
| Female                 | 7.96          | 7                      | 88         | Female              | 3.79         | 1   | NC* |  |  |
| Total                  | 16.48         | 21                     | 127        | Total               | 7.78         | 5   | 64  |  |  |
| <b>Breast</b>          |               | Non-Hodgkin's Lymphoma |            |                     |              |     |     |  |  |
| Male                   | 1.20          | 1                      | NC*        | Male                | 17.49        | 17  | 97  |  |  |
| Female                 | 146.79        | 166                    | 113        | Female              | 15.38        | 16  | 104 |  |  |
| Total                  | 147.99        | 167                    | 113        | Total               | 32.88        | 33  | 100 |  |  |
| <u>Cervix Uteri</u>    |               |                        | <u>O</u> : | <u>ral Cavity a</u> | nd Pharynx   |     |     |  |  |
|                        |               |                        |            | Male                | 16.97        | 17  | 100 |  |  |
| Female                 | 9.85          | 4                      | NC*        | Female              | 7.34         | 8   | 109 |  |  |
|                        |               |                        |            | Total               | 24.30        | 25  | 103 |  |  |
| Colon / Rectum         | <u>1</u>      |                        | <u>O</u>   | <u>vary</u>         |              |     |     |  |  |
| Male                   | 57.57         | 60                     | 104        |                     |              |     |     |  |  |
| Female                 | 54.70         | 58                     | 106        | Female              | 18.03        | 22  | 122 |  |  |
| Total                  | 112.26        | 118                    | 105        |                     |              |     |     |  |  |
| <b>Esophagus</b>       |               |                        | <u>Pa</u>  | ancreas             |              |     |     |  |  |
| Male                   | 8.11          | 8                      | 99         | Male                | 8.38         | 10  | 119 |  |  |
| Female                 | 2.72          | 5                      | 183        | Female              | 8.74         | 5   | 57  |  |  |
| Total                  | 10.83         | 13                     | 120        | Total               | 17.12        | 15  | 88  |  |  |
| <b>Hodgkin's Dis</b>   | ease          |                        | <u>P</u> 1 | <u>rostate</u>      |              |     |     |  |  |
| Male                   | 3.99          | 5                      | 125        | Male                | 128.28       | 126 | 98  |  |  |
| Female                 | 3.21          | 3                      | NC*        |                     |              |     |     |  |  |
| Total                  | 7.20          | 8                      | 111        |                     |              |     |     |  |  |
| Kidney and Re          | enal Pelvis   |                        | <u>St</u>  | <u>omach</u>        |              |     |     |  |  |
| Male                   | 14.02         | 14                     | 100        | Male                | 9.56         | 10  | 105 |  |  |
| Female                 | 8.36          | 7                      | 84         | Female              | 5.98         | 4   | NC* |  |  |
| Total                  | 22.38         | 21                     | 94         | Total               | 15.54        | 14  | 90  |  |  |
| <u>Larynx</u>          |               |                        | <u>T</u>   | <u>estis</u>        |              |     |     |  |  |
| Male                   | 9.02          | 9                      | 100        | Male                | 5.94         | 8   | 135 |  |  |
| Female                 | 2.55          | 1                      | NC*        |                     |              |     |     |  |  |
| Total                  | 11.58         | 10                     | 86         |                     |              |     |     |  |  |
| <b>Leukemia</b>        |               |                        | <u>T</u>   | <u>nyroid</u>       |              |     |     |  |  |
| Male                   | 9.34          | 6                      | 64         | Male                | 2.51         | 1   | NC* |  |  |
| Female                 | 7.14          | 9                      | 126        | Female              | 6.89         | 7   | 102 |  |  |
| Total                  | 16.48         | 15                     | 91         | Total               | 9.40         | 8   | 85  |  |  |
| <b>Liver and Intra</b> | ahepatic Bile | <u>Ducts</u>           | <u>U</u> 1 | teri, Corpus        | and Uterus.  | NOS |     |  |  |
| Male                   | 3.85          | 3                      | NC*        |                     |              |     |     |  |  |
| Female                 | 1.71          | 1                      | NC*        | Female              | 27.63        | 26  | 94  |  |  |
| Total                  | 5.56          | 4                      | NC*        |                     |              |     |     |  |  |

| <b>Lung and Bro</b> |        | All Sites / Types |       |        |        |     |    |
|---------------------|--------|-------------------|-------|--------|--------|-----|----|
| Male                | 75.69  | 71                | 94    | Male   | 450.63 | 445 | 99 |
| Female              | 54.37  | 35                | 64 ~- | Female | 443.40 | 422 | 95 |
| Total               | 130.06 | 106               | 82 #- | Total  | 894.03 | 867 | 97 |

**Obs** = observed case count

SIR = standardized incidence ratio [ (Obs / Exp) X 100]

#### **CHELSEA**

#### Cancer Incidence by Sex, 1990 - 1995

#### **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|                      | <b>Exp</b>   | <u>Obs</u>    | <u>SIR</u> |               | <b>Exp</b>  | <u>Obs</u> | <u>SIR</u> |  |
|----------------------|--------------|---------------|------------|---------------|-------------|------------|------------|--|
| Bladder, Urina       | <u>ry</u>    |               | <u>M</u>   | elanoma of    | <u>Skin</u> |            |            |  |
| Male                 | 22.19        | 25            | 113        | Male          | 11.26       | 12         | 107        |  |
| Female               | 7.33         | 1             | NC*        | Female        | 8.73        | 6          | 69         |  |
| Total                | 29.52        | 26            | 88         | Total         | 19.99       | 18         | 90         |  |
| <b>Brain and Cen</b> | tral Nervous | <u>System</u> | <u>M</u>   | ultiple Mye   | <u>loma</u> |            |            |  |
| Male                 | 7.65         | 9             | 118        | Male          | 3.97        | 6          | 151        |  |
| Female               | 6.69         | 8             | 120        | Female        | 3.23        | 4          | NC*        |  |
| Total                | 14.34        | 17            | 119        | Total         | 7.20        | 10         | 139        |  |
| <u>Breast</u>        |              |               | No         | on-Hodgkin'   | s Lymphoma  | <u>a</u>   |            |  |
| Male                 | 1.16         | 3             | NC*        | Male          | 16.59       | 24         | 145        |  |
| Female               | 117.32       | 80            | 68 ^-      | Female        | 13.34       | 14         | 105        |  |
| Total                | 118.49       | 83            | 70 ^-      | Total         | 29.93       | 38         | 127        |  |
| <u>Cervix Uteri</u>  |              |               | <u>O</u> 1 | ral Cavity aı | nd Pharynx  |            |            |  |
|                      |              |               |            | Male          | 14.24       | 16         | 112        |  |
| Female               | 8.26         | 9             | 109        | Female        | 5.93        | 10         | 169        |  |
|                      |              |               |            | Total         | 20.18       | 26         | 129        |  |
| Colon / Rectun       | <u>n_</u>    | <u>Ovary</u>  |            |               |             |            |            |  |
| Male                 | 58.71        | 79            | 135 #+     |               |             |            |            |  |
| Female               | 49.24        | 55            | 112        | Female        | 14.46       | 20         | 138        |  |
| Total                | 107.96       | 134           | 124 #+     |               |             |            |            |  |

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} <= 0.05$  level

<sup>~</sup> indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

| <b>Esophagus</b>    |                    |         | <u>P</u> | ancreas                    |             |         |        |
|---------------------|--------------------|---------|----------|----------------------------|-------------|---------|--------|
| Male                | 7.24               | 11      | 152      | Male                       | 7.97        | 8       | 100    |
| Female              | 2.42               | 3       | NC*      | Female                     | 7.67        | 13      | 170    |
| Total               | 9.66               | 14      | 145      | Total                      | 15.64       | 21      | 134    |
| Hodgkin's Dis       | sease_             |         | <u>P</u> | <u>rostate</u>             |             |         |        |
| Male                | 3.78               | 4       | NC*      | Male                       | 130.12      | 111     | 85     |
| Female              | 3.01               | 3       | NC*      |                            |             |         |        |
| Total               | 6.79               | 7       | 103      |                            |             |         |        |
| Kidney and R        | <u>enal Pelvis</u> |         | <u>S</u> | tomach_                    |             |         |        |
| Male                | 12.49              | 12      | 96       | Male                       | 9.77        | 13      | 133    |
| Female              | 6.90               | 17      | 246 ~+   | Female                     | 5.45        | 9       | 165    |
| Total               | 19.39              | 29      | 150 #+   | Total                      | 15.23       | 22      | 144    |
| <u>Larynx</u>       |                    |         | <u>1</u> | <u>Cestis</u>              |             |         |        |
| Male                | 7.70               | 11      | 143      | Male                       | 5.67        | 3       | NC*    |
| Female              | 1.90               | 6       | 316 #+   |                            |             |         |        |
| Total               | 9.60               | 17      | 177 #+   |                            |             |         |        |
| <u>Leukemia</u>     |                    |         | 1        | <u>Chyroid</u>             |             |         |        |
| Male                | 9.03               | 13      | 144      | Male                       | 2.20        | 2       | NC*    |
| Female              | 6.41               | 9       | 140      | Female                     | 5.95        | 6       | 101    |
| Total               | 15.44              | 22      | 142      | Total                      | 8.14        | 8       | 98     |
| Liver and Intr      | ahepatic Bile      | e Ducts | <u>I</u> | I <mark>teri, Corpu</mark> | s and Uteru | ıs, NOS |        |
| Male                | 3.56               | 6       | 169      |                            |             |         |        |
| Female              | 1.49               | 2       | NC*      | Female                     | 21.41       | 26      | 121    |
| Total               | 5.05               | 8       | 158      |                            |             |         |        |
| <b>Lung and Bro</b> | <u>nchus</u>       |         | <u>A</u> | All Sites / Ty             | pes         |         |        |
| Male                | 70.00              | 80      | 114      | Male                       | 436.73      | 483     | 111 #+ |
| Female              | 43.61              | 66      | 151 ~+   | Female                     | 368.31      | 402     | 109    |
| Total               | 113.61             | 146     | 129 ~+   | Total                      | 805.04      | 885     | 110 ~+ |

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

#### **CHESHIRE**

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} \le 0.05$  level

<sup>~</sup> indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\bar{\bf p}$  <= 0.001 level, as well as at the  $\bar{\bf p}$  <= 0.05 and  $\bar{\bf p}$  <= 0.01 levels

# Cancer Incidence by Sex, 1990 - 1995 Expected and Observed Case Counts, with Standardized Incidence Ratios

|                       | Exp               | <u>Obs</u>    | SIR                      |                     | <b>Exp</b>  | <u>Obs</u> | SIR   |  |
|-----------------------|-------------------|---------------|--------------------------|---------------------|-------------|------------|-------|--|
| Bladder, Urinar       | <u> </u>          |               | $\underline{\mathbf{M}}$ | <u>lelanoma of</u>  | <u>Skin</u> |            |       |  |
| Male                  | 2.74              | 0             | NC*                      | Male                | 1.50        | 2          | NC*   |  |
| Female                | 0.86              | 0             | NC*                      | Female              | 1.11        | 0          | NC*   |  |
| Total                 | 3.61              | 0             | NC*                      | Total               | 2.61        | 2          | NC*   |  |
| <b>Brain and Cent</b> | ral Nervous S     | <u>System</u> | $\underline{\mathbf{M}}$ | <u>lultiple Mye</u> | <u>loma</u> |            |       |  |
| Male                  | 1.02              | 0             | NC*                      | Male                | 0.51        | 0          | NC*   |  |
| Female                | 0.85              | 0             | NC*                      | Female              | 0.40        | 0          | NC*   |  |
| Total                 | 1.87              | 0             | NC*                      | Total               | 0.90        | 0          | NC*   |  |
| <u>Breast</u>         |                   |               | N                        | <u>on-Hodgkin'</u>  | s Lymphoma  | <u>1</u>   |       |  |
| Male                  | 0.15              | 0             | NC*                      | Male                | 2.12        | 1          | NC*   |  |
| Female                | 15.47             | 16            | 103                      | Female              | 1.61        | 2          | NC*   |  |
| Total                 | 15.62             | 16            | 102                      | Total               | 3.73        | 3          | NC*   |  |
| <u>Cervix Uteri</u>   |                   |               | Oral Cavity and Pharynx  |                     |             |            |       |  |
|                       |                   |               |                          | Male                | 2.06        | 1          | NC*   |  |
| Female                | 1.04              | 1             | NC*                      | Female              | 0.77        | 1          | NC*   |  |
|                       |                   |               |                          | Total               | 2.84        | 2          | NC*   |  |
| Colon / Rectum        | _                 |               | <u>O</u>                 | <u>vary</u>         |             |            |       |  |
| Male                  | 7.33              | 6             | 82                       |                     |             |            |       |  |
| Female                | 5.61              | 2             | NC*                      | Female              | 1.90        | 0          | NC*   |  |
| Total                 | 12.94             | 8             | 62                       |                     |             |            |       |  |
| <b>Esophagus</b>      |                   |               | <u>Pa</u>                | ancreas             |             |            |       |  |
| Male                  | 1.01              | 3             | NC*                      | Male                | 1.06        | 1          | NC*   |  |
| Female                | 0.28              | 0             | NC*                      | Female              | 0.91        | 0          | NC*   |  |
| Total                 | 1.29              | 3             | NC*                      | Total               | 1.97        | 1          | NC*   |  |
| Hodgkin's Dise        | ease_             |               |                          | <u>rostate</u>      |             |            |       |  |
| Male                  | 0.45              | 1             | NC*                      | Male                | 16.66       | 8          | 48 #- |  |
| Female                | 0.34              | 0             | NC*                      |                     |             |            |       |  |
| Total                 | 0.79              | 1             | NC*                      |                     |             |            |       |  |
| Kidney and Re         | <u>nal Pelvis</u> |               | St                       | omach_              |             |            |       |  |
| Male                  | 1.74              | 0             | NC*                      | Male                | 1.20        | 2          | NC*   |  |
| Female                | 0.90              | 0             | NC*                      | Female              | 0.60        | 0          | NC*   |  |
| Total                 | 2.64              | 0             | NC*                      | Total               | 1.81        | 2          | NC*   |  |
| <u>Larynx</u>         |                   |               | $\underline{\mathbf{T}}$ | <u>estis</u>        |             |            |       |  |
| Male                  | 1.12              | 2             | NC*                      | Male                | 0.64        | 0          | NC*   |  |
| Female                | 0.27              | 1             | NC*                      |                     |             |            |       |  |
| Total                 | 1.39              | 3             | NC*                      |                     |             |            |       |  |
| <u>Leukemia</u>       |                   |               | <u>T</u>                 | <u>hyroid</u>       |             |            |       |  |
| Male                  | 1.14              | 0             | NC*                      | Male                | 0.29        | 0          | NC*   |  |
| Female                | 0.75              | 0             | NC*                      | Female              | 0.73        | 0          | NC*   |  |
|                       |                   |               |                          |                     |             |            |       |  |

| Total                             | 1.89        | 0  | NC*                           | Total  | 1.02   | 0  | NC*   |  |  |
|-----------------------------------|-------------|----|-------------------------------|--------|--------|----|-------|--|--|
| Liver and Intrahepatic Bile Ducts |             |    | Uteri, Corpus and Uterus, NOS |        |        |    |       |  |  |
| Male                              | 0.48        | 1  | NC*                           |        |        |    |       |  |  |
| Female                            | 0.18        | 0  | NC*                           | Female | 2.95   | 4  | NC*   |  |  |
| Total                             | 0.66        | 1  | NC*                           |        |        |    |       |  |  |
| <b>Lung and Bron</b>              | <u>chus</u> |    | All Sites / Types             |        |        |    |       |  |  |
| Male                              | 9.60        | 9  | 94                            | Male   | 56.77  | 40 | 70 #- |  |  |
| Female                            | 5.90        | 3  | NC*                           | Female | 46.70  | 32 | 69 #- |  |  |
| Total                             | 15.50       | 12 | 77                            | Total  | 103.47 | 72 | 70 ~- |  |  |

**Obs** = observed case count

SIR = standardized incidence ratio [ (Obs / Exp) X 100]

#### **CHESTER**

#### Cancer Incidence by Sex, 1990 - 1995

## **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|                       | <b>Exp</b>    | <u>Obs</u>              | SIR      |              | $\mathbf{\underline{Exp}}$ | <u>Obs</u> | <u>SIR</u> |  |
|-----------------------|---------------|-------------------------|----------|--------------|----------------------------|------------|------------|--|
| Bladder, Urinar       | <u>v</u>      |                         | <u>M</u> | elanoma of S | <u>Skin</u>                |            |            |  |
| Male                  | 0.91          | 0                       | NC*      | Male         | 0.51                       | 0          | NC*        |  |
| Female                | 0.30          | 0                       | NC*      | Female       | 0.38                       | 0          | NC*        |  |
| Total                 | 1.21          | 0                       | NC*      | Total        | 0.89                       | 0          | NC*        |  |
| <b>Brain and Cent</b> | ral Nervous S | <u>vstem</u>            | <u>M</u> | ultiple Myel | loma_                      |            |            |  |
| Male                  | 0.36          | 1                       | NC*      | Male         | 0.17                       | 0          | NC*        |  |
| Female                | 0.30          | 0                       | NC*      | Female       | 0.14                       | 0          | NC*        |  |
| Total                 | 0.65          | 1                       | NC*      | Total        | 0.30                       | 0          | NC*        |  |
| <b>Breast</b>         |               |                         | No       | on-Hodgkin's | s Lymphoma                 | <u>1</u>   |            |  |
| Male                  | 0.05          | 0                       | NC*      | Male         | 0.73                       | 0          | NC*        |  |
| Female                | 5.16          | 4                       | NC*      | Female       | 0.56                       | 0          | NC*        |  |
| Total                 | 5.21          | 4                       | NC*      | Total        | 1.29                       | 0          | NC*        |  |
| Cervix Uteri          |               | Oral Cavity and Pharynx |          |              |                            |            |            |  |
|                       |               |                         |          | Male         | 0.69                       | 0          | NC*        |  |
| Female                | 0.36          | 0                       | NC*      | Female       | 0.26                       | 0          | NC*        |  |

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} <= 0.05$  level

<sup>~</sup> indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

|                     |                        |             |               | Total               | 0.95        | 0    | NC* |  |
|---------------------|------------------------|-------------|---------------|---------------------|-------------|------|-----|--|
| Colon / Rectur      | <u>n</u>               |             | <u>O</u>      | <u>vary</u>         |             |      |     |  |
| Male                | 2.43                   | 2           | NC*           |                     |             |      |     |  |
| Female              | 1.99                   | 4           | NC*           | Female              | 0.64        | 0    | NC* |  |
| Total               | 4.42                   | 6           | 136           |                     |             |      |     |  |
| <b>Esophagus</b>    |                        |             | <u>Pa</u>     | ancreas             |             |      |     |  |
| Male                | 0.33                   | 0           | NC*           | Male                | 0.35        | 0    | NC* |  |
| Female              | 0.10                   | 0           | NC*           | Female              | 0.32        | 1    | NC* |  |
| Total               | 0.43                   | 0           | NC*           | Total               | 0.67        | 1    | NC* |  |
| Hodgkin's Dis       | sease_                 |             | <u>Pr</u>     | <u>rostate</u>      |             |      |     |  |
| Male                | 0.17                   | 0           | NC*           | Male                | 5.53        | 5    | 90  |  |
| Female              | 0.13                   | 0           | NC*           |                     |             |      |     |  |
| Total               | 0.30                   | 0           | NC*           |                     |             |      |     |  |
| Kidney and R        | <u>enal Pelvis</u>     |             | <u>St</u>     | <u>omach</u>        |             |      |     |  |
| Male                | 0.58                   | 0           | NC*           | Male                | 0.40        | 0    | NC* |  |
| Female              | 0.31                   | 1           | NC*           | Female              | 0.22        | 0    | NC* |  |
| Total               | 0.89                   | 1           | NC*           | Total               | 0.61        | 0    | NC* |  |
| <u>Larynx</u>       |                        |             | <u>Testis</u> |                     |             |      |     |  |
| Male                | 0.37                   | 0           | NC*           | Male                | 0.25        | 0    | NC* |  |
| Female              | 0.09                   | 0           | NC*           |                     |             |      |     |  |
| Total               | 0.46                   | 0           | NC*           |                     |             |      |     |  |
| <u>Leukemia</u>     |                        |             | <u>Tl</u>     | <u>nyroid</u>       |             |      |     |  |
| Male                | 0.40                   | 1           | NC*           | Male                | 0.10        | 0    | NC* |  |
| Female              | 0.27                   | 0           | NC*           | Female              | 0.26        | 1    | NC* |  |
| Total               | 0.67                   | 1           | NC*           | Total               | 0.36        | 1    | NC* |  |
| Liver and Intr      | <u>ahepatic Bile D</u> | <u>ucts</u> |               | <u>teri, Corpus</u> | and Uterus, | NOS_ |     |  |
| Male                | 0.16                   | 0           | NC*           |                     |             |      |     |  |
| Female              | 0.06                   | 0           | NC*           | Female              | 0.97        | 0    | NC* |  |
| Total               | 0.22                   | 0           | NC*           |                     |             |      |     |  |
| <b>Lung and Bro</b> | nchus_                 |             |               | ll Sites / Typ      | <u>oes</u>  |      |     |  |
| Male                | 3.18                   | 2           | NC*           | Male                | 19.00       | 12   | 63  |  |
| Female              | 1.97                   | 5           | 253           | Female              | 15.93       | 17   | 107 |  |
| Total               | 5.15                   | 7           | 136           | Total               | 34.94       | 29   | 83  |  |
|                     |                        |             |               |                     |             |      |     |  |

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} \le 0.05$  level

 $<sup>\</sup>sim$  indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

# **CHESTERFIELD**

# Cancer Incidence by Sex, 1990 - 1995

# **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|                          | <b>Exp</b> | <u>Obs</u>              | <u>SIR</u> |                      | Exp             | <u>Obs</u> | <u>SIR</u> |  |  |
|--------------------------|------------|-------------------------|------------|----------------------|-----------------|------------|------------|--|--|
| <b>Bladder, Urinary</b>  |            |                         | <u>M</u>   | <u>lelanoma of S</u> | <u>Skin</u>     |            |            |  |  |
| Male                     | 0.72       | 0                       | NC*        | Male                 | 0.40            | 0          | NC*        |  |  |
| Female                   | 0.20       | 0                       | NC*        | Female               | 0.28            | 0          | NC*        |  |  |
| Total                    | 0.92       | 0                       | NC*        | Total                | 0.68            | 0          | NC*        |  |  |
| <b>Brain and Central</b> | l Nervous  | <u>System</u>           | <u>M</u>   | <u>lultiple Myel</u> | <u>oma</u>      |            |            |  |  |
| Male                     | 0.28       | 0                       | NC*        | Male                 | 0.13            | 0          | NC*        |  |  |
| Female                   | 0.21       | 2                       | NC*        | Female               | 0.09            | 1          | NC*        |  |  |
| Total                    | 0.49       | 2                       | NC*        | Total                | 0.22            | 1          | NC*        |  |  |
| <u>Breast</u>            |            |                         | <u>N</u>   | on-Hodgkin's         | <u>Lymphoma</u> | <u>l</u>   |            |  |  |
| Male                     | 0.04       | 0                       | NC*        | Male                 | 0.58            | 1          | NC*        |  |  |
| Female                   | 3.73       | 4                       | NC*        | Female               | 0.38            | 0          | NC*        |  |  |
| Total                    | 3.76       | 4                       | NC*        | Total                | 0.96            | 1          | NC*        |  |  |
| <u>Cervix Uteri</u>      |            | Oral Cavity and Pharynx |            |                      |                 |            |            |  |  |
|                          |            |                         |            | Male                 | 0.53            | 0          | NC*        |  |  |
| Female                   | 0.27       | 0                       | NC*        | Female               | 0.18            | 0          | NC*        |  |  |
|                          |            |                         |            | Total                | 0.72            | 0          | NC*        |  |  |
| Colon / Rectum           |            |                         | <u>O</u>   | <u>vary</u>          |                 |            |            |  |  |
| Male                     | 1.91       | 0                       | NC*        |                      |                 |            |            |  |  |
| Female                   | 1.30       | 1                       | NC*        | Female               | 0.47            | 1          | NC*        |  |  |
| Total                    | 3.21       | 1                       | NC*        |                      |                 |            |            |  |  |
| <b>Esophagus</b>         |            |                         |            | <u>ancreas</u>       |                 |            |            |  |  |
| Male                     | 0.26       | 1                       | NC*        | Male                 | 0.27            | 0          | NC*        |  |  |
| Female                   | 0.06       | 0                       | NC*        | Female               | 0.21            | 0          | NC*        |  |  |
| Total                    | 0.32       | 1                       | NC*        | Total                | 0.48            | 0          | NC*        |  |  |
| <b>Hodgkin's Diseas</b>  | <u>e</u> _ |                         | <u>Pr</u>  | <u>rostate</u>       |                 |            |            |  |  |
| Male                     | 0.14       | 0                       | NC*        | Male                 | 4.28            | 2          | NC*        |  |  |
| Female                   | 0.09       | 0                       | NC*        |                      |                 |            |            |  |  |
| Total                    | 0.23       | 0                       | NC*        |                      |                 |            |            |  |  |
| Kidney and Renal         | l Pelvis   |                         | <u>St</u>  | <u>omach</u>         |                 |            |            |  |  |
| Male                     | 0.45       | 1                       | NC*        | Male                 | 0.32            | 1          | NC*        |  |  |
| Female                   | 0.21       | 0                       | NC*        | Female               | 0.14            | 0          | NC*        |  |  |
| Total                    | 0.66       | 1                       | NC*        | Total                | 0.46            | 1          | NC*        |  |  |
| <u>Larynx</u>            |            |                         |            | <u>estis</u>         |                 |            |            |  |  |
| Male                     | 0.28       | 0                       | NC*        | Male                 | 0.21            | 0          | NC*        |  |  |

| Female                | 0.06            | 0           | NC*        |                |             |      |     |
|-----------------------|-----------------|-------------|------------|----------------|-------------|------|-----|
| Total                 | 0.35            | 0           | NC*        |                |             |      |     |
| <b>Leukemia</b>       |                 |             | <u>Tl</u>  | <u>nyroid</u>  |             |      |     |
| Male                  | 0.31            | 0           | NC*        | Male           | 0.08        | 0    | NC* |
| Female                | 0.19            | 0           | NC*        | Female         | 0.19        | 1    | NC* |
| Total                 | 0.50            | 0           | NC*        | Total          | 0.27        | 1    | NC* |
| <b>Liver and Intr</b> | ahepatic Bile D | <u>ucts</u> | <u>U</u> 1 | teri, Corpus   | and Uterus, | NOS_ |     |
| Male                  | 0.12            | 0           | NC*        |                |             |      |     |
| Female                | 0.04            | 0           | NC*        | Female         | 0.70        | 2    | NC* |
| Total                 | 0.17            | 0           | NC*        |                |             |      |     |
| <b>Lung and Bro</b>   | <u>nchus</u>    |             | <u>A</u> ] | ll Sites / Tyr | <u>oes</u>  |      |     |
| Male                  | 2.45            | 2           | NC*        | Male           | 14.85       | 9    | 61  |
| Female                | 1.37            | 1           | NC*        | Female         | 11.16       | 15   | 134 |
| Total                 | 3.82            | 3           | NC*        | Total          | 26.01       | 24   | 92  |
|                       |                 |             |            |                |             |      |     |

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

#### **CHICOPEE**

#### Cancer Incidence by Sex, 1990 - 1995

# **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|                      | <b>Exp</b>     | <u>Obs</u>             | <u>SIR</u>       |        | <b>Exp</b> | <u>Obs</u> | <u>SIR</u> |  |
|----------------------|----------------|------------------------|------------------|--------|------------|------------|------------|--|
| Bladder, Urina       | <u>ry</u>      |                        | Melanoma of Skin |        |            |            |            |  |
| Male                 | 48.04          | 43                     | 90               | Male   | 23.73      | 17         | 72         |  |
| Female               | 19.51          | 13                     | 67               | Female | 20.44      | 10         | 49 #-      |  |
| Total                | 67.55          | 56                     | 83               | Total  | 44.17      | 27         | 61 ~-      |  |
| <b>Brain and Cen</b> | tral Nervous S | <u>System</u>          | Multiple Myeloma |        |            |            |            |  |
| Male                 | 15.69          | 24                     | 153              | Male   | 8.63       | 9          | 104        |  |
| Female               | 15.97          | 16                     | 100              | Female | 8.67       | 8          | 92         |  |
| Total                | 31.65          | 40                     | 126              | Total  | 17.30      | 17         | 98         |  |
| <b>Breast</b>        |                | Non-Hodgkin's Lymphoma |                  |        |            |            |            |  |
| Male                 | 2.52           | 4                      | NC*              | Male   | 34.48      | 33         | 96         |  |

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} <= 0.05$  level

<sup>~</sup> indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

| Female                | 296.51              | 256 | 86 #-      | Female              | 34.09        | 13    | 38 ^-  |
|-----------------------|---------------------|-----|------------|---------------------|--------------|-------|--------|
| Total                 | 299.03              | 260 | 87 #-      | Total               | 68.56        | 46    | 67 ~-  |
| <u>Cervix Uteri</u>   |                     |     | <u>O</u>   | ral Cavity a        | nd Pharynx   | •     |        |
|                       |                     |     |            | Male                | 31.36        | 30    | 96     |
| Female                | 18.08               | 18  | 100        | Female              | 15.28        | 8     | 52     |
|                       |                     |     |            | Total               | 46.64        | 38    | 81     |
| Colon / Rectun        | <u>1</u>            |     | <u>o</u>   | <u>vary</u>         |              |       |        |
| Male                  | 127.79              | 130 | 102        |                     |              |       |        |
| Female                | 131.08              | 132 | 101        | Female              | 35.48        | 34    | 96     |
| Total                 | 258.87              | 262 | 101        |                     |              |       |        |
| <b>Esophagus</b>      |                     |     |            | <u>ancreas</u>      |              |       |        |
| Male                  | 16.13               | 19  | 118        | Male                | 17.60        | 12    | 68     |
| Female                | 6.55                | 12  | 183        | Female              | 20.65        | 21    | 102    |
| Total                 | 22.68               | 31  | 137        | Total               | 38.25        | 33    | 86     |
| <b>Hodgkin's Dis</b>  |                     |     |            | <u>rostate</u>      |              |       |        |
| Male                  | 6.88                | 4   | NC*        | Male                | 292.62       | 265   | 91     |
| Female                | 5.97                | 7   | 117        |                     |              |       |        |
| Total                 | 12.85               | 11  | 86         |                     |              |       |        |
| Kidney and Ro         | enal Pelvis         |     |            | tomach_             |              |       |        |
| Male                  | 27.57               | 29  | 105        | Male                | 20.93        | 21    | 100    |
| Female                | 18.01               | 19  | 106        | Female              | 14.26        | 17    | 119    |
| Total                 | 45.57               | 48  | 105        | Total               | 35.20        | 38    | 108    |
| <u>Larynx</u>         |                     |     |            | <u>estis</u>        |              |       |        |
| Male                  | 17.38               | 28  | 161 #+     | Male                | 9.68         | 11    | 114    |
| Female                | 5.07                | 2   | NC*        |                     |              |       |        |
| Total                 | 22.45               | 30  | 134        |                     |              |       |        |
| <u>Leukemia</u>       |                     |     |            | <u>hyroid</u>       |              |       |        |
| Male                  | 18.70               | 14  | 75         | Male                | 4.31         | 5     | 116    |
| Female                | 15.25               | 9   | 59         | Female              | 12.47        | 11    | 88     |
| Total                 | 33.94               | 23  | 68         | Total               | 16.78        | 16    | 95     |
| <b>Liver and Intr</b> | <u>ahepatic Bil</u> |     | <u>U</u> 1 | <u>teri, Corpus</u> | s and Uterus | , NOS |        |
| Male                  | 7.81                | 7   | 90         |                     |              |       |        |
| Female                | 3.91                | 7   | 179        | Female              | 56.06        | 73    | 130 #+ |
| Total                 | 11.72               | 14  | 119        |                     |              |       |        |
| <b>Lung and Bron</b>  | <u>ichus</u>        |     | <u>A</u>   | ll Sites / Ty       |              |       |        |
| Male                  | 157.62              | 152 | 96         | Male                | 955.18       | 915   | 96     |
| Female                | 118.25              | 98  | 83         | Female              | 941.55       | 860   | 91 ~-  |
| Total                 | 275.87              | 250 | 91         | Total               | 1896.74      | 1775  | 94 ~-  |
|                       |                     |     |            |                     |              |       |        |

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the  $\mathbf{p} \le 0.05$  level
- ~ indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level
- ^ indicates statistical significance at the  $\mathbf{p} <= 0.001$  level, as well as at the  $\mathbf{p} <= 0.05$  and  $\mathbf{p} <= 0.01$  levels

#### **CHILMARK**

#### Cancer Incidence by Sex, 1990 - 1995

# **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|                        | Exp              | <u>Obs</u>    | <u>SIR</u>              |                | <b>Exp</b>  | <u>Obs</u> | <u>SIR</u> |  |  |
|------------------------|------------------|---------------|-------------------------|----------------|-------------|------------|------------|--|--|
| Bladder, Urinary       | <u>v</u>         |               | <u>M</u>                | lelanoma of S  | <u>Skin</u> |            |            |  |  |
| Male                   | 0.67             | 0             | NC*                     | Male           | 0.32        | 0          | NC*        |  |  |
| Female                 | 0.20             | 0             | NC*                     | Female         | 0.21        | 0          | NC*        |  |  |
| Total                  | 0.87             | 0             | NC*                     | Total          | 0.53        | 0          | NC*        |  |  |
| <b>Brain and Centr</b> | ral Nervous S    | <u>System</u> | <u>M</u>                | ultiple Myel   | <u>oma</u>  |            |            |  |  |
| Male                   | 0.20             | 0             | NC*                     | Male           | 0.12        | 0          | NC*        |  |  |
| Female                 | 0.17             | 1             | NC*                     | Female         | 0.09        | 0          | NC*        |  |  |
| Total                  | 0.37             | 1             | NC*                     | Total          | 0.21        | 0          | NC*        |  |  |
| <b>Breast</b>          |                  |               | Non-Hodgkin's Lymphoma  |                |             |            |            |  |  |
| Male                   | 0.04             | 0             | NC*                     | Male           | 0.46        | 0          | NC*        |  |  |
| Female                 | 3.11             | 6             | 193                     | Female         | 0.35        | 0          | NC*        |  |  |
| Total                  | 3.15             | 6             | 191                     | Total          | 0.81        | 0          | NC*        |  |  |
| Cervix Uteri           |                  |               | Oral Cavity and Pharynx |                |             |            |            |  |  |
|                        |                  |               |                         | Male           | 0.42        | 0          | NC*        |  |  |
| Female                 | 0.19             | 1             | NC*                     | Female         | 0.16        | 0          | NC*        |  |  |
|                        |                  |               |                         | Total          | 0.58        | 0          | NC*        |  |  |
| Colon / Rectum         |                  |               | <u>O</u>                | <u>vary</u>    |             |            |            |  |  |
| Male                   | 1.79             | 1             | NC*                     |                |             |            |            |  |  |
| Female                 | 1.34             | 0             | NC*                     | Female         | 0.37        | 1          | NC*        |  |  |
| Total                  | 3.13             | 1             | NC*                     |                |             |            |            |  |  |
| <b>Esophagus</b>       |                  |               | <u>Pa</u>               | ancreas        |             |            |            |  |  |
| Male                   | 0.22             | 0             | NC*                     | Male           | 0.24        | 0          | NC*        |  |  |
| Female                 | 0.07             | 0             | NC*                     | Female         | 0.21        | 0          | NC*        |  |  |
| Total                  | 0.29             | 0             | NC*                     | Total          | 0.45        | 0          | NC*        |  |  |
| <b>Hodgkin's Dise</b>  | <u>ase</u>       |               | <u>P1</u>               | <u>rostate</u> |             |            |            |  |  |
| Male                   | 0.08             | 0             | NC*                     | Male           | 4.00        | 4          | NC*        |  |  |
| Female                 | 0.06             | 0             | NC*                     |                |             |            |            |  |  |
| Total                  | 0.14             | 0             | NC*                     |                |             |            |            |  |  |
| Kidney and Ren         | <u>al Pelvis</u> |               | <u>St</u>               | <u>omach</u>   |             |            |            |  |  |
| Male                   | 0.37             | 0             | NC*                     | Male           | 0.29        | 0          | NC*        |  |  |

| Female                 | 0.19                   | 0           | NC*        | Female              | 0.15        | 0    | NC* |
|------------------------|------------------------|-------------|------------|---------------------|-------------|------|-----|
| Total                  | 0.56                   | 0           | NC*        | Total               | 0.44        | 0    | NC* |
| <u>Larynx</u>          |                        |             | <u>T</u>   | <u>estis</u>        |             |      |     |
| Male                   | 0.23                   | 0           | NC*        | Male                | 0.11        | 0    | NC* |
| Female                 | 0.05                   | 0           | NC*        |                     |             |      |     |
| Total                  | 0.29                   | 0           | NC*        |                     |             |      |     |
| <u>Leukemia</u>        |                        |             | <u>T</u>   | <u>nyroid</u>       |             |      |     |
| Male                   | 0.25                   | 2           | NC*        | Male                | 0.05        | 0    | NC* |
| Female                 | 0.16                   | 0           | NC*        | Female              | 0.13        | 0    | NC* |
| Total                  | 0.41                   | 2           | NC*        | Total               | 0.19        | 0    | NC* |
| <b>Liver and Intra</b> | <u>thepatic Bile D</u> | <u>ucts</u> | <u>U</u> 1 | <u>teri, Corpus</u> | and Uterus, | NOS_ |     |
| Male                   | 0.11                   | 0           | NC*        |                     |             |      |     |
| Female                 | 0.04                   | 0           | NC*        | Female              | 0.59        | 1    | NC* |
| Total                  | 0.15                   | 0           | NC*        |                     |             |      |     |
| <b>Lung and Bron</b>   | <u>chus</u>            |             | <u>A</u> ] | ll Sites / Typ      | <u>oes</u>  |      |     |
| Male                   | 2.14                   | 2           | NC*        | Male                | 13.03       | 9    | 69  |
| Female                 | 1.21                   | 0           | NC*        | Female              | 9.77        | 11   | 113 |
| Total                  | 3.36                   | 2           | NC*        | Total               | 22.79       | 20   | 88  |
|                        |                        |             |            |                     |             |      |     |

SIR = standardized incidence ratio [ (Obs / Exp) X 100]

#### **CLARKSBURG**

## Cancer Incidence by Sex, 1990 - 1995

#### **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|                       | $\mathbf{\underline{Exp}}$ | <u>Obs</u>       | <u>SIR</u> |        | <b>Exp</b> | <u>Obs</u> | <u>SIR</u> |  |  |  |
|-----------------------|----------------------------|------------------|------------|--------|------------|------------|------------|--|--|--|
| Bladder, Urinar       | <u>v</u>                   | Melanoma of Skin |            |        |            |            |            |  |  |  |
| Male                  | 1.62                       | 0                | NC*        | Male   | 0.81       | 0          | NC*        |  |  |  |
| Female                | 0.54                       | 0                | NC*        | Female | 0.59       | 0          | NC*        |  |  |  |
| Total                 | 2.16                       | 0                | NC*        | Total  | 1.40       | 0          | NC*        |  |  |  |
| <b>Brain and Cent</b> | ral Nervous S              | <u>System</u>    |            |        |            |            |            |  |  |  |
| Male                  | 0.52                       | 1                | NC*        | Male   | 0.30       | 0          | NC*        |  |  |  |

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} \le 0.05$  level

<sup>~</sup> indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

| Female                 | 0.46              | 0            | NC*        | Female         | 0.24              | 0        | NC* |
|------------------------|-------------------|--------------|------------|----------------|-------------------|----------|-----|
| Total                  | 0.98              | 1            | NC*        | Total          | 0.54              | 0        | NC* |
| <b>Breast</b>          |                   |              | No         | on-Hodgkin'    | s Lymphoma        | <u>L</u> |     |
| Male                   | 0.09              | 0            | NC*        | Male           | 1.15              | 0        | NC* |
| Female                 | 8.62              | 6            | 70         | Female         | 0.95              | 0        | NC* |
| Total                  | 8.71              | 6            | 69         | Total          | 2.10              | 0        | NC* |
| Cervix Uteri           |                   |              | <u>O</u> : | ral Cavity aı  | <u>nd Pharynx</u> |          |     |
|                        |                   |              |            | Male           | 1.11              | 0        | NC* |
| Female                 | 0.52              | 0            | NC*        | Female         | 0.44              | 1        | NC* |
|                        |                   |              |            | Total          | 1.54              | 1        | NC* |
| Colon / Rectum         | _                 |              | <u>O</u>   | <u>vary</u>    |                   |          |     |
| Male                   | 4.31              | 3            | NC*        |                |                   |          |     |
| Female                 | 3.59              | 5            | 139        | Female         | 1.04              | 2        | NC* |
| Total                  | 7.90              | 8            | 101        |                |                   |          |     |
| <b>Esophagus</b>       |                   |              | <u>Pa</u>  | ancreas        |                   |          |     |
| Male                   | 0.56              | 0            | NC*        | Male           | 0.60              | 1        | NC* |
| Female                 | 0.18              | 0            | NC*        | Female         | 0.57              | 0        | NC* |
| Total                  | 0.74              | 0            | NC*        | Total          | 1.16              | 1        | NC* |
| <b>Hodgkin's Dise</b>  | ease_             |              | <u>P</u> 1 | <u>rostate</u> |                   |          |     |
| Male                   | 0.21              | 1            | NC*        | Male           | 9.66              | 5        | 52  |
| Female                 | 0.16              | 0            | NC*        |                |                   |          |     |
| Total                  | 0.37              | 1            | NC*        |                |                   |          |     |
| Kidney and Re          | <u>nal Pelvis</u> |              | <u>St</u>  | <u>omach</u>   |                   |          |     |
| Male                   | 0.95              | 2            | NC*        | Male           | 0.71              | 1        | NC* |
| Female                 | 0.51              | 0            | NC*        | Female         | 0.39              | 1        | NC* |
| Total                  | 1.46              | 2            | NC*        | Total          | 1.10              | 2        | NC* |
| <u>Larynx</u>          |                   |              | <u>T</u>   | <u>estis</u>   |                   |          |     |
| Male                   | 0.61              | 0            | NC*        | Male           | 0.27              | 0        | NC* |
| Female                 | 0.15              | 0            | NC*        |                |                   |          |     |
| Total                  | 0.76              | 0            | NC*        |                |                   |          |     |
| <u>Leukemia</u>        |                   |              | <u>T</u> ] | <u>nyroid</u>  |                   |          |     |
| Male                   | 0.62              | 1            | NC*        | Male           | 0.14              | 0        | NC* |
| Female                 | 0.43              | 0            | NC*        | Female         | 0.36              | 1        | NC* |
| Total                  | 1.05              | 1            | NC*        | Total          | 0.50              | 1        | NC* |
| <b>Liver and Intra</b> | hepatic Bile I    | <u>Oucts</u> | <u>U</u> 1 | teri, Corpus   | and Uterus,       | NOS_     |     |
| Male                   | 0.27              | 0            | NC*        |                |                   |          |     |
| Female                 | 0.11              | 0            | NC*        | Female         | 1.63              | 3        | NC* |
| Total                  | 0.37              | 0            | NC*        |                |                   |          |     |
| <b>Lung and Brone</b>  | <u>chus</u>       |              | <u>A</u> ] | ll Sites / Typ | <u>oes</u>        |          |     |
| Male                   | 5.38              | 6            | 112        | Male           | 32.07             | 23       | 72  |
| Female                 | 3.33              | 5            | 150        | Female         | 26.73             | 25       | 94  |
| Total                  | 8.72              | 11           | 126        | Total          | 58.81             | 48       | 82  |
|                        |                   |              |            |                |                   |          |     |

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

- \* = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the  $\mathbf{p} \le 0.05$  level
- $\sim$  indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level
- ^ indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

#### **CLINTON**

#### Cancer Incidence by Sex, 1990 - 1995

#### **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|                       | $\mathbf{Exp}$ | <u>Obs</u>    | <u>SIR</u>              |                     | $\mathbf{Exp}$ | <u>Obs</u> | <u>SIR</u> |  |
|-----------------------|----------------|---------------|-------------------------|---------------------|----------------|------------|------------|--|
| Bladder, Urinar       | <u>v</u>       |               | <u>M</u>                | elanoma of          | <u>Skin</u>    |            |            |  |
| Male                  | 9.71           | 4             | NC*                     | Male                | 5.11           | 3          | NC*        |  |
| Female                | 4.00           | 6             | 150                     | Female              | 4.57           | 1          | NC*        |  |
| Total                 | 13.71          | 10            | 73                      | Total               | 9.68           | 4          | NC*        |  |
| <b>Brain and Cent</b> | ral Nervous S  | <u>System</u> | M                       | <u>lultiple Mye</u> | <u>loma</u>    |            |            |  |
| Male                  | 3.44           | 3             | NC*                     | Male                | 1.75           | 3          | NC*        |  |
| Female                | 3.51           | 3             | NC*                     | Female              | 1.79           | 4          | NC*        |  |
| Total                 | 6.95           | 6             | 86                      | Total               | 3.54           | 7          | 198        |  |
| <b>Breast</b>         |                |               | No                      | <u>on-Hodgkin'</u>  | s Lymphoma     | <u>ı</u>   |            |  |
| Male                  | 0.52           | 1             | NC*                     | Male                | 7.44           | 9          | 121        |  |
| Female                | 63.75          | 60            | 94                      | Female              | 7.20           | 4          | NC*        |  |
| Total                 | 64.27          | 61            | 95                      | Total               | 14.63          | 13         | 89         |  |
| <u>Cervix Uteri</u>   |                |               | Oral Cavity and Pharynx |                     |                |            |            |  |
|                       |                |               |                         | Male                | 6.58           | 6          | 91         |  |
| Female                | 4.22           | 5             | 119                     | Female              | 3.23           | 5          | 155        |  |
|                       |                |               |                         | Total               | 9.81           | 11         | 112        |  |
| Colon / Rectum        | •              |               | <u>O</u>                | <u>vary</u>         |                |            |            |  |
| Male                  | 25.79          | 24            | 93                      |                     |                |            |            |  |
| Female                | 26.82          | 26            | 97                      | Female              | 7.75           | 6          | 77         |  |
| Total                 | 52.61          | 50            | 95                      |                     |                |            |            |  |
| <b>Esophagus</b>      |                |               | <u>Pa</u>               | ancreas             |                |            |            |  |
| Male                  | 3.29           | 5             | 152                     | Male                | 3.57           | 2          | NC*        |  |
| Female                | 1.33           | 2             | NC*                     | Female              | 4.23           | 3          | NC*        |  |
| Total                 | 4.62           | 7             | 152                     | Total               | 7.81           | 5          | 64         |  |
| <b>Hodgkin's Dise</b> | ease_          |               | <u>P</u> 1              | <u>rostate</u>      |                |            |            |  |

| Male                   | 1.69           | 0            | NC*        | Male          | 57.82       | 46  | 80  |
|------------------------|----------------|--------------|------------|---------------|-------------|-----|-----|
| Female                 | 1.45           | 2            | NC*        |               |             |     |     |
| Total                  | 3.14           | 2            | NC*        |               |             |     |     |
| Kidney and Re          | nal Pelvis     |              | <u>St</u>  | <u>omach</u>  |             |     |     |
| Male                   | 5.69           | 5            | 88         | Male          | 4.27        | 9   | 211 |
| Female                 | 3.80           | 4            | NC*        | Female        | 2.93        | 1   | NC* |
| Total                  | 9.48           | 9            | 95         | Total         | 7.20        | 10  | 139 |
| <u>Larynx</u>          |                |              | <u>T</u>   | <u>estis</u>  |             |     |     |
| Male                   | 3.55           | 2            | NC*        | Male          | 2.59        | 4   | NC* |
| Female                 | 1.07           | 0            | NC*        |               |             |     |     |
| Total                  | 4.62           | 2            | NC*        |               |             |     |     |
| <b>Leukemia</b>        |                |              | <u>Tl</u>  | <u>hyroid</u> |             |     |     |
| Male                   | 3.96           | 2            | NC*        | Male          | 1.01        | 0   | NC* |
| Female                 | 3.30           | 6            | 182        | Female        | 2.97        | 4   | NC* |
| Total                  | 7.26           | 8            | 110        | Total         | 3.98        | 4   | NC* |
| <b>Liver and Intra</b> | hepatic Bile I | <u>Ducts</u> | <u>U1</u>  | teri, Corpus  | and Uterus, | NOS |     |
| Male                   | 1.60           | 0            | NC*        | _             |             |     |     |
| Female                 | 0.81           | 1            | NC*        | Female        | 11.89       | 14  | 118 |
| Total                  | 2.42           | 1            | NC*        |               |             |     |     |
| <b>Lung and Bron</b>   | chus_          |              | <u>A</u> l | ll Sites / Ty | pes         |     |     |
| Male                   | 31.72          | 35           | 110        | Male          | 195.00      | 182 | 93  |
| Female                 | 24.67          | 18           | 73         | Female        | 199.99      | 189 | 95  |
| Total                  | 56.39          | 53           | 94         | Total         | 394.99      | 371 | 94  |
|                        |                |              |            |               |             |     |     |

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

#### **COHASSET**

Cancer Incidence by Sex, 1990 - 1995

**Expected and Observed Case Counts, with Standardized Incidence Ratios** 

Exp Obs SIR Exp Obs SIR

Bladder, Urinary Melanoma of Skin

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} \le 0.05$  level

<sup>~</sup> indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

| Male                     | 5.62            | 4             | NC*          | Male                | 3.00        | 6        | 200    |  |
|--------------------------|-----------------|---------------|--------------|---------------------|-------------|----------|--------|--|
| Female                   | 2.27            | 1             | NC*          | Female              | 2.50        | 8        | 320 ~+ |  |
| Total                    | 7.90            | 5             | 63           | Total               | 5.50        | 14       | 254 ~+ |  |
| <b>Brain and Cent</b>    | tral Nervous S  | <u>System</u> | $\mathbf{M}$ | <u>lultiple Mye</u> | <u>loma</u> |          |        |  |
| Male                     | 1.99            | 2             | NC*          | Male                | 1.03        | 2        | NC*    |  |
| Female                   | 1.93            | 0             | NC*          | Female              | 1.02        | 0        | NC*    |  |
| Total                    | 3.92            | 2             | NC*          | Total               | 2.05        | 2        | NC*    |  |
| <b>Breast</b>            |                 |               | <u>N</u>     | on-Hodgkin          | 's Lymphoma | <u>1</u> |        |  |
| Male                     | 0.31            | 1             | NC*          | Male                | 4.20        | 3        | NC*    |  |
| Female                   | 36.46           | 36            | 99           | Female              | 4.01        | 4        | NC*    |  |
| Total                    | 36.77           | 37            | 101          | Total               | 8.21        | 7        | 85     |  |
| Cervix Uteri             |                 |               | <u>o</u>     | ral Cavity a        | nd Pharynx  |          |        |  |
|                          |                 |               |              | Male                | 4.17        | 0        | NC*    |  |
| Female                   | 2.21            | 3             | NC*          | Female              | 1.85        | 1        | NC*    |  |
|                          |                 |               |              | Total               | 6.03        | 1        | NC*    |  |
| Colon / Rectum           | <u>L</u>        |               | <u>O</u>     | <u>vary</u>         |             |          |        |  |
| Male                     | 14.97           | 15            | 100          |                     |             |          |        |  |
| Female                   | 15.15           | 11            | 73           | Female              | 4.38        | 5        | 114    |  |
| Total                    | 30.12           | 26            | 86           |                     |             |          |        |  |
| <b>Esophagus</b>         | <u>Pancreas</u> |               |              |                     |             |          |        |  |
| Male                     | 2.06            | 0             | NC*          | Male                | 2.14        | 2        | NC*    |  |
| Female                   | 0.75            | 0             | NC*          | Female              | 2.40        | 1        | NC*    |  |
| Total                    | 2.81            | 0             | NC*          | Total               | 4.54        | 3        | NC*    |  |
| Hodgkin's Disc           | <u>ease</u>     |               | <u>P</u> 1   | <u>rostate</u>      |             |          |        |  |
| Male                     | 0.83            | 2             | NC*          | Male                | 33.75       | 46       | 136    |  |
| Female                   | 0.69            | 1             | NC*          |                     |             |          |        |  |
| Total                    | 1.52            | 3             | NC*          |                     |             |          |        |  |
| Kidney and Re            | enal Pelvis     |               | St           | <u>omach</u>        |             |          |        |  |
| Male                     | 3.50            | 0             | NC*          | Male                | 2.47        | 3        | NC*    |  |
| Female                   | 2.15            | 4             | NC*          | Female              | 1.65        | 1        | NC*    |  |
| Total                    | 5.65            | 4             | NC*          | Total               | 4.12        | 4        | NC*    |  |
| <u>Larynx</u>            |                 |               | $\mathbf{T}$ | <u>estis</u>        |             |          |        |  |
| Male                     | 2.27            | 1             | NC*          | Male                | 1.13        | 2        | NC*    |  |
| Female                   | 0.63            | 0             | NC*          |                     |             |          |        |  |
| Total                    | 2.90            | 1             | NC*          |                     |             |          |        |  |
| <u>Leukemia</u>          |                 |               | <u>T</u>     | <u>hyroid</u>       |             |          |        |  |
| Male                     | 2.27            | 3             | NC*          | Male                | 0.55        | 0        | NC*    |  |
| Female                   | 1.80            | 0             | NC*          | Female              | 1.51        | 4        | NC*    |  |
| Total                    | 4.07            | 3             | NC*          | Total               | 2.06        | 4        | NC*    |  |
| Liver and Intra          | <u>-</u>        |               | · ·          | <u>teri, Corpus</u> | and Uterus, | NOS_     |        |  |
| Male                     | 0.97            | 1             | NC*          |                     |             |          |        |  |
| Female                   | 0.45            | 0             | NC*          | Female              | 6.92        | 5        | 72     |  |
| Total                    | 1.42            | 1             | NC*          |                     |             |          |        |  |
| <b>Lung and Bronchus</b> |                 |               | <u>A</u>     | ll Sites / Typ      | <u>pes</u>  |          |        |  |

| Male   | 19.39 | 14 | 72 | Male   | 114.52 | 112 | 98 |
|--------|-------|----|----|--------|--------|-----|----|
| Female | 14.13 | 10 | 71 | Female | 113.12 | 102 | 90 |
| Total  | 33.52 | 24 | 72 | Total  | 227.65 | 214 | 94 |

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

#### **COLRAIN**

#### Cancer Incidence by Sex, 1990 - 1995

#### **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|                          | <b>Exp</b> | <u>Obs</u>                | SIR                      |                     | <b>Exp</b>  | <u>Obs</u> | SIR |  |
|--------------------------|------------|---------------------------|--------------------------|---------------------|-------------|------------|-----|--|
| Bladder, Urinary         |            |                           | $\underline{\mathbf{N}}$ | <u>lelanoma of </u> | <u>Skin</u> |            |     |  |
| Male                     | 1.17       | 1                         | NC*                      | Male                | 0.63        | 1          | NC* |  |
| Female                   | 0.38       | 0                         | NC*                      | Female              | 0.48        | 0          | NC* |  |
| Total                    | 1.55       | 1                         | NC*                      | Total               | 1.11        | 1          | NC* |  |
| <b>Brain and Central</b> | l Nervou   | s System Multiple Myeloma |                          |                     |             |            |     |  |
| Male                     | 0.44       | 0                         | NC*                      | Male                | 0.21        | 0          | NC* |  |
| Female                   | 0.37       | 0                         | NC*                      | Female              | 0.17        | 0          | NC* |  |
| Total                    | 0.81       | 0                         | NC*                      | Total               | 0.39        | 0          | NC* |  |
| <b>Breast</b>            |            | Non-Hodgkin's Lymphoma    |                          |                     |             |            |     |  |
| Male                     | 0.06       | 0                         | NC*                      | Male                | 0.92        | 0          | NC* |  |
| Female                   | 6.58       | 7                         | 106                      | Female              | 0.71        | 2          | NC* |  |
| Total                    | 6.64       | 7                         | 105                      | Total               | 1.62        | 2          | NC* |  |
| Cervix Uteri             |            |                           | <u>O</u>                 | ral Cavity ar       | nd Pharynx  |            |     |  |
|                          |            |                           |                          | Male                | 0.83        | 1          | NC* |  |
| Female                   | 0.46       | 1                         | NC*                      | Female              | 0.33        | 1          | NC* |  |
|                          |            |                           |                          | Total               | 1.16        | 2          | NC* |  |
| Colon / Rectum           |            |                           | <u>O</u>                 | <u>vary</u>         |             |            |     |  |
| Male                     | 3.12       | 8                         | 257 #+                   |                     |             |            |     |  |
| Female                   | 2.52       | 4                         | NC*                      | Female              | 0.81        | 0          | NC* |  |
| Total                    | 5.63       | 12                        | 213 #+                   |                     |             |            |     |  |
| <b>Esophagus</b>         |            |                           | <u>P</u> :               | ancreas             |             |            |     |  |

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} <= 0.05$  level

 $<sup>\</sup>sim$  indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

| Male                   | 0.41            | 0            | NC*             | Male           | 0.44        | 2   | NC* |  |
|------------------------|-----------------|--------------|-----------------|----------------|-------------|-----|-----|--|
| Female                 | 0.13            | 0            | NC*             | Female         | 0.40        | 0   | NC* |  |
| Total                  | 0.54            | 0            | NC*             | Total          | 0.84        | 2   | NC* |  |
| <b>Hodgkin's Dis</b>   | <u>ease</u>     |              | <b>Prostate</b> |                |             |     |     |  |
| Male                   | 0.21            | 0            | NC*             | Male           | 6.96        | 8   | 115 |  |
| Female                 | 0.16            | 0            | NC*             |                |             |     |     |  |
| Total                  | 0.37            | 0            | NC*             |                |             |     |     |  |
| Kidney and Re          | enal Pelvis     |              | St              | <u>omach</u>   |             |     |     |  |
| Male                   | 0.71            | 2            | NC*             | Male           | 0.52        | 1   | NC* |  |
| Female                 | 0.38            | 1            | NC*             | Female         | 0.27        | 0   | NC* |  |
| Total                  | 1.10            | 3            | NC*             | Total          | 0.79        | 1   | NC* |  |
| <u>Larynx</u>          |                 |              | <u>T</u>        | <u>estis</u>   |             |     |     |  |
| Male                   | 0.45            | 0            | NC*             | Male           | 0.31        | 0   | NC* |  |
| Female                 | 0.11            | 1            | NC*             |                |             |     |     |  |
| Total                  | 0.56            | 1            | NC*             |                |             |     |     |  |
| <b>Leukemia</b>        |                 |              | <u>T</u>        | <u>hyroid</u>  |             |     |     |  |
| Male                   | 0.50            | 0            | NC*             | Male           | 0.13        | 0   | NC* |  |
| Female                 | 0.34            | 0            | NC*             | Female         | 0.32        | 1   | NC* |  |
| Total                  | 0.84            | 0            | NC*             | Total          | 0.45        | 1   | NC* |  |
| <b>Liver and Intra</b> | ahepatic Bile D | <u>Oucts</u> | <u>U</u> 1      | teri, Corpus   | and Uterus, | NOS |     |  |
| Male                   | 0.20            | 0            | NC*             |                |             |     |     |  |
| Female                 | 0.08            | 0            | NC*             | Female         | 1.23        | 2   | NC* |  |
| Total                  | 0.28            | 0            | NC*             |                |             |     |     |  |
| <b>Lung and Bron</b>   | <u>ichus</u>    |              | <u>A</u> ]      | ll Sites / Typ | <u>oes</u>  |     |     |  |
| Male                   | 3.92            | 4            | NC*             | Male           | 23.86       | 30  | 126 |  |
| Female                 | 2.46            | 3            | NC*             | Female         | 20.14       | 25  | 124 |  |
| Total                  | 6.38            | 7            | 110             | Total          | 44.00       | 55  | 125 |  |
|                        |                 |              |                 |                |             |     |     |  |

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

#### **CONCORD**

Cancer Incidence by Sex, 1990 - 1995

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} <= 0.05$  level

<sup>~</sup> indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

# **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|                      | Exp           | <u>Obs</u>    | SIR                      |                     | Exp         | <u>Obs</u> | SIR    |
|----------------------|---------------|---------------|--------------------------|---------------------|-------------|------------|--------|
| Bladder, Urina       | ary           |               | $\underline{\mathbf{M}}$ | <u>lelanoma of</u>  | <u>Skin</u> |            |        |
| Male                 | 15.48         | 8             | 52                       | Male                | 8.30        | 12         | 145    |
| Female               | 5.34          | 2             | NC*                      | Female              | 5.84        | 14         | 240 ~+ |
| Total                | 20.82         | 10            | 48 #-                    | Total               | 14.15       | 26         | 184 ~+ |
| <b>Brain and Cer</b> | ntral Nervous | <u>System</u> | <u>M</u>                 | <u>lultiple Mye</u> | <u>loma</u> |            |        |
| Male                 | 5.39          | 6             | 111                      | Male                | 2.80        | 5          | 178    |
| Female               | 4.47          | 6             | 134                      | Female              | 2.39        | 1          | NC*    |
| Total                | 9.85          | 12            | 122                      | Total               | 5.19        | 6          | 116    |
| <b>Breast</b>        |               |               | No                       | on-Hodgkin          | s Lymphom   | <u>a</u>   |        |
| Male                 | 0.84          | 2             | NC*                      | Male                | 11.71       | 11         | 94     |
| Female               | 85.57         | 97            | 113                      | Female              | 9.34        | 6          | 64     |
| Total                | 86.40         | 99            | 115                      | Total               | 21.05       | 17         | 81     |
| <u>Cervix Uteri</u>  |               |               | <u>O</u> :               | ral Cavity a        | nd Pharynx  |            |        |
|                      |               |               |                          | Male                | 11.13       | 8          | 72     |
| Female               | 5.10          | 3             | NC*                      | Female              | 4.36        | 3          | NC*    |
|                      |               |               |                          | Total               | 15.49       | 11         | 71     |
| Colon / Rectur       | <u>n</u>      |               | <u>O</u>                 | <u>vary</u>         |             |            |        |
| Male                 | 40.97         | 22            | 54 ~-                    |                     |             |            |        |
| Female               | 35.54         | 29            | 82                       | Female              | 10.25       | 12         | 117    |
| Total                | 76.51         | 51            | 67 ~-                    |                     |             |            |        |
| <b>Esophagus</b>     |               |               | <u>Pa</u>                | ancreas             |             |            |        |
| Male                 | 5.47          | 1             | NC*                      | Male                | 5.76        | 7          | 122    |
| Female               | 1.77          | 3             | NC*                      | Female              | 5.58        | 7          | 125    |
| Total                | 7.24          | 4             | NC*                      | Total               | 11.34       | 14         | 123    |
| Hodgkin's Dis        | <u>sease</u>  |               | <u>P</u> 1               | <u>rostate</u>      |             |            |        |
| Male                 | 2.44          | 4             | NC*                      | Male                | 89.82       | 78         | 87     |
| Female               | 1.55          | 2             | NC*                      |                     |             |            |        |
| Total                | 3.99          | 6             | 150                      |                     |             |            |        |
| Kidney and R         | enal Pelvis   |               | <u>St</u>                | omach_              |             |            |        |
| Male                 | 9.27          | 8             | 86                       | Male                | 6.86        | 3          | NC*    |
| Female               | 4.99          | 4             | NC*                      | Female              | 3.91        | 5          | 128    |
| Total                | 14.25         | 12            | 84                       | Total               | 10.77       | 8          | 74     |
| <u>Larynx</u>        |               |               | <u>T</u>                 | <u>estis</u>        |             |            |        |
| Male                 | 5.97          | 4             | NC*                      | Male                | 3.65        | 4          | NC*    |
| Female               | 1.49          | 1             | NC*                      |                     |             |            |        |
| Total                | 7.46          | 5             | 67                       |                     |             |            |        |
| <u>Leukemia</u>      |               |               | <u>T</u>                 | <u>hyroid</u>       |             |            |        |
| Male                 | 6.13          | 5             | 82                       | Male                | 1.57        | 3          | NC*    |
| Female               | 4.20          | 9             | 215                      | Female              | 3.47        | 9          | 259 #+ |
| Total                | 10.32         | 14            | 136                      | Total               | 5.05        | 12         | 238 #+ |

| <b>Liver and Intrahepatic Bile Ducts</b> |              |                   | <u>U</u> 1 | <u>Uteri, Corpus and Uterus, NOS</u> |        |     |       |  |
|--|--------------|-------------------|------------|--------------------------------------|--------|-----|-------|--|
| Male                                     | 2.58         | 3                 | NC*        |                                      |        |     |       |  |
| Female                                   | 1.06         | 1                 | NC*        | Female                               | 16.22  | 13  | 80    |  |
| Total                                    | 3.64         | 4                 | NC*        |                                      |        |     |       |  |
| <b>Lung and Bro</b>                      | <u>nchus</u> | All Sites / Types |            |                                      |        |     |       |  |
| Male                                     | 51.13        | 24                | 47 ^-      | Male                                 | 309.08 | 226 | 73 ^- |  |
| Female                                   | 32.58        | 13                | 40 ^-      | Female                               | 264.36 | 260 | 98    |  |
| Total                                    | 83.72        | 37                | 44 ^-      | Total                                | 573.44 | 486 | 85 ^- |  |

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

#### **CONWAY**

#### Cancer Incidence by Sex, 1990 - 1995

#### **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|                       | <b>Exp</b>    | <u>Obs</u>    | <u>SIR</u>              |              | $\mathbf{Exp}$      | <u>Obs</u> | <b>SIR</b> |  |
|-----------------------|---------------|---------------|-------------------------|--------------|---------------------|------------|------------|--|
| Bladder, Urinar       | <u>y</u>      |               | <u>M</u>                | elanoma of S | <u>Skin</u>         |            |            |  |
| Male                  | 1.03          | 0             | NC*                     | Male         | 0.60                | 0          | NC*        |  |
| Female                | 0.34          | 0             | NC*                     | Female       | 0.45                | 0          | NC*        |  |
| Total                 | 1.36          | 0             | NC*                     | Total        | 1.05                | 0          | NC*        |  |
| <b>Brain and Cent</b> | ral Nervous S | <u>system</u> | <u>M</u>                | ultiple Myel | <u>iple Myeloma</u> |            |            |  |
| Male                  | 0.41          | 1             | NC*                     | Male         | 0.19                | 1          | NC*        |  |
| Female                | 0.34          | 0             | NC*                     | Female       | 0.15                | 0          | NC*        |  |
| Total                 | 0.76          | 1             | NC*                     | Total        | 0.34                | 1          | NC*        |  |
| <b>Breast</b>         |               |               | No                      | on-Hodgkin's | s Lymphoma          | <u>a</u>   |            |  |
| Male                  | 0.06          | 0             | NC*                     | Male         | 0.84                | 1          | NC*        |  |
| Female                | 6.01          | 3             | NC*                     | Female       | 0.64                | 0          | NC*        |  |
| Total                 | 6.07          | 3             | NC*                     | Total        | 1.48                | 1          | NC*        |  |
| Cervix Uteri          |               |               | Oral Cavity and Pharynx |              |                     |            |            |  |
|                       |               |               |                         | Male         | 0.80                | 2          | NC*        |  |
| Female                | 0.44          | 0             | NC*                     | Female       | 0.30                | 1          | NC*        |  |
|                       |               |               |                         | Total        | 1.10                | 3          | NC*        |  |

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} <= 0.05$  level

<sup>~</sup> indicates statistical significance at the  $p \le 0.01$  level, as well as at the  $p \le 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

| Colon / Rectur   | <u>n</u>               |               | <u>O</u>  | <u>vary</u>         |             |      |     |
|------------------|------------------------|---------------|-----------|---------------------|-------------|------|-----|
| Male             | 2.73                   | 1             | NC*       |                     |             |      |     |
| Female           | 2.21                   | 4             | NC*       | Female              | 0.75        | 0    | NC* |
| Total            | 4.93                   | 5             | 101       |                     |             |      |     |
| <b>Esophagus</b> |                        |               | <u>Pa</u> | ncreas              |             |      |     |
| Male             | 0.38                   | 0             | NC*       | Male                | 0.39        | 0    | NC* |
| Female           | 0.11                   | 0             | NC*       | Female              | 0.35        | 0    | NC* |
| Total            | 0.49                   | 0             | NC*       | Total               | 0.74        | 0    | NC* |
| Hodgkin's Dis    | <u>sease</u>           |               | <u>Pr</u> | <u>ostate</u>       |             |      |     |
| Male             | 0.20                   | 0             | NC*       | Male                | 5.87        | 5    | 85  |
| Female           | 0.16                   | 1             | NC*       |                     |             |      |     |
| Total            | 0.36                   | 1             | NC*       |                     |             |      |     |
| Kidney and R     | <u>enal Pelvis</u>     |               |           | <u>omach</u>        |             |      |     |
| Male             | 0.66                   | 1             | NC*       | Male                | 0.46        | 0    | NC* |
| Female           | 0.34                   | 0             | NC*       | Female              | 0.24        | 0    | NC* |
| Total            | 1.00                   | 1             | NC*       | Total               | 0.70        | 0    | NC* |
| <u>Larynx</u>    |                        |               | <u>Te</u> | <u>estis</u>        |             |      |     |
| Male             | 0.42                   | 0             | NC*       | Male                | 0.30        | 0    | NC* |
| Female           | 0.10                   | 0             | NC*       |                     |             |      |     |
| Total            | 0.52                   | 0             | NC*       |                     |             |      |     |
| <u>Leukemia</u>  |                        |               | <u>Tł</u> | <u>iyroid</u>       |             |      |     |
| Male             | 0.45                   | 1             | NC*       | Male                | 0.12        | 0    | NC* |
| Female           | 0.31                   | 0             | NC*       | Female              | 0.32        | 0    | NC* |
| Total            | 0.77                   | 1             | NC*       | Total               | 0.44        | 0    | NC* |
|                  | <u>ahepatic Bile D</u> | ucts          |           | <u>teri, Corpus</u> | and Uterus, | NOS_ |     |
| Male             | 0.18                   | 0             | NC*       |                     |             |      |     |
| Female           | 0.07                   | 0             | NC*       | Female              | 1.10        | 2    | NC* |
| Total            | 0.25                   | 0             | NC*       |                     |             |      |     |
| Lung and Bro     |                        | l Sites / Typ |           |                     |             |      |     |
| Male             | 3.49                   | 4             | NC*       | Male                | 21.14       | 17   | 80  |
| Female           | 2.15                   | 0             | NC*       | Female              | 18.18       | 13   | 72  |
| Total            | 5.65                   | 4             | NC*       | Total               | 39.32       | 30   | 76  |

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} <= 0.05$  level

<sup>~</sup> indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

# **CUMMINGTON**

# Cancer Incidence by Sex, 1990 - 1995

# **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|                          | <u>Exp</u> | <u>Obs</u>    | <u>SIR</u>               |                       | Exp              | <u>Obs</u> | <u>SIR</u> |  |  |  |
|--------------------------|------------|---------------|--------------------------|-----------------------|------------------|------------|------------|--|--|--|
| <b>Bladder, Urinary</b>  |            |               | $\underline{\mathbf{M}}$ | <u> lelanoma of S</u> | <u>Skin</u>      |            |            |  |  |  |
| Male                     | 0.61       | 0             | NC*                      | Male                  | 0.32             | 1          | NC*        |  |  |  |
| Female                   | 0.19       | 1             | NC*                      | Female                | 0.23             | 1          | NC*        |  |  |  |
| Total                    | 0.80       | 1             | NC*                      | Total                 | 0.55             | 2          | NC*        |  |  |  |
| <b>Brain and Central</b> | l Nervous  | <u>System</u> | $\underline{\mathbf{M}}$ | <u> Iultiple Myel</u> | <u>oma</u>       |            |            |  |  |  |
| Male                     | 0.22       | 0             | NC*                      | Male                  | 0.11             | 0          | NC*        |  |  |  |
| Female                   | 0.17       | 1             | NC*                      | Female                | 0.08             | 0          | NC*        |  |  |  |
| Total                    | 0.39       | 1             | NC*                      | Total                 | 0.19             | 0          | NC*        |  |  |  |
| <b>Breast</b>            |            |               | <u>N</u>                 | on-Hodgkin's          | <u> Lymphoma</u> | <u>l</u>   |            |  |  |  |
| Male                     | 0.03       | 0             | NC*                      | Male                  | 0.46             | 0          | NC*        |  |  |  |
| Female                   | 3.10       | 2             | NC*                      | Female                | 0.35             | 0          | NC*        |  |  |  |
| Total                    | 3.13       | 2             | NC*                      | Total                 | 0.81             | 0          | NC*        |  |  |  |
| Cervix Uteri             |            |               | Oral Cavity and Pharynx  |                       |                  |            |            |  |  |  |
|                          |            |               |                          | Male                  | 0.42             | 0          | NC*        |  |  |  |
| Female                   | 0.22       | 0             | NC*                      | Female                | 0.16             | 0          | NC*        |  |  |  |
|                          |            |               |                          | Total                 | 0.58             | 0          | NC*        |  |  |  |
| Colon / Rectum           |            |               | <u>o</u>                 | <u>vary</u>           |                  |            |            |  |  |  |
| Male                     | 1.62       | 3             | NC*                      |                       |                  |            |            |  |  |  |
| Female                   | 1.26       | 2             | NC*                      | Female                | 0.38             | 0          | NC*        |  |  |  |
| Total                    | 2.88       | 5             | 173                      |                       |                  |            |            |  |  |  |
| <b>Esophagus</b>         |            |               | <u>P</u> :               | <u>ancreas</u>        |                  |            |            |  |  |  |
| Male                     | 0.21       | 0             | NC*                      | Male                  | 0.23             | 0          | NC*        |  |  |  |
| Female                   | 0.06       | 0             | NC*                      | Female                | 0.20             | 0          | NC*        |  |  |  |
| Total                    | 0.27       | 0             | NC*                      | Total                 | 0.42             | 0          | NC*        |  |  |  |
| Hodgkin's Diseas         | <u>e</u>   |               | <u>P</u> 1               | <u>rostate</u>        |                  |            |            |  |  |  |
| Male                     | 0.10       | 1             | NC*                      | Male                  | 3.61             | 2          | NC*        |  |  |  |
| Female                   | 0.08       | 0             | NC*                      |                       |                  |            |            |  |  |  |
| Total                    | 0.18       | 1             | NC*                      |                       |                  |            |            |  |  |  |
| Kidney and Renal         | l Pelvis   |               | <u>St</u>                | tomach_               |                  |            |            |  |  |  |
| Male                     | 0.36       | 0             | NC*                      | Male                  | 0.27             | 1          | NC*        |  |  |  |
| Female                   | 0.18       | 0             | NC*                      | Female                | 0.14             | 0          | NC*        |  |  |  |
| Total                    | 0.54       | 0             | NC*                      | Total                 | 0.41             | 1          | NC*        |  |  |  |
| <u>Larynx</u>            |            |               | $\underline{\mathbf{T}}$ | <u>estis</u>          |                  |            |            |  |  |  |
| Male                     | 0.23       | 0             | NC*                      | Male                  | 0.15             | 0          | NC*        |  |  |  |
| Female                   | 0.05       | 0             | NC*                      |                       |                  |            |            |  |  |  |
| remale                   | 0.05       | U             | NC*                      |                       |                  |            |            |  |  |  |

| Total               | 0.28             | 0   | NC*        |               |       |     |     |
|---------------------|------------------|---|------------|---------------|-------|-----|-----|
| <b>Leukemia</b>     |                  |   | <u>Tl</u>  | <u>ıyroid</u> |       |     |     |
| Male                | 0.25             | 0   | NC*        | Male          | 0.06  | 0   | NC* |
| Female              | 0.16             | 0   | NC*        | Female        | 0.15  | 0   | NC* |
| Total               | 0.42             | 0   | NC*        | Total         | 0.22  | 0   | NC* |
| Liver and Inti      | rahepatic Bile D | <u>le Ducts</u> <u>Uteri, Corpus and Uterus, NO</u> |            |               |       | NOS |     |
| Male                | 0.10             | 0   | NC*        |               |       |     |     |
| Female              | 0.04             | 0   | NC*        | Female        | 0.57  | 2   | NC* |
| Total               | 0.14             | 0   | NC*        |               |       |     |     |
| <b>Lung and Bro</b> | <u>nchus</u>     |   | <u>A</u> ] | <u> </u>      |       |     |     |
| Male                | 2.01             | 0   | NC*        | Male          | 12.26 | 9   | 73  |
| Female              | 1.16             | 0   | NC*        | Female        | 9.65  | 9   | 93  |
| Total               | 3.18             | 0   | NC*        | Total         | 21.90 | 18  | 82  |

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the  $\mathbf{p} <= 0.05$  level
- ~ indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level

#### **DALTON**

#### Cancer Incidence by Sex, 1990 - 1995

#### **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|                       | Exp           | <u>Obs</u>    | SIR      |                       | Exp         | <u>Obs</u> | SIR |
|-----------------------|---------------|---------------|----------|-----------------------|-------------|------------|-----|
| Bladder, Urinar       | <u>v</u>      |               | <u>M</u> | <u>lelanoma of S</u>  | <u>Skin</u> |            |     |
| Male                  | 5.58          | 1             | NC*      | Male                  | 2.80        | 3          | NC* |
| Female                | 2.07          | 2             | NC*      | Female                | 2.26        | 2          | NC* |
| Total                 | 7.65          | 3             | NC*      | Total                 | 5.06        | 5          | 99  |
| <b>Brain and Cent</b> | ral Nervous S | <u>System</u> | <u>M</u> | <u> [ultiple Myel</u> | <u>loma</u> |            |     |
| Male                  | 1.85          | 3             | NC*      | Male                  | 1.01        | 1          | NC* |
| Female                | 1.78          | 1             | NC*      | Female                | 0.93        | 0          | NC* |
| Total                 | 3.63          | 4             | NC*      | Total                 | 1.94        | 1          | NC* |
| <b>Breast</b>         |               |               | <u>N</u> | on-Hodgkin's          | s Lymphoma  | <u>a</u>   |     |
| Male                  | 0.30          | 0             | NC*      | Male                  | 4.00        | 3          | NC* |
| Female                | 33.01         | 41            | 124      | Female                | 3.66        | 3          | NC* |

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

| Total                 | 33.30          | 41           | 123          | Total          | 7.67        | 6   | 78                |  |  |
|-----------------------|----------------|--------------|--------------|----------------|-------------|-----|-------------------|--|--|
| <u>Cervix Uteri</u>   |                |              | <u>O</u> 1   | •              | nd Pharynx  | _   |                   |  |  |
|                       |                | _            |              | Male           | 3.76        | 3   | NC*               |  |  |
| Female                | 1.99           | 3            | NC*          | Female         | 1.68        | 2   | NC*               |  |  |
|                       |                |              |              | Total          | 5.44        | 5   | 92                |  |  |
| Colon / Rectum        | <del>_</del> ' | 4.4          |              | <u>vary</u>    |             |     |                   |  |  |
| Male                  | 14.77          | 11           | 74           |                | • • •       | _   |                   |  |  |
| Female                | 13.83          | 16           | 116          | Female         | 3.97        | 2   | NC*               |  |  |
| Total                 | 28.60          | 27           | 94           |                |             |     |                   |  |  |
| <b>Esophagus</b>      |                |              |              | <u>ancreas</u> |             |     |                   |  |  |
| Male                  | 1.91           | 1            | NC*          | Male           | 2.04        | 3   | NC*               |  |  |
| Female                | 0.69           | 0            | NC*          | Female         | 2.19        | 3   | NC*               |  |  |
| Total                 | 2.60           | 1            | NC*          | Total          | 4.23        | 6   | 142               |  |  |
| <b>Hodgkin's Dise</b> | <u>ease</u>    |              |              | <u>costate</u> |             |     |                   |  |  |
| Male                  | 0.78           | 3            | NC*          | Male           | 32.83       | 14  | 43 ^-             |  |  |
| Female                | 0.65           | 0            | NC*          |                |             |     |                   |  |  |
| Total                 | 1.43           | 3            | NC*          |                |             |     |                   |  |  |
| Kidney and Re         |                | <u>St</u>    | <u>omach</u> |                |             |     |                   |  |  |
| Male                  | 3.24           | 2            | NC*          | Male           | 2.45        | 1   | NC*               |  |  |
| Female                | 1.98           | 2            | NC*          | Female         | 1.50        | 0   | NC*               |  |  |
| Total                 | 5.21           | 4            | NC*          | Total          | 3.95        | 1   | NC*               |  |  |
| <u>Larynx</u>         |                |              | <u>T</u>     | <u>estis</u>   |             |     |                   |  |  |
| Male                  | 2.06           | 5            | 243          | Male           | 1.05        | 3   | NC*               |  |  |
| Female                | 0.57           | 0            | NC*          |                |             |     |                   |  |  |
| Total                 | 2.63           | 5            | 190          |                |             |     |                   |  |  |
| <b>Leukemia</b>       |                |              | <u>Tl</u>    | <u>ivroid</u>  |             |     |                   |  |  |
| Male                  | 2.20           | 1            | NC*          | Male           | 0.50        | 0   | NC*               |  |  |
| Female                | 1.68           | 1            | NC*          | Female         | 1.37        | 2   | NC*               |  |  |
| Total                 | 3.87           | 2            | NC*          | Total          | 1.87        | 2   | NC*               |  |  |
| Liver and Intra       | hepatic Bile   | <b>Ducts</b> | <u>U1</u>    | teri, Corpus   | and Uterus, | NOS |                   |  |  |
| Male                  | 0.91           | 0            | NC*          |                |             |     |                   |  |  |
| Female                | 0.42           | 0            | NC*          | Female         | 6.28        | 6   | 96                |  |  |
| Total                 | 1.33           | 0            | NC*          |                |             |     |                   |  |  |
| <b>Lung and Bron</b>  | chus_          |              |              |                |             |     |                   |  |  |
| Male                  | 18.18          | 14           | 77           | Male           | 109.86      | 79  | 72 ~-             |  |  |
| Female                | 12.97          | 8            | 62           | Female         | 103.02      | 98  | 95                |  |  |
| Total                 | 31.15          | 22           | 71           | Total          | 212.88      | 177 | 83 #-             |  |  |
|                       |                |              |              | <del></del>    |             |     | - <del>-</del> ·· |  |  |

**Obs** = observed case count

SIR = standardized incidence ratio [ (Obs / Exp) X 100]

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the  $\mathbf{p} \le 0.05$  level
- $\sim$  indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level

# **DANVERS**

# Cancer Incidence by Sex, 1990 - 1995

# **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|                      | <b>Exp</b>          | <u>Obs</u>    | <u>SIR</u>              |                     | <u>Exp</u>   | <u>Obs</u> | <u>SIR</u> |  |  |  |
|----------------------|---------------------|---------------|-------------------------|---------------------|--------------|------------|------------|--|--|--|
| Bladder, Urina       | <u>ry</u>           |               | <u>M</u>                | <u>lelanoma of</u>  | Skin         |            |            |  |  |  |
| Male                 | 19.01               | 13            | 68                      | Male                | 9.86         | 10         | 101        |  |  |  |
| Female               | 7.77                | 7             | 90                      | Female              | 8.41         | 11         | 131        |  |  |  |
| Total                | 26.78               | 20            | 75                      | Total               | 18.27        | 21         | 115        |  |  |  |
| <b>Brain and Cen</b> | <u>tral Nervous</u> | <b>System</b> | <u>M</u>                | <u>lultiple Mye</u> | <u>eloma</u> |            |            |  |  |  |
| Male                 | 6.53                | 9             | 138                     | Male                | 3.43         | 6          | 175        |  |  |  |
| Female               | 6.46                | 10            | 155                     | Female              | 3.44         | 7          | 203        |  |  |  |
| Total                | 13.00               | 19            | 146                     | Total               | 6.87         | 13         | 189 #+     |  |  |  |
| <b>Breast</b>        |                     |               |                         | <u>on-Hodgkin</u>   | 's Lymphoma  | <u>a</u>   |            |  |  |  |
| Male                 | 1.01                | 3             | NC*                     | Male                | 14.12        | 15         | 106        |  |  |  |
| Female               | 120.59              | 125           | 104                     | Female              | 13.60        | 16         | 118        |  |  |  |
| Total                | 121.61              | 128           | 105                     | Total               | 27.72        | 31         | 112        |  |  |  |
| <u>Cervix Uteri</u>  |                     |               | Oral Cavity and Pharynx |                     |              |            |            |  |  |  |
|                      |                     |               |                         | Male                | 13.21        | 9          | 68         |  |  |  |
| Female               | 7.49                | 6             | 80                      | Female              | 6.20         | 4          | NC*        |  |  |  |
|                      |                     |               |                         | Total               | 19.41        | 13         | 67         |  |  |  |
| Colon / Rectum       | <u>1</u>            |               | <u>O</u>                | <u>vary</u>         |              |            |            |  |  |  |
| Male                 | 50.56               | 45            | 89                      |                     |              |            |            |  |  |  |
| Female               | 51.94               | 70            | 135 #+                  | Female              | 14.50        | 17         | 117        |  |  |  |
| Total                | 102.50              | 115           | 112                     |                     |              |            |            |  |  |  |
| <b>Esophagus</b>     |                     |               | <u>Pa</u>               | ancreas             |              |            |            |  |  |  |
| Male                 | 6.62                | 12            | 181                     | Male                | 7.10         | 13         | 183        |  |  |  |
| Female               | 2.59                | 3             | NC*                     | Female              | 8.13         | 7          | 86         |  |  |  |
| Total                | 9.21                | 15            | 163                     | Total               | 15.23        | 20         | 131        |  |  |  |
| <b>Hodgkin's Dis</b> | <u>ease</u>         |               | <u>P</u> 1              | <u>rostate</u>      |              |            |            |  |  |  |
| Male                 | 2.91                | 2             | NC*                     | Male                | 115.15       | 124        | 108        |  |  |  |
| Female               | 2.43                | 1             | NC*                     |                     |              |            |            |  |  |  |
| Total                | 5.34                | 3             | NC*                     |                     |              |            |            |  |  |  |
| Kidney and Re        | enal Pelvis         |               | <u>St</u>               | omach_              |              |            |            |  |  |  |
| Male                 | 11.31               | 16            | 141                     | Male                | 8.33         | 6          | 72         |  |  |  |
| Female               | 7.16                | 7             | 98                      | Female              | 5.71         | 2          | NC*        |  |  |  |

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

| Total               | 18.47          | 23                | 125                                  | Total        | 14.04  | 8   | 57     |  |  |
|---------------------|----------------|-------------------|--------------------------------------|--------------|--------|-----|--------|--|--|
| <u>Larynx</u>       |                |                   | <u>Te</u>                            | <u>estis</u> |        |     |        |  |  |
| Male                | 7.23           | 7                 | 97                                   | Male         | 4.22   | 8   | 190    |  |  |
| Female              | 2.06           | 2                 | NC*                                  |              |        |     |        |  |  |
| Total               | 9.29           | 9                 | 97                                   |              |        |     |        |  |  |
| <b>Leukemia</b>     |                | <u>Thyroid</u>    |                                      |              |        |     |        |  |  |
| Male                | 7.56           | 5                 | 66                                   | Male         | 1.84   | 3   | NC*    |  |  |
| Female              | 6.15           | 6                 | 98                                   | Female       | 5.17   | 3   | NC*    |  |  |
| Total               | 13.71          | 11                | 80                                   | Total        | 7.01   | 6   | 86     |  |  |
| Liver and Inti      | rahepatic Bile | <b>Ducts</b>      | <u>Uteri, Corpus and Uterus, NOS</u> |              |        |     |        |  |  |
| Male                | 3.18           | 3                 | NC*                                  |              |        |     |        |  |  |
| Female              | 1.55           | 1                 | NC*                                  | Female       | 22.69  | 25  | 110    |  |  |
| Total               | 4.72           | 4                 | NC*                                  |              |        |     |        |  |  |
| <b>Lung and Bro</b> | <u>nchus</u>   | All Sites / Types |                                      |              |        |     |        |  |  |
| Male                | 63.67          | 76                | 119                                  | Male         | 383.40 | 413 | 108    |  |  |
| Female              | 46.55          | 64                | 137 #+                               | Female       | 378.70 | 425 | 112 #+ |  |  |
| Total               | 110.22         | 140               | 127 ~+                               | Total        | 762.10 | 838 | 110 ~+ |  |  |

**Obs** = observed case count

SIR = standardized incidence ratio [ (Obs / Exp) X 100]

#### **DARTMOUTH**

# Cancer Incidence by Sex, 1990 - 1995

#### **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|                     | Exp              | <u>Obs</u>    | <u>SIR</u>                 |        | <b>Exp</b> | <u>Obs</u> | <u>SIR</u> |  |  |
|---------------------|------------------|---------------|----------------------------|--------|------------|------------|------------|--|--|
| Bladder, Urir       | <u>nary</u>      |               | Melanoma of Skin           |        |            |            |            |  |  |
| Male                | 23.64            | 22            | 93                         | Male   | 11.81      | 12         | 102        |  |  |
| Female              | 8.96             | 8             | 89                         | Female | 9.58       | 13         | 136        |  |  |
| Total               | 32.61            | 30            | 92                         | Total  | 21.39      | 25         | 117        |  |  |
| <b>Brain and Ce</b> | entral Nervous S | <u>System</u> | em <u>Multiple Myeloma</u> |        |            |            |            |  |  |
| Male                | 7.79             | 3             | NC*                        | Male   | 4.27       | 3          | NC*        |  |  |
| Female              | 7.48             | 8             | 107                        | Female | 4.00       | 2          | NC*        |  |  |

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} \le 0.05$  level

 $<sup>\</sup>sim$  indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

| Total                 | 15.28              | 11  | 72         | Total          | 8.27         | 5         | 60     |
|-----------------------|--------------------|-----|------------|----------------|--------------|-----------|--------|
| <b>Breast</b>         |                    |     | <u>N</u>   | on-Hodgkin     | 's Lymphon   | <u>1a</u> |        |
| Male                  | 1.25               | 0   | NC*        | Male           | 17.03        | 18        | 106    |
| Female                | 138.94             | 122 | 88         | Female         | 15.72        | 21        | 134    |
| Total                 | 140.19             | 122 | 87         | Total          | 32.75        | 39        | 119    |
| Cervix Uteri          |                    |     | <u>O</u> 1 | ral Cavity a   | nd Pharynx   | <b>-</b>  |        |
|                       |                    |     |            | Male           | 15.72        | 16        | 102    |
| Female                | 8.46               | 6   | 71         | Female         | 7.12         | 4         | NC*    |
|                       |                    |     |            | Total          | 22.85        | 20        | 88     |
| Colon / Rectun        | <u>n</u>           |     | <u>O</u>   | <u>vary</u>    |              |           |        |
| Male                  | 62.78              | 78  | 124        |                |              |           |        |
| Female                | 60.05              | 54  | 90         | Female         | 16.67        | 21        | 126    |
| Total                 | 122.82             | 132 | 107        |                |              |           |        |
| <b>Esophagus</b>      |                    |     | <u>Pa</u>  | ancreas        |              |           |        |
| Male                  | 8.04               | 9   | 112        | Male           | 8.64         | 17        | 197 #+ |
| Female                | 2.99               | 2   | NC*        | Female         | 9.46         | 11        | 116    |
| Total                 | 11.03              | 11  | 100        | Total          | 18.11        | 28        | 155 #+ |
| <b>Hodgkin's Dis</b>  | <u>sease</u>       |     | <u>Pr</u>  | <u>rostate</u> |              |           |        |
| Male                  | 3.37               | 5   | 148        | Male           | 141.16       | 146       | 103    |
| Female                | 2.77               | 1   | NC*        |                |              |           |        |
| Total                 | 6.14               | 6   | 98         |                |              |           |        |
| Kidney and Re         | <u>enal Pelvis</u> |     | <u>St</u>  | <u>omach</u>   |              |           |        |
| Male                  | 13.67              | 16  | 117        | Male           | 10.34        | 12        | 116    |
| Female                | 8.35               | 7   | 84         | Female         | 6.55         | 5         | 76     |
| Total                 | 22.03              | 23  | 104        | Total          | 16.89        | 17        | 101    |
| <u>Larynx</u>         |                    |     | <u>T</u>   | <u>estis</u>   |              |           |        |
| Male                  | 8.64               | 6   | 69         | Male           | 4.67         | 6         | 129    |
| Female                | 2.38               | 2   | NC*        |                |              |           |        |
| Total                 | 11.03              | 8   | 73         |                |              |           |        |
| <u>Leukemia</u>       |                    |     | <u>Tl</u>  | <u>nyroid</u>  |              |           |        |
| Male                  | 9.26               | 8   | 86         | Male           | 2.13         | 4         | NC*    |
| Female                | 7.12               | 16  | 225 ~+     | Female         | 5.84         | 6         | 103    |
| Total                 | 16.38              | 24  | 147        | Total          | 7.97         | 10        | 125    |
| <b>Liver and Intr</b> | _                  |     |            | teri, Corpus   | s and Uterus | s, NOS    |        |
| Male                  | 3.85               | 2   | NC*        |                |              |           |        |
| Female                | 1.80               | 1   | NC*        | Female         | 26.28        | 32        | 122    |
| Total                 | 5.65               | 3   | NC*        |                |              |           |        |
| <b>Lung and Bron</b>  |                    |     |            | ll Sites / Ty  |              |           |        |
| Male                  | 77.35              | 78  | 101        | Male           | 467.91       | 485       | 104    |
| Female                | 54.67              | 31  | 57 ^-      | Female         | 437.58       | 411       | 94     |
| Total                 | 132.03             | 109 | 83 #-      | Total          | 905.49       | 896       | 99     |
|                       |                    |     |            |                |              |           |        |

37 of 84

**Obs** = observed case count

SIR = standardized incidence ratio [ (Obs / Exp) X 100]

- \* = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the  $\mathbf{p} \le 0.05$  level
- ~ indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level
- ^ indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

# **DEDHAM**

## Cancer Incidence by Sex, 1990 - 1995

## **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|                       | <b>Exp</b>          | <u>Obs</u>              | <u>SIR</u> |                     | <b>Exp</b>   | <u>Obs</u> | <u>SIR</u> |  |
|-----------------------|---------------------|-------------------------|------------|---------------------|--------------|------------|------------|--|
| Bladder, Urina        | <u>ry</u>           |                         | <u>M</u>   | <u>lelanoma of</u>  | Skin         |            |            |  |
| Male                  | 20.24               | 17                      | 84         | Male                | 10.18        | 10         | 98         |  |
| Female                | 7.67                | 4                       | NC*        | Female              | 8.41         | 10         | 119        |  |
| Total                 | 27.91               | 21                      | 75         | Total               | 18.59        | 20         | 108        |  |
| <b>Brain and Cent</b> | <u>tral Nervous</u> | <b>System</b>           | <u>M</u>   | <u>lultiple Mye</u> | <u>eloma</u> |            |            |  |
| Male                  | 6.66                | 8                       | 120        | Male                | 3.65         | 6          | 164        |  |
| Female                | 6.50                | 10                      | 154        | Female              | 3.45         | 4          | NC*        |  |
| Total                 | 13.16               | 18                      | 137        | Total               | 7.10         | 10         | 141        |  |
| <b>Breast</b>         |                     |                         | No         | <u>on-Hodgkin</u>   | 's Lymphom   | <u>a</u>   |            |  |
| Male                  | 1.07                | 0                       | NC*        | Male                | 14.68        | 20         | 136        |  |
| Female                | 122.55              | 156                     | 127 ~+     | Female              | 13.54        | 23         | 170 #+     |  |
| Total                 | 123.62              | 156                     | 126 ~+     | Total               | 28.22        | 43         | 152 #+     |  |
| <u>Cervix Uteri</u>   |                     | Oral Cavity and Pharynx |            |                     |              |            |            |  |
|                       |                     |                         |            | Male                | 13.53        | 18         | 133        |  |
| Female                | 7.46                | 6                       | 80         | Female              | 6.25         | 14         | 224 #+     |  |
|                       |                     |                         |            | Total               | 19.78        | 32         | 162 #+     |  |
| Colon / Rectum        | <u>1</u>            |                         | <u>O</u>   | <u>vary</u>         |              |            |            |  |
| Male                  | 53.83               | 44                      | 82         |                     |              |            |            |  |
| Female                | 51.01               | 49                      | 96         | Female              | 14.71        | 15         | 102        |  |
| Total                 | 104.83              | 93                      | 89         |                     |              |            |            |  |
| <b>Esophagus</b>      |                     |                         | <u>Pa</u>  | <u>ancreas</u>      |              |            |            |  |
| Male                  | 6.89                | 4                       | NC*        | Male                | 7.45         | 4          | NC*        |  |
| Female                | 2.55                | 3                       | NC*        | Female              | 8.12         | 4          | NC*        |  |
| Total                 | 9.44                | 7                       | 74         | Total               | 15.57        | 8          | 51         |  |
| <b>Hodgkin's Dis</b>  | <u>ease</u>         |                         | <u>Pı</u>  | <u>rostate</u>      |              |            |            |  |
| Male                  | 2.92                | 4                       | NC*        | Male                | 122.31       | 162        | 132 ^+     |  |

| Female                | 2.36         | 0       | NC*                      |               |              |        |        |
|-----------------------|--------------|---------|--------------------------|---------------|--------------|--------|--------|
| Total                 | 5.28         | 4       | NC*                      |               |              |        |        |
| Kidney and R          | enal Pelvis  |         | <u>St</u>                | omach_        |              |        |        |
| Male                  | 11.75        | 16      | 136                      | Male          | 8.85         | 8      | 90     |
| Female                | 7.30         | 5       | 69                       | Female        | 5.53         | 5      | 90     |
| Total                 | 19.04        | 21      | 110                      | Total         | 14.37        | 13     | 90     |
| <u>Larynx</u>         |              |         | $\mathbf{T}$             | <u>estis</u>  |              |        |        |
| Male                  | 7.45         | 9       | 121                      | Male          | 4.19         | 4      | NC*    |
| Female                | 2.14         | 6       | 280 #+                   |               |              |        |        |
| Total                 | 9.59         | 15      | 156                      |               |              |        |        |
| <b>Leukemia</b>       |              |         | $\mathbf{T}$             | <u>hyroid</u> |              |        |        |
| Male                  | 7.85         | 4       | NC*                      | Male          | 1.86         | 0      | NC*    |
| Female                | 6.03         | 11      | 183                      | Female        | 5.11         | 5      | 98     |
| Total                 | 13.88        | 15      | 108                      | Total         | 6.97         | 5      | 72     |
| <b>Liver and Intr</b> | ahepatic Bil | e Ducts | $\underline{\mathbf{U}}$ | teri, Corpus  | s and Uterus | s, NOS |        |
| Male                  | 3.31         | 8       | 241 #+                   |               |              |        |        |
| Female                | 1.54         | 1       | NC*                      | Female        | 23.36        | 29     | 124    |
| Total                 | 4.86         | 9       | 185                      |               |              |        |        |
| <b>Lung and Bro</b>   | nchus_       |         | <u>A</u>                 | ll Sites / Ty | <u>pes</u>   |        |        |
| Male                  | 66.74        | 56      | 84                       | Male          | 403.22       | 430    | 107    |
| Female                | 48.27        | 64      | 133 #+                   | Female        | 381.52       | 448    | 117 ^+ |
| Total                 | 115.01       | 120     | 104                      | Total         | 784.74       | 878    | 112 ~+ |
|                       |              |         |                          |               |              |        |        |

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

#### **DEERFIELD**

## Cancer Incidence by Sex, 1990 - 1995

# **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|                  | <b>Exp</b> | <u>Obs</u> | <u>SIR</u> |              | <u>Exp</u>  | <u>Obs</u> | <u>SIR</u> |
|------------------|------------|------------|------------|--------------|-------------|------------|------------|
| Bladder, Urinary |            |            | <u>M</u> e | elanoma of S | <u>Skin</u> |            |            |
| Male             | 4.09       | 3          | NC*        | Male         | 2.15        | 6          | 278 #+     |

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} \le 0.05$  level

<sup>~</sup> indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

| Female                 | 1.50          | 2            | NC*                          | Female                | 1.76        | 4             | NC*    |
|------------------------|---------------|--------------|------------------------------|-----------------------|-------------|---------------|--------|
| Total                  | 5.60          | 5            | 89                           | Total                 | 3.91        | 10            | 256 #+ |
| Brain and Cen          |               | _            |                              | Iolai<br>[ultiple Mye |             | 10            | 230 #∓ |
| Male                   | 1.42          | 2            | NC*                          | Male                  | 0.75        | 1             | NC*    |
| Female                 | 1.42          | 4            | NC*                          | Female                | 0.73        | 0             | NC*    |
| Total                  | 2.76          | 6            | 218                          | Total                 | 1.42        | 1             | NC*    |
| Breast                 | 2.70          | U            |                              |                       | s Lymphoma  |               | 110    |
| Male                   | 0.22          | 0            | NC*                          | Male                  | 3.07        | <u>*</u><br>4 | NC*    |
| Female                 | 24.80         | 26           | 105                          | Female                | 2.71        | 1             | NC*    |
| Total                  | 25.02         | 26           | 103                          | Total                 | 5.78        | 5             | 86     |
| Cervix Uteri           | 23.02         | 20           |                              | ral Cavity a          |             | 3             | 80     |
| Cervix Oterr           |               |              | <u>U</u>                     | Male                  | 2.87        | 3             | NC*    |
| Female                 | 1.61          | 2            | NC*                          | Female                |             | 1             | NC*    |
| remaie                 | 1.01          | 2            | NC.                          | Total                 | 1.25        | 4             | NC*    |
| Colon / Rectum         |               |              | 0                            |                       | 4.13        | 4             | NC*    |
|                        |               | 0            |                              | <u>vary</u>           |             |               |        |
| Male                   | 10.85         | 9            | 83                           | Esmals                | 2.01        | 4             | NC*    |
| Female                 | 9.97          | 5            | 50                           | Female                | 3.01        | 4             | NC*    |
| Total                  | 20.82         | 14           | 67                           |                       |             |               |        |
| <b>Esophagus</b>       | 1 42          | 1            |                              | ancreas N. 1          | 1.51        | 2             | NOT    |
| Male                   | 1.43          | 1            | NC*                          | Male                  | 1.51        | 3             | NC*    |
| Female                 | 0.50          | 1            | NC*                          | Female                | 1.59        | 3             | NC*    |
| Total                  | 1.93          | 2            | NC*                          | Total                 | 3.10        | 6             | 194    |
| Hodgkin's Disc         |               |              |                              | <u>rostate</u>        |             |               |        |
| Male                   | 0.64          | 2            | NC*                          | Male                  | 23.83       | 17            | 71     |
| Female                 | 0.53          | 2            | NC*                          |                       |             |               |        |
| Total                  | 1.17          | 4            | NC*                          |                       |             |               |        |
| Kidney and Re          |               |              |                              | <u>omach</u>          |             |               |        |
| Male                   | 2.44          | 2            | NC*                          | Male                  | 1.80        | 1             | NC*    |
| Female                 | 1.45          | 1            | NC*                          | Female                | 1.09        | 0             | NC*    |
| Total                  | 3.89          | 3            | NC*                          | Total                 | 2.89        | 1             | NC*    |
| <u>Larynx</u>          |               |              | <u>T</u>                     | <u>estis</u>          |             |               |        |
| Male                   | 1.55          | 2            | NC*                          | Male                  | 0.93        | 0             | NC*    |
| Female                 | 0.43          | 0            | NC*                          |                       |             |               |        |
| Total                  | 1.97          | 2            | NC*                          |                       |             |               |        |
| <u>Leukemia</u>        |               |              | <u>T</u>                     | <u>hyroid</u>         |             |               |        |
| Male                   | 1.64          | 4            | NC*                          | Male                  | 0.41        | 1             | NC*    |
| Female                 | 1.23          | 0            | NC*                          | Female                | 1.12        | 1             | NC*    |
| Total                  | 2.87          | 4            | NC*                          | Total                 | 1.53        | 2             | NC*    |
| <b>Liver and Intra</b> | ahepatic Bile | <u>Ducts</u> | $\underline{\mathbf{U}}_{1}$ | <u>teri, Corpus</u>   | and Uterus, | NOS_          |        |
| Male                   | 0.68          | 1            | NC*                          |                       |             |               |        |
| Female                 | 0.31          | 0            | NC*                          | Female                | 4.67        | 2             | NC*    |
| Total                  | 0.99          | 1            | NC*                          |                       |             |               |        |
| <b>Lung and Bron</b>   | chus          |              | <u>A</u>                     | ll Sites / Typ        | <u>oes</u>  |               |        |
| Male                   | 13.50         | 9            | 67                           | Male                  | 81.55       | 75            | 92     |

40 of 84

| Female | 9.51  | 14 | 147 | Female | 76.58  | 78  | 102 |
|--------|-------|----|-----|--------|--------|-----|-----|
| Total  | 23.02 | 23 | 100 | Total  | 158.14 | 153 | 97  |

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

# DENNIS Cancer Incidence by Sex, 1990 - 1995

#### **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|                      | <b>Exp</b>   | <u>Obs</u>    | SIR        |              | Exp         | <u>Obs</u> | SIR    |
|----------------------|--------------|---------------|------------|--------------|-------------|------------|--------|
| Bladder, Urina       | <u>ry</u>    |               | <u>M</u>   | elanoma of   | <u>Skin</u> |            |        |
| Male                 | 19.13        | 22            | 115        | Male         | 8.03        | 11         | 137    |
| Female               | 7.47         | 5             | 67         | Female       | 6.48        | 4          | NC*    |
| Total                | 26.60        | 27            | 102        | Total        | 14.51       | 15         | 103    |
| <b>Brain and Cen</b> | tral Nervous | <u>System</u> | <u>M</u>   | ultiple Mye  | <u>loma</u> |            |        |
| Male                 | 4.85         | 5             | 103        | Male         | 3.37        | 9          | 267 #+ |
| Female               | 5.15         | 1             | NC*        | Female       | 3.26        | 3          | NC*    |
| Total                | 10.00        | 6             | 60         | Total        | 6.63        | 12         | 181    |
| <b>Breast</b>        |              |               | <u>N</u>   | on-Hodgkin   | s Lymphom   | <u>a</u>   |        |
| Male                 | 0.96         | 1             | NC*        | Male         | 11.80       | 25         | 212 ~+ |
| Female               | 101.19       | 132           | 130 ~+     | Female       | 12.31       | 14         | 114    |
| Total                | 102.14       | 133           | 130 ~+     | Total        | 24.11       | 39         | 162 ~+ |
| Cervix Uteri         |              |               | <u>O</u> 1 | ral Cavity a | nd Pharynx  |            |        |
|                      |              |               |            | Male         | 10.55       | 19         | 180 #+ |
| Female               | 5.16         | 8             | 155        | Female       | 5.35        | 5          | 93     |
|                      |              |               |            | Total        | 15.90       | 24         | 151    |
| Colon / Rectun       | <u>1</u>     |               | <u>O</u>   | <u>vary</u>  |             |            |        |
| Male                 | 50.51        | 54            | 107        |              |             |            |        |
| Female               | 51.05        | 66            | 129        | Female       | 11.68       | 14         | 120    |
| Total                | 101.56       | 120           | 118        |              |             |            |        |
| <b>Esophagus</b>     |              |               | <u>Pa</u>  | ancreas      |             |            |        |
| Male                 | 5.89         | 4             | NC*        | Male         | 6.58        | 3          | NC*    |

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} <= 0.05$  level

<sup>~</sup> indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

| Female                | 2.54         | 2       | NC*      | Female                    | 7.89        | 12      | 152    |
|-----------------------|--------------|---------|----------|---------------------------|-------------|---------|--------|
| Total                 | 8.43         | 6       | 71       | Total                     | 14.48       | 15      | 104    |
| Hodgkin's Dis         | <u>sease</u> |         | <u>I</u> | <u>Prostate</u>           |             |         |        |
| Male                  | 1.69         | 4       | NC*      | Male                      | 114.54      | 147     | 128 ~+ |
| Female                | 1.53         | 0       | NC*      |                           |             |         |        |
| Total                 | 3.22         | 4       | NC*      |                           |             |         |        |
| Kidney and R          | enal Pelvis  |         | <u>S</u> | Stomach_                  |             |         |        |
| Male                  | 9.67         | 10      | 103      | Male                      | 8.27        | 9       | 109    |
| Female                | 6.35         | 8       | 126      | Female                    | 5.60        | 9       | 161    |
| Total                 | 16.02        | 18      | 112      | Total                     | 13.87       | 18      | 130    |
| <u>Larynx</u>         |              |         | 1        | <u> Testis</u>            |             |         |        |
| Male                  | 6.08         | 10      | 164      | Male                      | 1.93        | 2       | NC*    |
| Female                | 1.72         | 1       | NC*      |                           |             |         |        |
| Total                 | 7.81         | 11      | 141      |                           |             |         |        |
| <b>Leukemia</b>       |              |         | 1        | <u>Chyroid</u>            |             |         |        |
| Male                  | 6.46         | 8       | 124      | Male                      | 1.16        | 0       | NC*    |
| Female                | 5.24         | 8       | 153      | Female                    | 3.40        | 1       | NC*    |
| Total                 | 11.71        | 16      | 137      | Total                     | 4.56        | 1       | NC*    |
| <b>Liver and Intr</b> | ahepatic Bil | e Ducts | <u>I</u> | <mark>Jteri, Corpu</mark> | s and Uteru | is, NOS |        |
| Male                  | 2.82         | 4       | NC*      |                           |             |         |        |
| Female                | 1.44         | 0       | NC*      | Female                    | 19.28       | 12      | 62     |
| Total                 | 4.26         | 4       | NC*      |                           |             |         |        |
| <b>Lung and Bro</b>   | <u>nchus</u> |         | <u> </u> | All Sites / Ty            | <u>pes</u>  |         |        |
| Male                  | 58.20        | 70      | 120      | Male                      | 356.05      | 445     | 125 ^+ |
| Female                | 41.96        | 55      | 131      | Female                    | 331.80      | 388     | 117 ~+ |
| Total                 | 100.16       | 125     | 125 #+   | Total                     | 687.86      | 833     | 121 ^+ |
|                       |              |         |          |                           |             |         |        |

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

## **DIGHTON**

Cancer Incidence by Sex, 1990 - 1995

**Expected and Observed Case Counts, with Standardized Incidence Ratios** 

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases  $\mu$  indicates statistical significance at the  $\mu$  <= 0.05 level

<sup>~</sup> indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

|                        | Exp           | Obs           | SIR        |                     | Exp         | <u>Obs</u> | <u>SIR</u> |
|------------------------|---------------|---------------|------------|---------------------|-------------|------------|------------|
| Bladder, Urinar        | <u>v</u>      |               | <u>M</u>   | lelanoma of         | <u>Skin</u> |            |            |
| Male                   | 4.75          | 2             | NC*        | Male                | 2.44        | 1          | NC*        |
| Female                 | 1.49          | 0             | NC*        | Female              | 1.75        | 1          | NC*        |
| Total                  | 6.24          | 2             | NC*        | Total               | 4.19        | 2          | NC*        |
| <b>Brain and Cent</b>  | ral Nervous S | <u>System</u> | <u>M</u>   | <u>lultiple Mye</u> | <u>loma</u> |            |            |
| Male                   | 1.62          | 3             | NC*        | Male                | 0.86        | 1          | NC*        |
| Female                 | 1.36          | 4             | NC*        | Female              | 0.67        | 0          | NC*        |
| Total                  | 2.97          | 7             | 235        | Total               | 1.53        | 1          | NC*        |
| <b>Breast</b>          |               |               | No         | <u>on-Hodgkin'</u>  | s Lymphoma  | <u>L</u>   |            |
| Male                   | 0.25          | 1             | NC*        | Male                | 3.47        | 1          | NC*        |
| Female                 | 24.83         | 22            | 89         | Female              | 2.69        | 1          | NC*        |
| Total                  | 25.09         | 23            | 92         | Total               | 6.16        | 2          | NC*        |
| <u>Cervix Uteri</u>    |               |               | <u>O</u> 1 | ral Cavity aı       | nd Pharynx  |            |            |
|                        |               |               |            | Male                | 3.28        | 1          | NC*        |
| Female                 | 1.60          | 1             | NC*        | Female              | 1.26        | 2          | NC*        |
|                        |               |               |            | Total               | 4.54        | 3          | NC*        |
| Colon / Rectum         | _             |               | <u>O</u>   | <u>vary</u>         |             |            |            |
| Male                   | 12.56         | 8             | 64         |                     |             |            |            |
| Female                 | 9.86          | 8             | 81         | Female              | 3.02        | 4          | NC*        |
| Total                  | 22.43         | 16            | 71         |                     |             |            |            |
| <b>Esophagus</b>       |               |               | <u>Pa</u>  | ancreas             |             |            |            |
| Male                   | 1.65          | 1             | NC*        | Male                | 1.75        | 2          | NC*        |
| Female                 | 0.49          | 0             | NC*        | Female              | 1.57        | 1          | NC*        |
| Total                  | 2.14          | 1             | NC*        | Total               | 3.31        | 3          | NC*        |
| Hodgkin's Dise         | ease          |               | <u>P1</u>  | <u>rostate</u>      |             |            |            |
| Male                   | 0.70          | 0             | NC*        | Male                | 27.87       | 27         | 97         |
| Female                 | 0.53          | 0             | NC*        |                     |             |            |            |
| Total                  | 1.23          | 0             | NC*        |                     |             |            |            |
| Kidney and Re          | nal Pelvis    |               | <u>St</u>  | <u>omach</u>        |             |            |            |
| Male                   | 2.79          | 2             | NC*        | Male                | 2.09        | 3          | NC*        |
| Female                 | 1.45          | 2             | NC*        | Female              | 1.08        | 0          | NC*        |
| Total                  | 4.24          | 4             | NC*        | Total               | 3.17        | 3          | NC*        |
| <u>Larynx</u>          |               |               | <u>T</u>   | <u>estis</u>        |             |            |            |
| Male                   | 1.79          | 0             | NC*        | Male                | 0.97        | 1          | NC*        |
| Female                 | 0.43          | 1             | NC*        |                     |             |            |            |
| Total                  | 2.22          | 1             | NC*        |                     |             |            |            |
| <b>Leukemia</b>        |               |               | <u>Tl</u>  | <u>hyroid</u>       |             |            |            |
| Male                   | 1.90          | 1             | NC*        | Male                | 0.44        | 0          | NC*        |
| Female                 | 1.25          | 3             | NC*        | Female              | 1.11        | 0          | NC*        |
| Total                  | 3.15          | 4             | NC*        | Total               | 1.56        | 0          | NC*        |
| <b>Liver and Intra</b> | hepatic Bile  | <u>Ducts</u>  | <u>U</u> 1 | <u>teri, Corpus</u> | and Uterus, | NOS_       |            |
| Male                   | 0.78          | 0             | NC*        |                     |             |            |            |
|                        |               |               |            |                     |             |            |            |

| Female               | 0.30         | 0  | NC*        | Female        | 4.70   | 5   | 106   |
|----------------------|--------------|----|------------|---------------|--------|-----|-------|
| Total                | 1.09         | 0  | NC*        |               |        |     |       |
| <b>Lung and Bron</b> | <u>nchus</u> |    | <u>A</u> ] | ll Sites / Ty | pes    |     |       |
| Male                 | 15.56        | 12 | 77         | Male          | 94.10  | 74  | 79 #- |
| Female               | 9.46         | 13 | 137        | Female        | 76.46  | 71  | 93    |
| Total                | 25.02        | 25 | 100        | Total         | 170.56 | 145 | 85    |

**Obs** = observed case count

SIR = standardized incidence ratio [ (Obs / Exp) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the  $\mathbf{p} \le 0.05$  level
- ~ indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level

## **DOUGLAS**

#### Cancer Incidence by Sex, 1990 - 1995

#### **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|                       | Exp           | <u>Obs</u>    | <u>SIR</u>       |               | Exp         | <u>Obs</u> | <u>SIR</u> |
|-----------------------|---------------|---------------|------------------|---------------|-------------|------------|------------|
| Bladder, Urinar       | <u>v</u>      |               | <u>M</u>         | elanoma of S  | <u>Skin</u> |            |            |
| Male                  | 3.46          | 4             | NC*              | Male          | 1.96        | 2          | NC*        |
| Female                | 1.24          | 1             | NC*              | Female        | 1.60        | 5          | 313 #+     |
| Total                 | 4.69          | 5             | 107              | Total         | 3.55        | 7          | 197        |
| <b>Brain and Cent</b> | ral Nervous S | <u>System</u> | Multiple Myeloma |               |             |            |            |
| Male                  | 1.39          | 3             | NC*              | Male          | 0.63        | 1          | NC*        |
| Female                | 1.23          | 0             | NC*              | Female        | 0.55        | 0          | NC*        |
| Total                 | 2.62          | 3             | NC*              | Total         | 1.18        | 1          | NC*        |
| <b>Breast</b>         |               |               | <u>N</u>         | on-Hodgkin's  | s Lymphoma  | <u>1</u>   |            |
| Male                  | 0.19          | 0             | NC*              | Male          | 2.85        | 2          | NC*        |
| Female                | 20.98         | 17            | 81               | Female        | 2.32        | 1          | NC*        |
| Total                 | 21.17         | 17            | 80               | Total         | 5.17        | 3          | NC*        |
| Cervix Uteri          |               |               | <u>O</u> :       | ral Cavity an | d Pharynx   |            |            |
|                       |               |               |                  | Male          | 2.48        | 1          | NC*        |
| Female                | 1.55          | 1             | NC*              | Female        | 1.05        | 0          | NC*        |
|                       |               |               |                  | Total         | 3.53        | 1          | NC*        |
| Colon / Rectum        | <u>Ovary</u>  |               |                  |               |             |            |            |
| Male                  | 9.15          | 10            | 109              |               |             |            |            |

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

| Female                 | 8.24              | 5            | 61         | Female              | 2.62        | 1   | NC* |
|------------------------|-------------------|--------------|------------|---------------------|-------------|-----|-----|
| Total                  | 17.39             | 15           | 86         |                     |             |     |     |
| <b>Esophagus</b>       |                   |              | <u>Pa</u>  | <u>ancreas</u>      |             |     |     |
| Male                   | 1.20              | 1            | NC*        | Male                | 1.27        | 0   | NC* |
| Female                 | 0.40              | 0            | NC*        | Female              | 1.30        | 0   | NC* |
| Total                  | 1.60              | 1            | NC*        | Total               | 2.57        | 0   | NC* |
| Hodgkin's Disc         | ease              |              | <u>P</u> 1 | <u>rostate</u>      |             |     |     |
| Male                   | 0.74              | 0            | NC*        | Male                | 19.47       | 19  | 98  |
| Female                 | 0.58              | 1            | NC*        |                     |             |     |     |
| Total                  | 1.31              | 1            | NC*        |                     |             |     |     |
| Kidney and Re          | <u>nal Pelvis</u> |              | <u>St</u>  | omach_              |             |     |     |
| Male                   | 2.11              | 1            | NC*        | Male                | 1.54        | 3   | NC* |
| Female                 | 1.22              | 0            | NC*        | Female              | 0.91        | 1   | NC* |
| Total                  | 3.33              | 1            | NC*        | Total               | 2.45        | 4   | NC* |
| <u>Larynx</u>          |                   |              | <u>T</u>   | <u>estis</u>        |             |     |     |
| Male                   | 1.29              | 2            | NC*        | Male                | 1.14        | 1   | NC* |
| Female                 | 0.34              | 0            | NC*        |                     |             |     |     |
| Total                  | 1.63              | 2            | NC*        |                     |             |     |     |
| <u>Leukemia</u>        |                   |              | <u>T</u>   | <u>hyroid</u>       |             |     |     |
| Male                   | 1.56              | 2            | NC*        | Male                | 0.42        | 0   | NC* |
| Female                 | 1.15              | 3            | NC*        | Female              | 1.13        | 2   | NC* |
| Total                  | 2.71              | 5            | 184        | Total               | 1.55        | 2   | NC* |
| <b>Liver and Intra</b> | hepatic Bile      | <u>Ducts</u> | <u>U</u> 1 | <u>teri, Corpus</u> | and Uterus, | NOS |     |
| Male                   | 0.59              | 0            | NC*        |                     |             |     |     |
| Female                 | 0.26              | 0            | NC*        | Female              | 3.82        | 7   | 183 |
| Total                  | 0.84              | 0            | NC*        |                     |             |     |     |
| <b>Lung and Bron</b>   | <u>chus</u>       |              | <u>A</u> ] | ll Sites / Ty       | pes         |     |     |
| Male                   | 11.21             | 11           | 98         | Male                | 69.91       | 67  | 96  |
| Female                 | 7.66              | 4            | NC*        | Female              | 64.91       | 52  | 80  |
| Total                  | 18.87             | 15           | 80         | Total               | 134.82      | 119 | 88  |
|                        |                   |              |            |                     |             |     |     |

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} \le 0.05$  level

<sup>~</sup> indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

DOVER

Cancer Incidence by Sex, 1990 - 1995

# **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|                       | Exp               | <u>Obs</u>    | <u>SIR</u>              |               | $\mathbf{\underline{Exp}}$ | <u>Obs</u> | <u>SIR</u> |  |  |
|-----------------------|-------------------|---------------|-------------------------|---------------|----------------------------|------------|------------|--|--|
| Bladder, Urinar       | <u>v</u>          |               | <u>M</u>                | elanoma of    | <u>Skin</u>                |            |            |  |  |
| Male                  | 4.34              | 2             | NC*                     | Male          | 2.27                       | 4          | NC*        |  |  |
| Female                | 1.20              | 1             | NC*                     | Female        | 1.60                       | 1          | NC*        |  |  |
| Total                 | 5.54              | 3             | NC*                     | Total         | 3.87                       | 5          | 129        |  |  |
| <b>Brain and Cent</b> | ral Nervous S     | <u>System</u> | <u>M</u>                | ultiple Mye   | <u>loma</u>                |            |            |  |  |
| Male                  | 1.50              | 3             | NC*                     | Male          | 0.79                       | 1          | NC*        |  |  |
| Female                | 1.22              | 2             | NC*                     | Female        | 0.56                       | 0          | NC*        |  |  |
| Total                 | 2.72              | 5             | 184                     | Total         | 1.35                       | 1          | NC*        |  |  |
| <b>Breast</b>         |                   |               | Non-Hodgkin's Lymphoma  |               |                            |            |            |  |  |
| Male                  | 0.24              | 0             | NC*                     | Male          | 3.18                       | 3          | NC*        |  |  |
| Female                | 22.73             | 33            | 145                     | Female        | 2.26                       | 0          | NC*        |  |  |
| Total                 | 22.97             | 33            | 144                     | Total         | 5.44                       | 3          | NC*        |  |  |
| Cervix Uteri          |                   |               | Oral Cavity and Pharynx |               |                            |            |            |  |  |
|                       |                   |               |                         | Male          | 3.16                       | 0          | NC*        |  |  |
| Female                | 1.48              | 2             | NC*                     | Female        | 1.12                       | 0          | NC*        |  |  |
|                       |                   |               |                         | Total         | 4.28                       | 0          | NC*        |  |  |
| Colon / Rectum        | <u> </u>          |               | <u>O</u>                | <u>vary</u>   |                            |            |            |  |  |
| Male                  | 11.53             | 12            | 104                     |               |                            |            |            |  |  |
| Female                | 7.71              | 7             | 91                      | Female        | 2.80                       | 1          | NC*        |  |  |
| Total                 | 19.24             | 19            | 99                      |               |                            |            |            |  |  |
| <b>Esophagus</b>      |                   |               | <u>Pa</u>               | ncreas        |                            |            |            |  |  |
| Male                  | 1.57              | 2             | NC*                     | Male          | 1.63                       | 1          | NC*        |  |  |
| Female                | 0.39              | 0             | NC*                     | Female        | 1.27                       | 0          | NC*        |  |  |
| Total                 | 1.96              | 2             | NC*                     | Total         | 2.90                       | 1          | NC*        |  |  |
| <b>Hodgkin's Dise</b> | ease              |               | <u>P1</u>               | <u>ostate</u> |                            |            |            |  |  |
| Male                  | 0.61              | 0             | NC*                     | Male          | 25.78                      | 35         | 136        |  |  |
| Female                | 0.46              | 1             | NC*                     |               |                            |            |            |  |  |
| Total                 | 1.07              | 1             | NC*                     |               |                            |            |            |  |  |
| Kidney and Re         | <u>nal Pelvis</u> |               | <u>St</u>               | <u>omach</u>  |                            |            |            |  |  |
| Male                  | 2.66              | 5             | 188                     | Male          | 1.91                       | 1          | NC*        |  |  |
| Female                | 1.29              | 3             | NC*                     | Female        | 0.83                       | 1          | NC*        |  |  |
| Total                 | 3.94              | 8             | 203                     | Total         | 2.73                       | 2          | NC*        |  |  |
| <u>Larynx</u>         |                   |               | <u>T</u>                | <u>estis</u>  |                            |            |            |  |  |
| Male                  | 1.72              | 0             | NC*                     | Male          | 0.80                       | 2          | NC*        |  |  |
| Female                | 0.41              | 0             | NC*                     |               |                            |            |            |  |  |
| Total                 | 2.14              | 0             | NC*                     |               |                            |            |            |  |  |
| <u>Leukemia</u>       |                   |               | <u>Tl</u>               | <u>nyroid</u> |                            |            |            |  |  |

| Male                   | 1.74            | 0          | NC*                        | Male          | 0.40   | 1   | NC* |
|------------------------|-----------------|------------|----------------------------|---------------|--------|-----|-----|
| Female                 | 1.05            | 0          | NC*                        | Female        | 1.03   | 2   | NC* |
| Total                  | 2.79            | 0          | NC*                        | Total         | 1.43   | 3   | NC* |
| <b>Liver and Intra</b> | ahepatic Bile I | <u>U</u> 1 | t <mark>eri, Corpus</mark> | and Uterus    | , NOS  |     |     |
| Male                   | 0.74            | 0          | NC*                        |               |        |     |     |
| Female                 | 0.25            | 0          | NC*                        | Female        | 4.37   | 7   | 160 |
| Total                  | 0.99            | 0          | NC*                        |               |        |     |     |
| <b>Lung and Bron</b>   | <u>chus</u>     |            | <u>A</u> ]                 | ll Sites / Ty | pes    |     |     |
| Male                   | 14.76           | 7          | 47 #-                      | Male          | 87.34  | 85  | 97  |
| Female                 | 8.52            | 7          | 82                         | Female        | 67.10  | 73  | 109 |
| Total                  | 23.28           | 14         | 60                         | Total         | 154.44 | 158 | 102 |
|                        |                 |            |                            |               |        |     |     |

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

# DRACUT

# Cancer Incidence by Sex, 1990 - 1995

# **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|                      | Exp                     | <u>Obs</u>                               | <u>SIR</u> |             | <b>Exp</b>  | <u>Obs</u> | <u>SIR</u> |  |  |
|----------------------|-------------------------|--|------------|-------------|-------------|------------|------------|--|--|
| Bladder, Urina       | <u>ry</u>               |  | <u>M</u>   | elanoma of  | <u>Skin</u> |            |            |  |  |
| Male                 | 16.38                   | 26                                       | 159 #+     | Male        | 9.47        | 6          | 63         |  |  |
| Female               | 5.83                    | 4  | NC*        | Female      | 7.87        | 8          | 102        |  |  |
| Total                | 22.21                   | 30                                       | 135        | Total       | 17.34       | 14         | 81         |  |  |
| <b>Brain and Cen</b> | tral Nervous S          | l Nervous System <u>Multiple Myeloma</u> |            |             |             |            |            |  |  |
| Male                 | 6.66                    | 8  | 120        | Male        | 3.00        | 6          | 200        |  |  |
| Female               | 5.95                    | 8  | 134        | Female      | 2.65        | 3          | NC*        |  |  |
| Total                | 12.61                   | 16                                       | 127        | Total       | 5.66        | 9          | 159        |  |  |
| <b>Breast</b>        |                         |  | No         | on-Hodgkin' | s Lymphoma  | <u>a</u>   |            |  |  |
| Male                 | 0.90                    | 0  | NC*        | Male        | 13.64       | 7          | 51         |  |  |
| Female               | 104.47                  | 98                                       | 94         | Female      | 11.11       | 13         | 117        |  |  |
| Total                | 105.38                  | 98                                       | 93         | Total       | 24.75       | 20         | 81         |  |  |
| Cervix Uteri         | Oral Cavity and Pharynx |  |            |             |             |            |            |  |  |

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} <= 0.05$  level

 $<sup>\</sup>sim$  indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

|                       |               |                 |            | Male          | 12.42       | 8      | 64  |  |
|-----------------------|---------------|-----------------|------------|---------------|-------------|--------|-----|--|
| Female                | 7.68          | 8               | 104        | Female        | 5.19        | 5      | 96  |  |
|                       |               |                 |            | Total         | 17.61       | 13     | 74  |  |
| Colon / Rectur        | <u>n</u>      |                 | <u>O</u>   | <u>vary</u>   |             |        |     |  |
| Male                  | 43.75         | 47              | 107        |               |             |        |     |  |
| Female                | 38.21         | 40              | 105        | Female        | 13.05       | 18     | 138 |  |
| Total                 | 81.96         | 87              | 106        |               |             |        |     |  |
| <b>Esophagus</b>      |               |                 | <u>Pa</u>  | ancreas       |             |        |     |  |
| Male                  | 5.94          | 6               | 101        | Male          | 6.31        | 10     | 158 |  |
| Female                | 1.90          | 2               | NC*        | Female        | 6.15        | 5      | 81  |  |
| Total                 | 7.85          | 8               | 102        | Total         | 12.46       | 15     | 120 |  |
| Hodgkin's Dis         | sease_        | <u>Prostate</u> |            |               |             |        |     |  |
| Male                  | 3.41          | 5               | 147        | Male          | 98.61       | 83     | 84  |  |
| Female                | 2.74          | 2               | NC*        |               |             |        |     |  |
| Total                 | 6.14          | 7               | 114        |               |             |        |     |  |
| Kidney and R          | enal Pelvis   |                 | St         | <u>omach</u>  |             |        |     |  |
| Male                  | 10.48         | 11              | 105        | Male          | 7.24        | 7      | 97  |  |
| Female                | 6.01          | 6               | 100        | Female        | 4.15        | 6      | 145 |  |
| Total                 | 16.49         | 17              | 103        | Total         | 11.39       | 13     | 114 |  |
| <u>Larynx</u>         |               |                 | <u>T</u>   | <u>estis</u>  |             |        |     |  |
| Male                  | 6.58          | 4               | NC*        | Male          | 5.30        | 7      | 132 |  |
| Female                | 1.77          | 4               | NC*        |               |             |        |     |  |
| Total                 | 8.35          | 8               | 96         |               |             |        |     |  |
| <b>Leukemia</b>       |               |                 | <u>Tl</u>  | <u>nyroid</u> |             |        |     |  |
| Male                  | 7.30          | 10              | 137        | Male          | 2.01        | 0      | NC* |  |
| Female                | 5.32          | 3               | NC*        | Female        | 5.51        | 5      | 91  |  |
| Total                 | 12.62         | 13              | 103        | Total         | 7.53        | 5      | 66  |  |
| <b>Liver and Inti</b> | ahepatic Bile | <u> Ducts</u>   | <u>U</u> 1 | teri, Corpus  | s and Uteru | s, NOS |     |  |
| Male                  | 2.90          | 3               | NC*        |               |             |        |     |  |
| Female                | 1.23          | 0               | NC*        | Female        | 19.40       | 25     | 129 |  |
| Total                 | 4.13          | 3               | NC*        |               |             |        |     |  |
| <b>Lung and Bro</b>   | nchus_        |                 | <u>A</u> ] | ll Sites / Ty | <u>pes</u>  |        |     |  |
| Male                  | 56.69         | 69              | 122        | Male          | 344.00      | 348    | 101 |  |
| Female                | 38.76         | 34              | 88         | Female        | 317.32      | 313    | 99  |  |
| Total                 | 95.45         | 103             | 108        | Total         | 661.33      | 661    | 100 |  |
|                       |               |                 |            |               |             |        |     |  |

**Obs** = observed case count

SIR = standardized incidence ratio [ (Obs / Exp) X 100]

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} \le 0.05$  level

**DUDLEY** 

# Cancer Incidence by Sex, 1990 - 1995

# **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|                       | $\mathbf{Exp}$ | <u>Obs</u>              | <u>SIR</u> |                | $\mathbf{Exp}$ | <u>Obs</u> | <u>SIR</u> |  |
|-----------------------|----------------|-------------------------|------------|----------------|----------------|------------|------------|--|
| Bladder, Urina        | <u>ry</u>      |                         | <u>M</u>   | elanoma of     | <u>Skin</u>    |            |            |  |
| Male                  | 7.27           | 10                      | 138        | Male           | 3.84           | 7          | 182        |  |
| Female                | 2.44           | 5                       | 205        | Female         | 3.00           | 2          | NC*        |  |
| Total                 | 9.71           | 15                      | 154        | Total          | 6.84           | 9          | 132        |  |
| <b>Brain and Cent</b> | tral Nervous S | <u>System</u>           | <u>M</u>   | ultiple Mye    | <u>loma</u>    |            |            |  |
| Male                  | 2.63           | 3                       | NC*        | Male           | 1.32           | 1          | NC*        |  |
| Female                | 2.32           | 1                       | NC*        | Female         | 1.11           | 2          | NC*        |  |
| Total                 | 4.95           | 4                       | NC*        | Total          | 2.43           | 3          | NC*        |  |
| <b>Breast</b>         |                |                         | No         | on-Hodgkin'    | s Lymphoma     | <u>1</u>   |            |  |
| Male                  | 0.39           | 1                       | NC*        | Male           | 5.58           | 3          | NC*        |  |
| Female                | 41.72          | 43                      | 103        | Female         | 4.51           | 3          | NC*        |  |
| Total                 | 42.11          | 44                      | 104        | Total          | 10.10          | 6          | 59         |  |
| <u>Cervix Uteri</u>   |                | Oral Cavity and Pharynx |            |                |                |            |            |  |
|                       |                |                         |            | Male           | 5.02           | 2          | NC*        |  |
| Female                | 2.81           | 2                       | NC*        | Female         | 2.09           | 0          | NC*        |  |
|                       |                |                         |            | Total          | 7.11           | 2          | NC*        |  |
| Colon / Rectum        | <u>L</u>       |                         | <u>O</u>   | <u>vary</u>    |                |            |            |  |
| Male                  | 19.36          | 11                      | 57         |                |                |            |            |  |
| Female                | 16.13          | 7                       | 43 #-      | Female         | 5.12           | 10         | 195        |  |
| Total                 | 35.49          | 18                      | 51 ~-      |                |                |            |            |  |
| <b>Esophagus</b>      |                |                         | <u>Pa</u>  | ancreas        |                |            |            |  |
| Male                  | 2.51           | 2                       | NC*        | Male           | 2.71           | 3          | NC*        |  |
| Female                | 0.81           | 1                       | NC*        | Female         | 2.60           | 3          | NC*        |  |
| Total                 | 3.31           | 3                       | NC*        | Total          | 5.31           | 6          | 113        |  |
| Hodgkin's Disc        | ease_          |                         | <u>P</u> 1 | <u>rostate</u> |                |            |            |  |
| Male                  | 1.26           | 2                       | NC*        | Male           | 43.75          | 33         | 75         |  |
| Female                | 0.97           | 2                       | NC*        |                |                |            |            |  |
| Total                 | 2.23           | 4                       | NC*        |                |                |            |            |  |
| Kidney and Re         | nal Pelvis     |                         | <u>St</u>  | <u>omach</u>   |                |            |            |  |
| Male                  | 4.36           | 3                       | NC*        | Male           | 3.19           | 3          | NC*        |  |
| Female                | 2.46           | 0                       | NC*        | Female         | 1.74           | 2          | NC*        |  |
| Total                 | 6.82           | 3                       | NC*        | Total          | 4.92           | 5          | 102        |  |
| <u>Larynx</u>         |                |                         | <u>T</u>   | <u>estis</u>   |                |            |            |  |

<sup>~</sup> indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

| Male  | 2.72                                  | 4            | NC*                                   | Male                                | 1.87                 | 3   | NC*      |
|---|---------------------------------------|--------------|---------------------------------------|-------------------------------------|----------------------|-----|----------|
| Female  | 0.72                                  | 0            | NC*                                   |                                     |                      |     |          |
| Total   | 3.44                                  | 4            | NC*                                   |                                     |                      |     |          |
| <b>Leukemia</b>                                 |                                       |              | <u>Tl</u>                             | <u>nyroid</u>                       |                      |     |          |
| Male  | 3.03                                  | 4            | NC*                                   | Male                                | 0.76                 | 3   | NC*      |
| Female  | 2.10                                  | 2            | NC*                                   | Female                              | 1.98                 | 0   | NC*      |
| Total   | 5.13                                  | 6            | 117                                   | Total                               | 2.74                 | 3   | NC*      |
| <b>Liver and Intr</b>                           | <u>U</u> 1                            | teri, Corpus | and Uterus,                           | NOS                                 |                      |     |          |
|   |                                       |              |                                       |                                     |                      |     |          |
| Male  | 1.22                                  | 5            | 410 #+                                |                                     |                      |     |          |
| Male<br>Female                                  | 1.22<br>0.51                          | 5<br>0       | 410 #+<br>NC*                         | Female                              | 7.87                 | 6   | 76       |
|   |                                       | _            |                                       | Female                              | 7.87                 | 6   | 76       |
| Female  | 0.51<br>1.73                          | 0            | NC*<br>289                            | Female                              |                      | 6   | 76       |
| Female<br>Total                                 | 0.51<br>1.73                          | 0            | NC*<br>289                            |                                     |                      | 6   | 76<br>92 |
| Female<br>Total<br><b>Lung and Bro</b> r        | 0.51<br>1.73<br><b>nchus</b>          | 0<br>5       | NC*<br>289<br><u><b>A</b>l</u>        | ll Sites / Ty                       | <u>pes</u>           |     |          |
| Female<br>Total<br><b>Lung and Bron</b><br>Male | 0.51<br>1.73<br><b>nchus</b><br>24.23 | 0<br>5<br>26 | NC*<br>289<br><u><b>A</b>l</u><br>107 | l <mark>l Sites / Ty</mark><br>Male | <u>pes</u><br>147.49 | 135 | 92       |

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

#### **DUNSTABLE**

## Cancer Incidence by Sex, 1990 - 1995

## **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|                                  | Exp      | <u>Obs</u>       | SIR      |                      | Exp        | <u>Obs</u> | SIR |  |  |
|----------------------------------|----------|------------------|----------|----------------------|------------|------------|-----|--|--|
| Bladder, Urinar                  | <u>y</u> | Melanoma of Skin |          |                      |            |            |     |  |  |
| Male                             | 1.18     | 0                | NC*      | Male                 | 0.78       | 2          | NC* |  |  |
| Female                           | 0.38     | 0                | NC*      | Female               | 0.62       | 0          | NC* |  |  |
| Total                            | 1.56     | 0                | NC*      | Total                | 1.40       | 2          | NC* |  |  |
| Brain and Central Nervous System |          |                  | <u>M</u> | <u>lultiple Myel</u> | <u>oma</u> |            |     |  |  |
| Male                             | 0.56     | 0                | NC*      | Male                 | 0.22       | 0          | NC* |  |  |
| Female                           | 0.46     | 2                | NC*      | Female               | 0.18       | 0          | NC* |  |  |
| Total                            | 1.02     | 2                | NC*      | Total                | 0.40       | 0          | NC* |  |  |
| Breast                           |          |                  | N        | on-Hodgkin's         | Lymphoma   | ı          |     |  |  |

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} \le 0.05$  level

 $<sup>\</sup>sim$  indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

| Male                   | 0.07           | 0           | NC*        | Male                       | 1.08        | 0    | NC* |
|------------------------|----------------|-------------|------------|----------------------------|-------------|------|-----|
| Female                 | 8.01           | 6           | 75         | Female                     | 0.78        | 1    | NC* |
| Total                  | 8.08           | 6           | 74         | Total                      | 1.86        | 1    | NC* |
| Cervix Uteri           |                |             | <u>O</u> : | ral Cavity aı              | nd Pharynx  |      |     |
|                        |                |             |            | Male                       | 1.08        | 0    | NC* |
| Female                 | 0.63           | 1           | NC*        | Female                     | 0.39        | 0    | NC* |
|                        |                |             |            | Total                      | 1.47        | 0    | NC* |
| Colon / Rectum         | <u>-</u>       |             | <u>O</u>   | <u>vary</u>                |             |      |     |
| Male                   | 3.15           | 4           | NC*        |                            |             |      |     |
| Female                 | 2.45           | 0           | NC*        | Female                     | 1.02        | 1    | NC* |
| Total                  | 5.60           | 4           | NC*        |                            |             |      |     |
| <b>Esophagus</b>       |                |             | <u>Pa</u>  | ancreas                    |             |      |     |
| Male                   | 0.49           | 1           | NC*        | Male                       | 0.48        | 2    | NC* |
| Female                 | 0.12           | 1           | NC*        | Female                     | 0.40        | 0    | NC* |
| Total                  | 0.61           | 2           | NC*        | Total                      | 0.88        | 2    | NC* |
| Hodgkin's Dise         | ease_          |             | <u>Pr</u>  | <u>costate</u>             |             |      |     |
| Male                   | 0.28           | 0           | NC*        | Male                       | 6.75        | 7    | 104 |
| Female                 | 0.22           | 0           | NC*        |                            |             |      |     |
| Total                  | 0.50           | 0           | NC*        |                            |             |      |     |
| Kidney and Re          | nal Pelvis     |             | <u>St</u>  | <u>omach</u>               |             |      |     |
| Male                   | 0.86           | 0           | NC*        | Male                       | 0.53        | 0    | NC* |
| Female                 | 0.43           | 0           | NC*        | Female                     | 0.27        | 0    | NC* |
| Total                  | 1.29           | 0           | NC*        | Total                      | 0.80        | 0    | NC* |
| <u>Larynx</u>          |                |             | <u>T</u>   | <u>estis</u>               |             |      |     |
| Male                   | 0.56           | 1           | NC*        | Male                       | 0.42        | 1    | NC* |
| Female                 | 0.14           | 0           | NC*        |                            |             |      |     |
| Total                  | 0.69           | 1           | NC*        |                            |             |      |     |
| <b>Leukemia</b>        |                |             | <u>Tl</u>  | <u>ıyroid</u>              |             |      |     |
| Male                   | 0.58           | 0           | NC*        | Male                       | 0.17        | 0    | NC* |
| Female                 | 0.39           | 0           | NC*        | Female                     | 0.46        | 0    | NC* |
| Total                  | 0.97           | 0           | NC*        | Total                      | 0.63        | 0    | NC* |
| <b>Liver and Intra</b> | hepatic Bile D | <u>ucts</u> | <u>U</u> 1 | t <mark>eri, Corpus</mark> | and Uterus, | NOS_ |     |
| Male                   | 0.23           | 0           | NC*        |                            |             |      |     |
| Female                 | 0.08           | 0           | NC*        | Female                     | 1.48        | 1    | NC* |
| Total                  | 0.31           | 0           | NC*        |                            |             |      |     |
| <b>Lung and Bron</b>   | <u>chus</u>    |             |            | ll Sites / Typ             | <u>oes</u>  |      |     |
| Male                   | 4.37           | 4           | NC*        | Male                       | 25.75       | 26   | 101 |
| Female                 | 2.77           | 1           | NC*        | Female                     | 23.25       | 15   | 65  |
| Total                  | 7.14           | 5           | 70         | Total                      | 49.00       | 41   | 84  |
|                        |                |             |            |                            |             |      |     |

 $\mathbf{Exp} = \text{expected case count}$ , based on the Massachusetts average age-specific incidence rates for this cancer  $\mathbf{Obs} = \text{observed case count}$ 

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

- \* = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the  $\mathbf{p} <= 0.05$  level
- ~ indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level
- ^ indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

# **DUXBURY**

#### Cancer Incidence by Sex, 1990 - 1995

#### **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|                       | <b>Exp</b>                             | <u>Obs</u> | <u>SIR</u>              |                    | <b>Exp</b>  | <u>Obs</u> | <u>SIR</u> |  |  |  |
|-----------------------|--|------------|-------------------------|--------------------|-------------|------------|------------|--|--|--|
| Bladder, Urina        | <u>ry</u>                              |            | <u>M</u>                | <u>lelanoma of</u> | <u>Skin</u> |            |            |  |  |  |
| Male                  | 9.83                                   | 9          | 92                      | Male               | 5.49        | 7          | 128        |  |  |  |
| Female                | 3.79                                   | 5          | 132                     | Female             | 4.55        | 8          | 176        |  |  |  |
| Total                 | 13.62                                  | 14         | 103                     | Total              | 10.04       | 15         | 149        |  |  |  |
| <b>Brain and Cent</b> | and Central Nervous System Multiple My |            |                         |                    |             |            |            |  |  |  |
| Male                  | 3.70                                   | 5          | 135                     | Male               | 1.81        | 4          | NC*        |  |  |  |
| Female                | 3.46                                   | 2          | NC*                     | Female             | 1.71        | 2          | NC*        |  |  |  |
| Total                 | 7.16                                   | 7          | 98                      | Total              | 3.52        | 6          | 171        |  |  |  |
| <b>Breast</b>         |  |            | No                      | on-Hodgkin'        | s Lymphoma  | <u>1</u>   |            |  |  |  |
| Male                  | 0.55                                   | 1          | NC*                     | Male               | 7.60        | 1          | NC*        |  |  |  |
| Female                | 64.45                                  | 55         | 85                      | Female             | 6.83        | 3          | NC*        |  |  |  |
| Total                 | 64.99                                  | 56         | 86                      | Total              | 14.43       | 4          | NC*        |  |  |  |
| Cervix Uteri          |  |            | Oral Cavity and Pharynx |                    |             |            |            |  |  |  |
|                       |  |            |                         | Male               | 7.67        | 6          | 78         |  |  |  |
| Female                | 4.11                                   | 4          | NC*                     | Female             | 3.23        | 0          | NC*        |  |  |  |
|                       |  |            |                         | Total              | 10.90       | 6          | 55         |  |  |  |
| Colon / Rectum        | <u>L</u>                               |            | <u>O</u>                | <u>vary</u>        |             |            |            |  |  |  |
| Male                  | 26.08                                  | 22         | 84                      |                    |             |            |            |  |  |  |
| Female                | 25.07                                  | 23         | 92                      | Female             | 7.85        | 12         | 153        |  |  |  |
| Total                 | 51.15                                  | 45         | 88                      |                    |             |            |            |  |  |  |
| <b>Esophagus</b>      |  |            | <u>Pa</u>               | <u>ancreas</u>     |             |            |            |  |  |  |
| Male                  | 3.70                                   | 2          | NC*                     | Male               | 3.76        | 2          | NC*        |  |  |  |
| Female                | 1.24                                   | 3          | NC*                     | Female             | 3.95        | 5          | 127        |  |  |  |
| Total                 | 4.94                                   | 5          | 101                     | Total              | 7.71        | 7          | 91         |  |  |  |
| Hodgkin's Disc        | ease_                                  |            | <u>P</u> 1              | <u>rostate</u>     |             |            |            |  |  |  |
| Male                  | 1.58                                   | 1          | NC*                     | Male               | 56.92       | 65         | 114        |  |  |  |
| Female                | 1.31                                   | 2          | NC*                     |                    |             |            |            |  |  |  |
| Total                 | 2.89                                   | 3          | NC*                     |                    |             |            |            |  |  |  |
|                       |  |            |                         |                    |             |            |            |  |  |  |

| Kidney and Re          | nal Pelvis             | <b>Stomach</b> |            |                              |        |     |     |
|------------------------|------------------------|----------------|------------|------------------------------|--------|-----|-----|
| Male                   | 6.28                   | 4              | NC*        | Male                         | 4.36   | 2   | NC* |
| Female                 | 3.67                   | 5              | 136        | Female                       | 2.77   | 1   | NC* |
| Total                  | 9.95                   | 9              | 90         | Total                        | 7.14   | 3   | NC* |
| <u>Larynx</u>          |                        |                | <u>T</u>   |                              |        |     |     |
| Male                   | 4.10                   | 5              | 122        | Male                         | 2.15   | 3   | NC* |
| Female                 | 1.11                   | 0              | NC*        |                              |        |     |     |
| Total                  | 5.21                   | 5              | 96         |                              |        |     |     |
| <u>Leukemia</u>        |                        |                | <u>Tl</u>  | <u>nyroid</u>                |        |     |     |
| Male                   | 4.15                   | 2              | NC*        | Male                         | 1.03   | 3   | NC* |
| Female                 | 3.20                   | 2              | NC*        | Female                       | 2.86   | 1   | NC* |
| Total                  | 7.35                   | 4              | NC*        | Total                        | 3.89   | 4   | NC* |
| <b>Liver and Intra</b> | <u>thepatic Bile l</u> | <u>Ducts</u>   | <u>U</u> 1 | teri, Corpus and Uterus, NOS |        |     |     |
| Male                   | 1.72                   | 2              | NC*        |                              |        |     |     |
| Female                 | 0.76                   | 1              | NC*        | Female                       | 12.09  | 8   | 66  |
| Total                  | 2.48                   | 3              | NC*        |                              |        |     |     |
| <b>Lung and Bron</b>   | <u>chus</u>            |                | <u>A</u> ] | All Sites / Types            |        |     |     |
| Male                   | 33.92                  | 28             | 83         | Male                         | 200.62 | 186 | 93  |
| Female                 | 23.65                  | 20             | 85         | Female                       | 195.80 | 175 | 89  |
| Total                  | 57.58                  | 48             | 83         | Total                        | 396.42 | 361 | 91  |

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

SIR = standardized incidence ratio [ (Obs / Exp) X 100]

# **EAST BRIDGEWATER**

Cancer Incidence by Sex, 1990 - 1995

# **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|                  | <b>Exp</b> | <u>Obs</u> | <u>SIR</u>               |                      | <b>Exp</b>  | <u>Obs</u> | <u>SIR</u> |
|------------------|------------|------------|--------------------------|----------------------|-------------|------------|------------|
| Bladder, Urinary |            |            | $\underline{\mathbf{M}}$ | <u>lelanoma of S</u> | <u>Skin</u> |            |            |
| Male             | 6.32       | 6          | 95                       | Male                 | 3.77        | 3          | NC*        |
| Female           | 2.61       | 2          | NC*                      | Female               | 3.36        | 1          | NC*        |
| Total            | 8.92       | 8          | 90                       | Total                | 7.13        | 4          | NC*        |

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} \le 0.05$  level

 $<sup>\</sup>sim$  indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

| <b>Brain and Cent</b> | ral Nervous       | System | Multiple Myeloma |                     |              |           |        |
|-----------------------|-------------------|--------|------------------|---------------------|--------------|-----------|--------|
| Male                  | 2.71              | 0      | NC*              | Male                | 1.16         | 0         | NC*    |
| Female                | 2.56              | 2      | NC*              | Female              | 1.17         | 3         | NC*    |
| Total                 | 5.27              | 2      | NC*              | Total               | 2.34         | 3         | NC*    |
| <b>Breast</b>         |                   |        | <u>N</u>         | on-Hodgkin          | 's Lymphon   | <u>1a</u> |        |
| Male                  | 0.35              | 2      | NC*              | Male                | 5.39         | 11        | 204 #+ |
| Female                | 45.28             | 41     | 91               | Female              | 4.87         | 6         | 123    |
| Total                 | 45.64             | 43     | 94               | Total               | 10.26        | 17        | 166    |
| Cervix Uteri          |                   |        | <u>O</u>         | ral Cavity a        | nd Pharynx   |           |        |
|                       |                   |        |                  | Male                | 4.98         | 4         | NC*    |
| Female                | 3.20              | 3      | NC*              | Female              | 2.26         | 1         | NC*    |
|                       |                   |        |                  | Total               | 7.24         | 5         | 69     |
| Colon / Rectum        | i                 |        | <u>O</u>         | <u>vary</u>         |              |           |        |
| Male                  | 16.83             | 24     | 143              |                     |              |           |        |
| Female                | 17.22             | 17     | 99               | Female              | 5.62         | 3         | NC*    |
| Total                 | 34.05             | 41     | 120              |                     |              |           |        |
| <b>Esophagus</b>      |                   |        | <u>Pa</u>        | ancreas             |              |           |        |
| Male                  | 2.35              | 6      | 256              | Male                | 2.45         | 7         | 286 #+ |
| Female                | 0.85              | 2      | NC*              | Female              | 2.73         | 3         | NC*    |
| Total                 | 3.20              | 8      | 250 #+           | Total               | 5.18         | 10        | 193    |
| <b>Hodgkin's Dise</b> | <u>ase</u>        |        | <u>P</u> 1       | <u>rostate</u>      |              |           |        |
| Male                  | 1.39              | 1      | NC*              | Male                | 37.24        | 39        | 105    |
| Female                | 1.13              | 4      | NC*              |                     |              |           |        |
| Total                 | 2.52              | 5      | 198              |                     |              |           |        |
| Kidney and Ren        | <u>nal Pelvis</u> |        | St               | <u>omach</u>        |              |           |        |
| Male                  | 4.14              | 3      | NC*              | Male                | 2.81         | 3         | NC*    |
| Female                | 2.60              | 3      | NC*              | Female              | 1.89         | 5         | 264    |
| Total                 | 6.75              | 6      | 89               | Total               | 4.70         | 8         | 170    |
| <u>Larynx</u>         |                   |        | <u>T</u>         | <u>estis</u>        |              |           |        |
| Male                  | 2.61              | 2      | NC*              | Male                | 2.12         | 9         | 424 ^+ |
| Female                | 0.76              | 1      | NC*              |                     |              |           |        |
| Total                 | 3.37              | 3      | NC*              |                     |              |           |        |
| <b>Leukemia</b>       |                   |        |                  | <u>hyroid</u>       |              |           |        |
| Male                  | 2.94              | 3      | NC*              | Male                | 0.81         | 0         | NC*    |
| Female                | 2.35              | 5      | 213              | Female              | 2.29         | 3         | NC*    |
| Total                 | 5.29              | 8      | 151              | Total               | 3.10         | 3         | NC*    |
| Liver and Intra       | _                 |        |                  | <u>teri, Corpus</u> | s and Uterus | , NOS     |        |
| Male                  | 1.14              | 1      | NC*              |                     |              |           |        |
| Female                | 0.54              | 0      | NC*              | Female              | 8.38         | 6         | 72     |
| Total                 | 1.68              | 1      | NC*              |                     |              |           |        |
| Lung and Bronc        |                   |        |                  | ll Sites / Ty       |              |           |        |
| Male                  | 21.98             | 15     | 68               | Male                | 133.37       | 145       | 109    |
| Female                | 16.64             | 14     | 84               | Female              | 138.28       | 134       | 97     |
| Total                 | 38.62             | 29     | 75               | Total               | 271.66       | 279       | 103    |

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

SIR = standardized incidence ratio [ (Obs / Exp) X 100]

#### EAST BROOKFIELD

## Cancer Incidence by Sex, 1990 - 1995

#### **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|   | $\underline{\mathbf{Exp}}$ | <u>Obs</u> | <u>SIR</u>             |                     | <b>Exp</b>        | <u>Obs</u> | <u>SIR</u> |  |  |
|---|----------------------------|------------|------------------------|---------------------|-------------------|------------|------------|--|--|
| Bladder, Urinaı                         | <u> </u>                   |            | <u>M</u>               | elanoma of S        | <u>Skin</u>       |            |            |  |  |
| Male                                    | 1.62                       | 0          | NC*                    | Male                | 0.84              | 2          | NC*        |  |  |
| Female                                  | 0.54                       | 1          | NC*                    | Female              | 0.61              | 1          | NC*        |  |  |
| Total                                   | 2.16                       | 1          | NC*                    | Total               | 1.45              | 3          | NC*        |  |  |
| <b>Brain and Central Nervous System</b> |                            |            | <u>M</u>               | <u>ultiple Myel</u> | <u>loma</u>       |            |            |  |  |
| Male                                    | 0.57                       | 0          | NC*                    | Male                | 0.29              | 0          | NC*        |  |  |
| Female                                  | 0.48                       | 0          | NC*                    | Female              | 0.24              | 0          | NC*        |  |  |
| Total                                   | 1.05                       | 0          | NC*                    | Total               | 0.54              | 0          | NC*        |  |  |
| <b>Breast</b>                           |                            |            | Non-Hodgkin's Lymphoma |                     |                   |            |            |  |  |
| Male                                    | 0.09                       | 0          | NC*                    | Male                | 1.22              | 0          | NC*        |  |  |
| Female                                  | 8.61                       | 7          | 81                     | Female              | 0.97              | 0          | NC*        |  |  |
| Total                                   | 8.70                       | 7          | 80                     | Total               | 2.18              | 0          | NC*        |  |  |
| <u>Cervix Uteri</u>                     |                            |            | <u>O</u> :             | ral Cavity an       | <u>nd Pharynx</u> |            |            |  |  |
|   |                            |            |                        | Male                | 1.11              | 0          | NC*        |  |  |
| Female                                  | 0.56                       | 0          | NC*                    | Female              | 0.44              | 0          | NC*        |  |  |
|   |                            |            |                        | Total               | 1.55              | 0          | NC*        |  |  |
| Colon / Rectum                          | _                          |            | <u>O</u>               | <u>vary</u>         |                   |            |            |  |  |
| Male                                    | 4.31                       | 7          | 162                    |                     |                   |            |            |  |  |
| Female                                  | 3.60                       | 4          | NC*                    | Female              | 1.05              | 0          | NC*        |  |  |
| Total                                   | 7.92                       | 11         | 139                    |                     |                   |            |            |  |  |
| <b>Esophagus</b>                        |                            |            | <u>Pa</u>              | <u>ancreas</u>      |                   |            |            |  |  |
| Male                                    | 0.56                       | 0          | NC*                    | Male                | 0.60              | 1          | NC*        |  |  |
| Female                                  | 0.18                       | 1          | NC*                    | Female              | 0.57              | 0          | NC*        |  |  |
| Total                                   | 0.74                       | 1          | NC*                    | Total               | 1.17              | 1          | NC*        |  |  |
|   |                            |            |                        |                     |                   |            |            |  |  |

<sup>\* =</sup> **SIR** and statistical significance not calculated when **Obs** < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} \le 0.05$  level

<sup>~</sup> indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

| <b>Hodgkin's Dis</b>  | <u>Prostate</u>        |              |                   |                     |                 |    |     |  |
|-----------------------|------------------------|--------------|-------------------|---------------------|-----------------|----|-----|--|
| Male                  | 0.26                   | 0            | NC*               | Male                | 9.67            | 9  | 93  |  |
| Female                | 0.19                   | 0            | NC*               |                     |                 |    |     |  |
| Total                 | 0.45                   | 0            | NC*               |                     |                 |    |     |  |
| Kidney and Ro         | enal Pelvis            |              | Stomach_          |                     |                 |    |     |  |
| Male                  | 0.96                   | 1            | NC*               | Male                | 0.71            | 1  | NC* |  |
| Female                | 0.51                   | 0            | NC*               | Female              | 0.39            | 0  | NC* |  |
| Total                 | 1.48                   | 1            | NC*               | Total               | 1.10            | 1  | NC* |  |
| <u>Larynx</u>         |                        |              | <u>T</u>          | <u>estis</u>        |                 |    |     |  |
| Male                  | 0.60                   | 2            | NC*               | Male                | 0.37            | 1  | NC* |  |
| Female                | 0.15                   | 0            | NC*               |                     |                 |    |     |  |
| Total                 | 0.75                   | 2            | NC*               |                     |                 |    |     |  |
| <u>Leukemia</u>       |                        |              | <u>Tł</u>         | <u> </u>            |                 |    |     |  |
| Male                  | 0.67                   | 1            | NC*               | Male                | 0.16            | 0  | NC* |  |
| Female                | 0.45                   | 0            | NC*               | Female              | 0.39            | 1  | NC* |  |
| Total                 | 1.12                   | 1            | NC*               | Total               | 0.55            | 1  | NC* |  |
| <b>Liver and Intr</b> | <u>ahepatic Bile I</u> | <u>Ducts</u> | <u>U1</u>         | <u>teri, Corpus</u> | and Uterus, NOS |    |     |  |
| Male                  | 0.27                   | 0            | NC*               |                     |                 |    |     |  |
| Female                | 0.11                   | 0            | NC*               | Female              | 1.61            | 4  | NC* |  |
| Total                 | 0.38                   | 0            | NC*               |                     |                 |    |     |  |
| <b>Lung and Bron</b>  | <u>nchus</u>           |              | All Sites / Types |                     |                 |    |     |  |
| Male                  | 5.37                   | 3            | NC*               | Male                | 32.56           | 31 | 95  |  |
| Female                | 3.34                   | 7            | 210               | Female              | 26.96           | 28 | 104 |  |
| Total                 | 8.71                   | 10           | 115               | Total               | 59.52           | 59 | 99  |  |
|                       |                        |              |                   |                     |                 |    |     |  |

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

#### EAST LONGMEADOW

Cancer Incidence by Sex, 1990 - 1995

**Expected and Observed Case Counts, with Standardized Incidence Ratios** 

<u>Exp</u> <u>Obs</u> <u>SIR</u> <u>Exp</u> <u>Obs</u> <u>SIR</u>

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the  $\mathbf{p} <= 0.05$  level

in interested statistical significance at the p < 0.00 fever

 $<sup>\</sup>sim$  indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

| Bladder, Urinar        | <u>v</u>      |               | <u>M</u>                 | lelanoma of         | <u>Skin</u> |          |     |
|------------------------|---------------|---------------|--------------------------|---------------------|-------------|----------|-----|
| Male                   | 12.27         | 11            | 90                       | Male                | 6.01        | 4        | NC* |
| Female                 | 5.61          | 7             | 125                      | Female              | 5.24        | 7        | 134 |
| Total                  | 17.88         | 18            | 101                      | Total               | 11.25       | 11       | 98  |
| <b>Brain and Cent</b>  | ral Nervous S | <u>System</u> | $\underline{\mathbf{M}}$ | <u>lultiple Mye</u> |             |          |     |
| Male                   | 3.94          | 3             | NC*                      | Male                | 2.20        | 1        | NC* |
| Female                 | 4.04          | 5             | 124                      | Female              | 2.41        | 1        | NC* |
| Total                  | 7.98          | 8             | 100                      | Total               | 4.61        | 2        | NC* |
| <b>Breast</b>          |               |               | <u>N</u>                 | on-Hodgkin'         | s Lymphoma  | <u>1</u> |     |
| Male                   | 0.64          | 0             | NC*                      | Male                | 8.63        | 13       | 151 |
| Female                 | 77.69         | 80            | 103                      | Female              | 9.32        | 7        | 75  |
| Total                  | 78.33         | 80            | 102                      | Total               | 17.95       | 20       | 111 |
| Cervix Uteri           |               |               | <u>O</u>                 | nd Pharynx          |             |          |     |
|                        |               |               |                          | Male                | 8.13        | 7        | 86  |
| Female                 | 4.36          | 5             | 115                      | Female              | 4.09        | 3        | NC* |
|                        |               |               |                          | Total               | 12.22       | 10       | 82  |
| Colon / Rectum         | _             |               | <u>O</u>                 | <u>vary</u>         |             |          |     |
| Male                   | 32.56         | 31            | 95                       |                     |             |          |     |
| Female                 | 38.20         | 42            | 110                      | Female              | 9.12        | 6        | 66  |
| Total                  | 70.77         | 73            | 103                      |                     |             |          |     |
| <b>Esophagus</b>       |               |               | <u>Pa</u>                | ancreas             |             |          |     |
| Male                   | 4.17          | 1             | NC*                      | Male                | 4.50        | 3        | NC* |
| Female                 | 1.89          | 0             | NC*                      | Female              | 5.80        | 2        | NC* |
| Total                  | 6.06          | 1             | NC*                      | Total               | 10.30       | 5        | 49  |
| Hodgkin's Dise         | <u>ease</u>   |               | <u>P</u> 1               | <u>rostate</u>      |             |          |     |
| Male                   | 1.62          | 2             | NC*                      | Male                | 74.20       | 76       | 102 |
| Female                 | 1.36          | 1             | NC*                      |                     |             |          |     |
| Total                  | 2.98          | 3             | NC*                      |                     |             |          |     |
| Kidney and Re          | nal Pelvis    |               | <u>St</u>                | omach_              |             |          |     |
| Male                   | 7.05          | 6             | 85                       | Male                | 5.36        | 2        | NC* |
| Female                 | 4.69          | 6             | 128                      | Female              | 4.28        | 4        | NC* |
| Total                  | 11.74         | 12            | 102                      | Total               | 9.64        | 6        | 62  |
| <u>Larynx</u>          |               |               | $\underline{\mathbf{T}}$ | <u>estis</u>        |             |          |     |
| Male                   | 4.52          | 4             | NC*                      | Male                | 2.15        | 1        | NC* |
| Female                 | 1.28          | 1             | NC*                      |                     |             |          |     |
| Total                  | 5.80          | 5             | 86                       |                     |             |          |     |
| <u>Leukemia</u>        |               |               | <u>T</u>                 | <u>hyroid</u>       |             |          |     |
| Male                   | 4.73          | 1             | NC*                      | Male                | 1.04        | 2        | NC* |
| Female                 | 4.15          | 0             | NC*                      | Female              | 2.96        | 3        | NC* |
| Total                  | 8.88          | 1             | NC*                      | Total               | 4.00        | 5        | 125 |
| <b>Liver and Intra</b> | hepatic Bile  | <u>Ducts</u>  | <u>U</u> 1               | <u>teri, Corpus</u> | and Uterus, | NOS_     |     |
| Male                   | 1.99          | 1             | NC*                      |                     |             |          |     |
| Female                 | 1.07          | 1             | NC*                      | Female              | 14.44       | 13       | 90  |
| Total                  | 3.06          | 2             | NC*                      |                     |             |          |     |

57 of 84

| <b>Lung and Bro</b> |       | All Sites / Types |    |        |        |     |       |
|---------------------|-------|-------------------|----|--------|--------|-----|-------|
| Male                | 40.29 | 29                | 72 | Male   | 242.56 | 212 | 87 #- |
| Female              | 30.01 | 28                | 93 | Female | 251.78 | 247 | 98    |
| Total               | 70.31 | 57                | 81 | Total  | 494.35 | 459 | 93    |

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

#### **EASTHAM**

#### Cancer Incidence by Sex, 1990 - 1995

#### **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|                | <b>Exp</b>     | <u>Obs</u>    | <u>SIR</u>       |               | <b>Exp</b>        | <u>Obs</u> | <u>SIR</u> |
|----------------|----------------|---------------|------------------|---------------|-------------------|------------|------------|
| Bladder, Urina | <u>iry</u>     |               | <u>M</u>         | elanoma of S  | <u>Skin</u>       |            |            |
| Male           | 6.02           | 8             | 133              | Male          | 2.63              | 4          | NC*        |
| Female         | 1.84           | 5             | 272              | Female        | 1.86              | 3          | NC*        |
| Total          | 7.87           | 13            | 165              | Total         | 4.48              | 7          | 156        |
| Brain and Cer  | tral Nervous S | <u>System</u> | Multiple Myeloma |               |                   |            |            |
| Male           | 1.64           | 2             | NC*              | Male          | 1.07              | 1          | NC*        |
| Female         | 1.48           | 2             | NC*              | Female        | 0.83              | 1          | NC*        |
| Total          | 3.12           | 4             | NC*              | Total         | 1.90              | 2          | NC*        |
| <b>Breast</b>  |                |               | No               | on-Hodgkin's  | s Lymphoma        | <u>a</u>   |            |
| Male           | 0.30           | 0             | NC*              | Male          | 3.83              | 3          | NC*        |
| Female         | 28.32          | 33            | 117              | Female        | 3.18              | 2          | NC*        |
| Total          | 28.63          | 33            | 115              | Total         | 7.02              | 5          | 71         |
| Cervix Uteri   |                |               | <u>O</u> 1       | ral Cavity an | <u>nd Pharynx</u> |            |            |
|                |                |               |                  | Male          | 3.56              | 4          | NC*        |
| Female         | 1.58           | 3             | NC*              | Female        | 1.47              | 3          | NC*        |
|                |                |               |                  | Total         | 5.03              | 7          | 139        |
| Colon / Rectur | <u>n</u>       |               | <u>O</u>         | <u>vary</u>   |                   |            |            |
| Male           | 16.02          | 18            | 112              |               |                   |            |            |
| Female         | 12.22          | 16            | 131              | Female        | 3.35              | 5          | 149        |
| Total          | 28.24          | 34            | 120              |               |                   |            |            |

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} \le 0.05$  level

<sup>~</sup> indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

| <b>Esophagus</b>       |               |              | <u>Pa</u>  | ancreas             |            |       |        |
|------------------------|---------------|--------------|------------|---------------------|------------|-------|--------|
| Male                   | 1.94          | 3            | NC*        | Male                | 2.16       | 2     | NC*    |
| Female                 | 0.62          | 0            | NC*        | Female              | 1.97       | 1     | NC*    |
| Total                  | 2.56          | 3            | NC*        | Total               | 4.12       | 3     | NC*    |
| <b>Hodgkin's Disc</b>  | ease          |              | <u>P1</u>  | <u>rostate</u>      |            |       |        |
| Male                   | 0.57          | 0            | NC*        | Male                | 37.67      | 53    | 141 #+ |
| Female                 | 0.47          | 1            | NC*        |                     |            |       |        |
| Total                  | 1.05          | 1            | NC*        |                     |            |       |        |
| Kidney and Re          | nal Pelvis    |              | <u>St</u>  | <u>omach</u>        |            |       |        |
| Male                   | 3.23          | 4            | NC*        | Male                | 2.59       | 2     | NC*    |
| Female                 | 1.75          | 2            | NC*        | Female              | 1.30       | 1     | NC*    |
| Total                  | 4.98          | 6            | 120        | Total               | 3.89       | 3     | NC*    |
| <u>Larynx</u>          |               |              | <u>T</u>   | <u>estis</u>        |            |       |        |
| Male                   | 2.06          | 0            | NC*        | Male                | 0.65       | 0     | NC*    |
| Female                 | 0.52          | 0            | NC*        |                     |            |       |        |
| Total                  | 2.58          | 0            | NC*        |                     |            |       |        |
| <b>Leukemia</b>        |               |              | <u>Tl</u>  | <u>hyroid</u>       |            |       |        |
| Male                   | 2.11          | 3            | NC*        | Male                | 0.40       | 0     | NC*    |
| Female                 | 1.36          | 3            | NC*        | Female              | 1.05       | 3     | NC*    |
| Total                  | 3.48          | 6            | 173        | Total               | 1.45       | 3     | NC*    |
| <b>Liver and Intra</b> | ahepatic Bile | <b>Ducts</b> | <u>U</u> 1 | <u>teri, Corpus</u> | and Uterus | , NOS |        |
| Male                   | 0.93          | 2            | NC*        |                     |            |       |        |
| Female                 | 0.37          | 1            | NC*        | Female              | 5.54       | 10    | 180    |
| Total                  | 1.30          | 3            | NC*        |                     |            |       |        |
| <b>Lung and Bron</b>   | <u>chus</u>   |              | <u>A</u> ] | ll Sites / Ty       | <u>pes</u> |       |        |
| Male                   | 19.39         | 16           | 83         | Male                | 116.37     | 132   | 113    |
| Female                 | 11.84         | 11           | 93         | Female              | 89.39      | 116   | 130 ~+ |
| Total                  | 31.23         | 27           | 86         | Total               | 205.75     | 248   | 121 ~+ |
|                        |               |              |            |                     |            |       |        |

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

## **EASTHAMPTON**

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} \le 0.05$  level

<sup>~</sup> indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

# Cancer Incidence by Sex, 1990 - 1995 Expected and Observed Case Counts, with Standardized Incidence Ratios

|                       | <u>Exp</u>  | <u>Obs</u>    | <u>SIR</u>               |                     | Exp         | <u>Obs</u> | SIR    |
|-----------------------|-------------|---------------|--------------------------|---------------------|-------------|------------|--------|
| Bladder, Urinaı       | <u>v</u>    |               | $\underline{\mathbf{M}}$ | <u>lelanoma of</u>  | <u>Skin</u> |            |        |
| Male                  | 12.09       | 9             | 74                       | Male                | 6.36        | 3          | NC*    |
| Female                | 4.23        | 4             | NC*                      | Female              | 5.03        | 3          | NC*    |
| Total                 | 16.32       | 13            | 80                       | Total               | 11.39       | 6          | 53     |
| <b>Brain and Cent</b> | ral Nervous | <u>System</u> |                          | <u>lultiple Mye</u> | <u>loma</u> |            |        |
| Male                  | 4.28        | 2             | NC*                      | Male                | 2.19        | 7          | 320 #+ |
| Female                | 3.84        | 3             | NC*                      | Female              | 1.91        | 1          | NC*    |
| Total                 | 8.12        | 5             | 62                       | Total               | 4.10        | 8          | 195    |
| <b>Breast</b>         |             |               | No                       | <u>on-Hodgkin'</u>  | s Lymphoma  | <u>1</u>   |        |
| Male                  | 0.65        | 0             | NC*                      | Male                | 9.22        | 3          | NC*    |
| Female                | 69.80       | 63            | 90                       | Female              | 7.72        | 5          | 65     |
| Total                 | 70.44       | 63            | 89                       | Total               | 16.93       | 8          | 47 #-  |
| Cervix Uteri          |             |               | Oral Cavity and Pharynx  |                     |             |            |        |
|                       |             |               |                          | Male                | 8.31        | 6          | 72     |
| Female                | 4.69        | 3             | NC*                      | Female              | 3.51        | 6          | 171    |
|                       |             |               |                          | Total               | 11.82       | 12         | 102    |
| Colon / Rectum        | _           |               | <u>O</u>                 | <u>vary</u>         |             |            |        |
| Male                  | 32.17       | 27            | 84                       |                     |             |            |        |
| Female                | 28.16       | 25            | 89                       | Female              | 8.53        | 11         | 129    |
| Total                 | 60.33       | 52            | 86                       |                     |             |            |        |
| <b>Esophagus</b>      |             |               | <u>Pa</u>                | ancreas_            |             |            |        |
| Male                  | 4.15        | 3             | NC*                      | Male                | 4.49        | 4          | NC*    |
| Female                | 1.40        | 1             | NC*                      | Female              | 4.49        | 7          | 156    |
| Total                 | 5.55        | 4             | NC*                      | Total               | 8.98        | 11         | 123    |
| Hodgkin's Dise        | <u>ease</u> |               | <u>P</u> 1               | <u>rostate</u>      |             |            |        |
| Male                  | 2.04        | 3             | NC*                      | Male                | 72.64       | 43         | 59 ^-  |
| Female                | 1.61        | 2             | NC*                      |                     |             |            |        |
| Total                 | 3.65        | 5             | 137                      |                     |             |            |        |
| Kidney and Re         | nal Pelvis  |               | St                       | omach_              |             |            |        |
| Male                  | 7.18        | 7             | 97                       | Male                | 5.30        | 6          | 113    |
| Female                | 4.12        | 5             | 121                      | Female              | 3.05        | 2          | NC*    |
| Total                 | 11.30       | 12            | 106                      | Total               | 8.36        | 8          | 96     |
| <u>Larynx</u>         |             |               | <u>T</u>                 | <u>estis</u>        |             |            |        |
| Male                  | 4.50        | 3             | NC*                      | Male                | 3.07        | 6          | 196    |
| Female                | 1.18        | 0             | NC*                      |                     |             |            |        |
| Total                 | 5.68        | 3             | NC*                      |                     |             |            |        |
| <u>Leukemia</u>       |             |               |                          | <u>hyroid</u>       |             |            |        |
| Male                  | 4.92        | 8             | 163                      | Male                | 1.24        | 1          | NC*    |
| Female                | 3.54        | 1             | NC*                      | Female              | 3.31        | 5          | 151    |
|                       |             |               |                          |                     |             |            |        |

| Total                                    | 8.46  | 9  | 106 | Total                      | 4.55       | 6   | 132   |  |  |
|--|-------|----|-----|----------------------------|------------|-----|-------|--|--|
| <b>Liver and Intrahepatic Bile Ducts</b> |       |    |     | t <mark>eri, Corpus</mark> | and Uterus | NOS |       |  |  |
| Male                                     | 2.02  | 2  | NC* |                            |            |     |       |  |  |
| Female                                   | 0.87  | 0  | NC* | Female                     | 13.07      | 9   | 69    |  |  |
| Total                                    | 2.88  | 2  | NC* |                            |            |     |       |  |  |
| <b>Lung and Bronchus</b>                 |       |    |     | All Sites / Types          |            |     |       |  |  |
| Male                                     | 40.11 | 36 | 90  | Male                       | 244.18     | 195 | 80 ~- |  |  |
| Female                                   | 26.97 | 26 | 96  | Female                     | 216.66     | 197 | 91    |  |  |
| Total                                    | 67.08 | 62 | 92  | Total                      | 460.84     | 392 | 85 ~- |  |  |

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

#### **EASTON**

# Cancer Incidence by Sex, 1990 - 1995

# **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|                       | Exp            | <u>Obs</u>              | <u>SIR</u> |             | <b>Exp</b>  | <u>Obs</u> | SIR |  |  |
|-----------------------|----------------|-------------------------|------------|-------------|-------------|------------|-----|--|--|
| Bladder, Urina        | <u>ry</u>      | Melanoma of Skin        |            |             |             |            |     |  |  |
| Male                  | 11.44          | 9                       | 79         | Male        | 6.86        | 6          | 87  |  |  |
| Female                | 4.21           | 5                       | 119        | Female      | 5.90        | 5          | 85  |  |  |
| Total                 | 15.65          | 14                      | 89         | Total       | 12.76       | 11         | 86  |  |  |
| <b>Brain and Cent</b> | tral Nervous S | <u>System</u>           | <u>M</u>   | ultiple Mye | <u>loma</u> |            |     |  |  |
| Male                  | 4.81           | 3                       | NC*        | Male        | 2.11        | 1          | NC* |  |  |
| Female                | 4.41           | 4                       | NC*        | Female      | 1.90        | 2          | NC* |  |  |
| Total                 | 9.22           | 7                       | 76         | Total       | 4.02        | 3          | NC* |  |  |
| <b>Breast</b>         |                |                         | <u>N</u>   | on-Hodgkin' | s Lymphoma  | <u>a</u> _ |     |  |  |
| Male                  | 0.64           | 0                       | NC*        | Male        | 9.70        | 4          | NC* |  |  |
| Female                | 76.87          | 86                      | 112        | Female      | 8.09        | 6          | 74  |  |  |
| Total                 | 77.52          | 86                      | 111        | Total       | 17.79       | 10         | 56  |  |  |
| Cervix Uteri          |                | Oral Cavity and Pharynx |            |             |             |            |     |  |  |
|                       |                |                         |            | Male        | 9.16        | 7          | 76  |  |  |
| Female                | 5.82           | 2                       | NC*        | Female      | 3.80        | 4          | NC* |  |  |

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} <= 0.05$  level

<sup>~</sup> indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

|                        |               |              |            | Total               | 12.95       | 11  | 85  |
|------------------------|---------------|--------------|------------|---------------------|-------------|-----|-----|
| Colon / Rectum         | <u>L</u>      |              | <u>O</u>   | <u>vary</u>         |             |     |     |
| Male                   | 30.43         | 26           | 85         |                     |             |     |     |
| Female                 | 27.59         | 29           | 105        | Female              | 9.67        | 14  | 145 |
| Total                  | 58.02         | 55           | 95         |                     |             |     |     |
| <b>Esophagus</b>       |               |              | <u>Pa</u>  | <u>ancreas</u>      |             |     |     |
| Male                   | 4.30          | 4            | NC*        | Male                | 4.44        | 7   | 158 |
| Female                 | 1.36          | 2            | NC*        | Female              | 4.39        | 5   | 114 |
| Total                  | 5.66          | 6            | 106        | Total               | 8.83        | 12  | 136 |
| Hodgkin's Disc         | <u>ease</u>   |              | <u>P</u> 1 | <u>rostate</u>      |             |     |     |
| Male                   | 2.42          | 4            | NC*        | Male                | 66.39       | 63  | 95  |
| Female                 | 2.09          | 4            | NC*        |                     |             |     |     |
| Total                  | 4.51          | 8            | 177        |                     |             |     |     |
| Kidney and Re          | enal Pelvis   |              | <u>St</u>  | <u>omach</u>        |             |     |     |
| Male                   | 7.51          | 14           | 186 #+     | Male                | 5.11        | 4   | NC* |
| Female                 | 4.32          | 1            | NC*        | Female              | 3.04        | 2   | NC* |
| Total                  | 11.84         | 15           | 127        | Total               | 8.15        | 6   | 74  |
| <u>Larynx</u>          |               |              | <u>T</u>   | <u>estis</u>        |             |     |     |
| Male                   | 4.78          | 6            | 125        | Male                | 3.72        | 2   | NC* |
| Female                 | 1.28          | 0            | NC*        |                     |             |     |     |
| Total                  | 6.06          | 6            | 99         |                     |             |     |     |
| <b>Leukemia</b>        |               |              | <u>T</u>   | <u>hyroid</u>       |             |     |     |
| Male                   | 5.20          | 5            | 96         | Male                | 1.46        | 0   | NC* |
| Female                 | 3.97          | 4            | NC*        | Female              | 4.21        | 6   | 143 |
| Total                  | 9.16          | 9            | 98         | Total               | 5.66        | 6   | 106 |
| <b>Liver and Intra</b> | ahepatic Bile | <u>Ducts</u> | <u>U</u> 1 | <u>teri, Corpus</u> | and Uterus, | NOS |     |
| Male                   | 2.06          | 4            | NC*        |                     |             |     |     |
| Female                 | 0.88          | 0            | NC*        | Female              | 14.08       | 14  | 99  |
| Total                  | 2.94          | 4            | NC*        |                     |             |     |     |
| <b>Lung and Bron</b>   | chus          |              | <u>A</u> ] | ll Sites / Ty       | <u>pes</u>  |     |     |
| Male                   | 39.74         | 38           | 96         | Male                | 239.98      | 220 | 92  |
| Female                 | 27.37         | 25           | 91         | Female              | 231.66      | 239 | 103 |
| Total                  | 67.11         | 63           | 94         | Total               | 471.65      | 459 | 97  |
|                        |               |              |            |                     |             |     |     |

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} \le 0.05$  level

 $<sup>\</sup>sim$  indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

# **EDGARTOWN**

# Cancer Incidence by Sex, 1990 - 1995

# **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|                       | Exp                  | <u>Obs</u>              | <u>SIR</u> |                     | <b>Exp</b>  | <u>Obs</u> | <u>SIR</u> |  |
|-----------------------|----------------------|-------------------------|------------|---------------------|-------------|------------|------------|--|
| Bladder, Urinaı       | <u>ry</u>            |                         | <u>M</u>   | elanoma of          | <u>Skin</u> |            |            |  |
| Male                  | 2.72                 | 2                       | NC*        | Male                | 1.43        | 2          | NC*        |  |
| Female                | 0.83                 | 1                       | NC*        | Female              | 1.00        | 4          | NC*        |  |
| Total                 | 3.55                 | 3                       | NC*        | Total               | 2.43        | 6          | 247        |  |
| <b>Brain and Cent</b> | <u>ral Nervous S</u> | <u>System</u>           | <u>M</u>   | <u>[ultiple Mye</u> | <u>loma</u> |            |            |  |
| Male                  | 0.94                 | 0                       | NC*        | Male                | 0.49        | 2          | NC*        |  |
| Female                | 0.78                 | 0                       | NC*        | Female              | 0.38        | 1          | NC*        |  |
| Total                 | 1.72                 | 0                       | NC*        | Total               | 0.87        | 3          | NC*        |  |
| <b>Breast</b>         |                      |                         | No         | on-Hodgkin'         | s Lymphoma  | <u>1</u>   |            |  |
| Male                  | 0.15                 | 0                       | NC*        | Male                | 2.03        | 0          | NC*        |  |
| Female                | 14.33                | 20                      | 140        | Female              | 1.51        | 1          | NC*        |  |
| Total                 | 14.48                | 20                      | 138        | Total               | 3.55        | 1          | NC*        |  |
| Cervix Uteri          |                      | Oral Cavity and Pharynx |            |                     |             |            |            |  |
|                       |                      |                         |            | Male                | 1.90        | 1          | NC*        |  |
| Female                | 0.92                 | 2                       | NC*        | Female              | 0.72        | 2          | NC*        |  |
|                       |                      |                         |            | Total               | 2.63        | 3          | NC*        |  |
| Colon / Rectum        | <u>L</u>             |                         | <u>O</u>   | <u>vary</u>         |             |            |            |  |
| Male                  | 7.23                 | 3                       | NC*        |                     |             |            |            |  |
| Female                | 5.43                 | 8                       | 147        | Female              | 1.75        | 1          | NC*        |  |
| Total                 | 12.65                | 11                      | 87         |                     |             |            |            |  |
| <b>Esophagus</b>      |                      |                         | <u>Pa</u>  | ancreas_            |             |            |            |  |
| Male                  | 0.95                 | 0                       | NC*        | Male                | 1.01        | 1          | NC*        |  |
| Female                | 0.27                 | 0                       | NC*        | Female              | 0.88        | 2          | NC*        |  |
| Total                 | 1.22                 | 0                       | NC*        | Total               | 1.89        | 3          | NC*        |  |
| <b>Hodgkin's Dise</b> | ease                 |                         | <u>Pı</u>  | <u>rostate</u>      |             |            |            |  |
| Male                  | 0.42                 | 0                       | NC*        | Male                | 16.07       | 9          | 56         |  |
| Female                | 0.30                 | 1                       | NC*        |                     |             |            |            |  |
| Total                 | 0.72                 | 1                       | NC*        |                     |             |            |            |  |
| Kidney and Re         | <u>nal Pelvis</u>    |                         | <u>St</u>  | <u>omach</u>        |             |            |            |  |
| Male                  | 1.62                 | 1                       | NC*        | Male                | 1.20        | 0          | NC*        |  |
| Female                | 0.84                 | 0                       | NC*        | Female              | 0.58        | 0          | NC*        |  |
| Total                 | 2.46                 | 1                       | NC*        | Total               | 1.78        | 0          | NC*        |  |
| <u>Larynx</u>         |                      |                         | <u>Te</u>  | <u>estis</u>        |             |            |            |  |
| Male                  | 1.03                 | 0                       | NC*        | Male                | 0.61        | 1          | NC*        |  |

| Female                | 0.26            | 0            | NC*        |                |             |     |       |
|-----------------------|-----------------|--------------|------------|----------------|-------------|-----|-------|
| Total                 | 1.29            | 0            | NC*        |                |             |     |       |
| <b>Leukemia</b>       |                 |              | <u>Tl</u>  | <u>hyroid</u>  |             |     |       |
| Male                  | 1.08            | 0            | NC*        | Male           | 0.27        | 0   | NC*   |
| Female                | 0.70            | 1            | NC*        | Female         | 0.64        | 0   | NC*   |
| Total                 | 1.78            | 1            | NC*        | Total          | 0.90        | 0   | NC*   |
| <b>Liver and Intr</b> | ahepatic Bile I | <u>Ducts</u> | <u>U</u> 1 | teri, Corpus   | and Uterus, | NOS |       |
| Male                  | 0.45            | 1            | NC*        |                |             |     |       |
| Female                | 0.17            | 0            | NC*        | Female         | 2.75        | 1   | NC*   |
| Total                 | 0.62            | 1            | NC*        |                |             |     |       |
| <b>Lung and Broi</b>  | <u>nchus</u>    |              | <u>A</u> ] | ll Sites / Typ | <u>oes</u>  |     |       |
| Male                  | 9.03            | 9            | 100        | Male           | 54.45       | 33  | 61 ~- |
| Female                | 5.53            | 6            | 108        | Female         | 43.64       | 56  | 128   |
| Total                 | 14.56           | 15           | 103        | Total          | 98.09       | 89  | 91    |
|                       |                 |              |            |                |             |     |       |

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

#### **EGREMONT**

# Cancer Incidence by Sex, 1990 - 1995

# **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|                       | Exp           | <u>Obs</u>                               | SIR                    |        | <b>Exp</b> | <u>Obs</u> | <u>SIR</u> |  |  |
|-----------------------|---------------|--|------------------------|--------|------------|------------|------------|--|--|
| Bladder, Urinar       | <u>v</u>      |  | Melanoma of Skin       |        |            |            |            |  |  |
| Male                  | 1.46          | 1  | NC*                    | Male   | 0.66       | 1          | NC*        |  |  |
| Female                | 0.39          | 0  | NC*                    | Female | 0.44       | 0          | NC*        |  |  |
| Total                 | 1.85          | 1  | NC*                    | Total  | 1.10       | 1          | NC*        |  |  |
| <b>Brain and Cent</b> | ral Nervous S | <u>is System</u> <u>Multiple Myeloma</u> |                        |        |            |            |            |  |  |
| Male                  | 0.41          | 0  | NC*                    | Male   | 0.26       | 0          | NC*        |  |  |
| Female                | 0.34          | 0  | NC*                    | Female | 0.18       | 0          | NC*        |  |  |
| Total                 | 0.76          | 0  | NC*                    | Total  | 0.44       | 0          | NC*        |  |  |
| <b>Breast</b>         |               |  | Non-Hodgkin's Lymphoma |        |            |            |            |  |  |
| Male                  | 0.07          | 0  | NC*                    | Male   | 0.96       | 1          | NC*        |  |  |

64 of 84

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} \le 0.05$  level

<sup>~</sup> indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

| Female                 | 6.51                   | 5            | 77         | Female              | 0.69        | 0    | NC*   |
|------------------------|------------------------|--------------|------------|---------------------|-------------|------|-------|
| Total                  | 6.59                   | 5            | 76         | Total               | 1.65        | 1    | NC*   |
| Cervix Uteri           |                        |              | <u>O</u> : | ral Cavity ar       | nd Pharynx  |      |       |
|                        |                        |              |            | Male                | 0.90        | 0    | NC*   |
| Female                 | 0.39                   | 0            | NC*        | Female              | 0.33        | 0    | NC*   |
|                        |                        |              |            | Total               | 1.23        | 0    | NC*   |
| Colon / Rectum         | <u>L</u>               |              | <u>O</u>   | <u>vary</u>         |             |      |       |
| Male                   | 3.88                   | 1            | NC*        |                     |             |      |       |
| Female                 | 2.56                   | 0            | NC*        | Female              | 0.78        | 1    | NC*   |
| Total                  | 6.44                   | 1            | NC*        |                     |             |      |       |
| <b>Esophagus</b>       |                        |              | <u>Pa</u>  | ancreas             |             |      |       |
| Male                   | 0.48                   | 0            | NC*        | Male                | 0.52        | 0    | NC*   |
| Female                 | 0.13                   | 0            | NC*        | Female              | 0.41        | 0    | NC*   |
| Total                  | 0.61                   | 0            | NC*        | Total               | 0.94        | 0    | NC*   |
| Hodgkin's Dise         | ease_                  |              | <u>P</u> 1 | <u>rostate</u>      |             |      |       |
| Male                   | 0.15                   | 2            | NC*        | Male                | 8.93        | 3    | NC*   |
| Female                 | 0.12                   | 0            | NC*        |                     |             |      |       |
| Total                  | 0.27                   | 2            | NC*        |                     |             |      |       |
| Kidney and Re          | St                     | <u>omach</u> |            |                     |             |      |       |
| Male                   | 0.80                   | 1            | NC*        | Male                | 0.63        | 0    | NC*   |
| Female                 | 0.38                   | 0            | NC*        | Female              | 0.28        | 0    | NC*   |
| Total                  | 1.18                   | 1            | NC*        | Total               | 0.91        | 0    | NC*   |
| <u>Larynx</u>          |                        |              | <u>T</u>   | <u>estis</u>        |             |      |       |
| Male                   | 0.51                   | 1            | NC*        | Male                | 0.19        | 0    | NC*   |
| Female                 | 0.12                   | 0            | NC*        |                     |             |      |       |
| Total                  | 0.63                   | 1            | NC*        |                     |             |      |       |
| <u>Leukemia</u>        |                        |              | <u>Tl</u>  | <u>nyroid</u>       |             |      |       |
| Male                   | 0.52                   | 0            | NC*        | Male                | 0.11        | 0    | NC*   |
| Female                 | 0.31                   | 0            | NC*        | Female              | 0.26        | 0    | NC*   |
| Total                  | 0.83                   | 0            | NC*        | Total               | 0.37        | 0    | NC*   |
| <b>Liver and Intra</b> | <u>thepatic Bile D</u> | <u>oucts</u> | <u>U</u> 1 | <u>teri, Corpus</u> | and Uterus, | NOS_ |       |
| Male                   | 0.23                   | 0            | NC*        |                     |             |      |       |
| Female                 | 0.08                   | 0            | NC*        | Female              | 1.26        | 1    | NC*   |
| Total                  | 0.31                   | 0            | NC*        |                     |             |      |       |
| <b>Lung and Bron</b>   |                        |              |            | ll Sites / Typ      | <u>oes</u>  |      |       |
| Male                   | 4.70                   | 4            | NC*        | Male                | 28.26       | 17   | 60 #- |
| Female                 | 2.54                   | 3            | NC*        | Female              | 19.91       | 12   | 60    |
| Total                  | 7.25                   | 7            | 97         | Total               | 48.16       | 29   | 60 ~- |
|                        |                        |              |            |                     |             |      |       |

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the  $\mathbf{p} \le 0.05$  level
- $\sim$  indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level
- ^ indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

# ERVING Cancer Incidence by Sex, 1990 - 1995

# **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|                        | <b>Exp</b>   | <u>Obs</u>    | <u>SIR</u>              |                      | Exp         | <u>Obs</u> | <u>SIR</u> |  |  |
|------------------------|--------------|---------------|-------------------------|----------------------|-------------|------------|------------|--|--|
| Bladder, Urinary       | <u>y</u>     |               | <u>M</u>                | lelanoma of S        | <u>Skin</u> |            |            |  |  |
| Male                   | 1.36         | 1             | NC*                     | Male                 | 0.68        | 0          | NC*        |  |  |
| Female                 | 0.41         | 0             | NC*                     | Female               | 0.47        | 2          | NC*        |  |  |
| Total                  | 1.77         | 1             | NC*                     | Total                | 1.15        | 2          | NC*        |  |  |
| <b>Brain and Centr</b> | al Nervous S | <u>System</u> | <u>M</u>                | <u>lultiple Myel</u> | <u>oma</u>  |            |            |  |  |
| Male                   | 0.45         | 0             | NC*                     | Male                 | 0.25        | 0          | NC*        |  |  |
| Female                 | 0.36         | 0             | NC*                     | Female               | 0.18        | 0          | NC*        |  |  |
| Total                  | 0.81         | 0             | NC*                     | Total                | 0.43        | 0          | NC*        |  |  |
| <b>Breast</b>          |              |               | No                      | on-Hodgkin's         | s Lymphoma  | <u>1</u>   |            |  |  |
| Male                   | 0.07         | 0             | NC*                     | Male                 | 0.98        | 0          | NC*        |  |  |
| Female                 | 6.64         | 3             | NC*                     | Female               | 0.73        | 0          | NC*        |  |  |
| Total                  | 6.71         | 3             | NC*                     | Total                | 1.71        | 0          | NC*        |  |  |
| <u>Cervix Uteri</u>    |              |               | Oral Cavity and Pharynx |                      |             |            |            |  |  |
|                        |              |               |                         | Male                 | 0.90        | 0          | NC*        |  |  |
| Female                 | 0.43         | 1             | NC*                     | Female               | 0.33        | 0          | NC*        |  |  |
|                        |              |               |                         | Total                | 1.24        | 0          | NC*        |  |  |
| Colon / Rectum         |              |               | <u>O</u>                | <u>vary</u>          |             |            |            |  |  |
| Male                   | 3.62         | 4             | NC*                     |                      |             |            |            |  |  |
| Female                 | 2.71         | 2             | NC*                     | Female               | 0.81        | 0          | NC*        |  |  |
| Total                  | 6.33         | 6             | 95                      |                      |             |            |            |  |  |
| <b>Esophagus</b>       |              |               |                         | <u>ancreas</u>       |             |            |            |  |  |
| Male                   | 0.46         | 0             | NC*                     | Male                 | 0.50        | 0          | NC*        |  |  |
| Female                 | 0.13         | 0             | NC*                     | Female               | 0.43        | 1          | NC*        |  |  |
| Total                  | 0.60         | 0             | NC*                     | Total                | 0.93        | 1          | NC*        |  |  |
| <b>Hodgkin's Disea</b> | <u>ase</u>   |               | <u>P1</u>               | <u>rostate</u>       |             |            |            |  |  |
| Male                   | 0.19         | 0             | NC*                     | Male                 | 8.13        | 6          | 74         |  |  |
| Female                 | 0.14         | 0             | NC*                     |                      |             |            |            |  |  |
| Total                  | 0.34         | 0             | NC*                     |                      |             |            |            |  |  |
| Kidney and Ren         | al Pelvis    |               |                         | <u>omach</u>         |             |            |            |  |  |
| Male                   | 0.78         | 1             | NC*                     | Male                 | 0.60        | 0          | NC*        |  |  |
|                        |              |               |                         |                      |             |            |            |  |  |

| Female                   | 0.39                  | 0           | NC*                                  | Female            | 0.29  | 1  | NC*   |  |  |
|--------------------------|-----------------------|-------------|--------------------------------------|-------------------|-------|----|-------|--|--|
| Total                    | 1.17                  | 1           | NC*                                  | Total             | 0.89  | 1  | NC*   |  |  |
| <u>Larynx</u>            |                       |             | <u>T</u>                             | <u>estis</u>      |       |    |       |  |  |
| Male                     | 0.49                  | 2           | NC*                                  | Male              | 0.27  | 0  | NC*   |  |  |
| Female                   | 0.11                  | 0           | NC*                                  |                   |       |    |       |  |  |
| Total                    | 0.61                  | 2           | NC*                                  |                   |       |    |       |  |  |
| <b>Leukemia</b>          |                       |             | <u>T</u>                             | <u>hyroid</u>     |       |    |       |  |  |
| Male                     | 0.53                  | 0           | NC*                                  | Male              | 0.12  | 0  | NC*   |  |  |
| Female                   | 0.33                  | 0           | NC*                                  | Female            | 0.30  | 0  | NC*   |  |  |
| Total                    | 0.86                  | 0           | NC*                                  | Total             | 0.42  | 0  | NC*   |  |  |
| <b>Liver and Intra</b>   | <u>hepatic Bile D</u> | <u>ucts</u> | <u>Uteri, Corpus and Uterus, NOS</u> |                   |       |    |       |  |  |
| Male                     | 0.22                  | 0           | NC*                                  |                   |       |    |       |  |  |
| Female                   | 0.08                  | 0           | NC*                                  | Female            | 1.25  | 1  | NC*   |  |  |
| Total                    | 0.30                  | 0           | NC*                                  |                   |       |    |       |  |  |
| <b>Lung and Bronchus</b> |                       |             |                                      | All Sites / Types |       |    |       |  |  |
| Male                     | 4.43                  | 5           | 113                                  | Male              | 26.91 | 20 | 74    |  |  |
| Female                   | 2.55                  | 1           | NC*                                  | Female            | 20.59 | 13 | 63    |  |  |
| Total                    | 6.99                  | 6           | 86                                   | Total             | 47.49 | 33 | 69 #- |  |  |
|                          |                       |             |                                      |                   |       |    |       |  |  |

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

SIR = standardized incidence ratio [ (Obs / Exp) X 100]

#### **ESSEX**

# Cancer Incidence by Sex, 1990 - 1995

## **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|   | <b>Exp</b> | <u>Obs</u>       | <u>SIR</u> |                      | <b>Exp</b> | <u>Obs</u> | <u>SIR</u> |  |  |
|---|------------|------------------|------------|----------------------|------------|------------|------------|--|--|
| Bladder, Urinary                        | <u>v</u>   | Melanoma of Skin |            |                      |            |            |            |  |  |
| Male                                    | 2.24       | 1                | NC*        | Male                 | 1.20       | 3          | NC*        |  |  |
| Female                                  | 0.73       | 1                | NC*        | Female               | 0.93       | 3          | NC*        |  |  |
| Total                                   | 2.96       | 2                | NC*        | Total                | 2.13       | 6          | 281 #+     |  |  |
| <b>Brain and Central Nervous System</b> |            |                  | <u>M</u>   | <u>lultiple Myel</u> |            |            |            |  |  |
| Male                                    | 0.81       | 1                | NC*        | Male                 | 0.41       | 0          | NC*        |  |  |

67 of 84

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} \le 0.05$  level

<sup>~</sup> indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

| Female           | 0.71        | 0       | NC*        | Female        | 0.34              | 1         | NC*    |
|------------------|-------------|---------|------------|---------------|-------------------|-----------|--------|
| Total            | 1.53        | 1       | NC*        | Total         | 0.74              | 1         | NC*    |
| <u>Breast</u>    |             |         | <u>N</u>   | on-Hodgkin    | <u>'s Lymphon</u> | <u>1a</u> |        |
| Male             | 0.12        | 1       | NC*        | Male          | 1.72              | 0         | NC*    |
| Female           | 13.09       | 24      | 183 ~+     | Female        | 1.36              | 2         | NC*    |
| Total            | 13.21       | 25      | 189 ~+     | Total         | 3.08              | 2         | NC*    |
| Cervix Uteri     |             |         | <u>O</u>   | ral Cavity a  | nd Pharynx        |           |        |
|                  |             |         |            | Male          | 1.59              | 0         | NC*    |
| Female           | 0.87        | 0       | NC*        | Female        | 0.65              | 1         | NC*    |
|                  |             |         |            | Total         | 2.24              | 1         | NC*    |
| Colon / Rectun   | <u>n</u>    |         | <u>O</u>   | <u>vary</u>   |                   |           |        |
| Male             | 5.96        | 13      | 218 #+     |               |                   |           |        |
| Female           | 4.75        | 9       | 190        | Female        | 1.61              | 1         | NC*    |
| Total            | 10.71       | 22      | 205 ~+     |               |                   |           |        |
| <b>Esophagus</b> |             |         | <u>P</u>   | ancreas       |                   |           |        |
| Male             | 0.79        | 0       | NC*        | Male          | 0.84              | 1         | NC*    |
| Female           | 0.24        | 0       | NC*        | Female        | 0.77              | 2         | NC*    |
| Total            | 1.02        | 0       | NC*        | Total         | 1.62              | 3         | NC*    |
| Hodgkin's Dis    | sease_      |         | <u>P</u>   | rostate       |                   |           |        |
| Male             | 0.38        | 1       | NC*        | Male          | 13.55             | 19        | 140    |
| Female           | 0.28        | 0       | NC*        |               |                   |           |        |
| Total            | 0.67        | 1       | NC*        |               |                   |           |        |
| Kidney and Ro    | enal Pelvis |         | <u>S</u> : | tomach_       |                   |           |        |
| Male             | 1.36        | 3       | NC*        | Male          | 0.98              | 0         | NC*    |
| Female           | 0.75        | 1       | NC*        | Female        | 0.51              | 0         | NC*    |
| Total            | 2.11        | 4       | NC*        | Total         | 1.49              | 0         | NC*    |
| <u>Larynx</u>    |             |         | T          | <u>'estis</u> |                   |           |        |
| Male             | 0.86        | 1       | NC*        | Male          | 0.57              | 1         | NC*    |
| Female           | 0.23        | 0       | NC*        |               |                   |           |        |
| Total            | 1.09        | 1       | NC*        |               |                   |           |        |
| <u>Leukemia</u>  |             |         | T          | <u>hyroid</u> |                   |           |        |
| Male             | 0.92        | 1       | NC*        | Male          | 0.24              | 0         | NC*    |
| Female           | 0.63        | 1       | NC*        | Female        | 0.61              | 1         | NC*    |
| Total            | 1.55        | 2       | NC*        | Total         | 0.84              | 1         | NC*    |
| Liver and Intr   |             | e Ducts | U          | teri, Corpus  |                   | NOS       |        |
| Male             | 0.38        | 0       | NC*        |               |                   |           |        |
| Female           | 0.15        | 0       | NC*        | Female        | 2.49              | 1         | NC*    |
| Total            | 0.53        | 0       | NC*        |               |                   |           |        |
| Lung and Bron    |             |         |            | ll Sites / Ty | pes               |           |        |
| Male             | 7.57        | 10      | 132        | Male          | 45.71             | 60        | 131 #+ |
| Female           | 4.96        | 4       | NC*        | Female        | 39.40             | 56        | 142 #+ |
| Total            | 12.53       | 14      | 112        | Total         | 85.11             | 116       | 136 ~+ |
|                  |             |         |            |               | •                 | -         |        |

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the  $\mathbf{p} \le 0.05$  level
- $\sim$  indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level
- ^ indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

EVERETT

Cancer Incidence by Sex, 1990 - 1995

**Expected and Observed Case Counts, with Standardized Incidence Ratios** 

|                      | <b>Exp</b>   | <u>Obs</u>    | SIR                     |                      | Exp         | <u>Obs</u> | <u>SIR</u> |  |
|----------------------|--------------|---------------|-------------------------|----------------------|-------------|------------|------------|--|
| Bladder, Urina       | ry           |               | <u>M</u>                | <u>lelanoma of S</u> | <u>Skin</u> |            |            |  |
| Male                 | 27.65        | 24            | 87                      | Male                 | 14.20       | 18         | 127        |  |
| Female               | 12.00        | 14            | 117                     | Female               | 13.00       | 8          | 62         |  |
| Total                | 39.64        | 38            | 96                      | Total                | 27.20       | 26         | 96         |  |
| <b>Brain and Cen</b> | tral Nervous | <u>System</u> | <u>M</u>                | <u>lultiple Myel</u> | oma         |            |            |  |
| Male                 | 9.36         | 16            | 171                     | Male                 | 4.96        | 9          | 181        |  |
| Female               | 9.92         | 9             | 91                      | Female               | 5.32        | 5          | 94         |  |
| Total                | 19.28        | 25            | 130                     | Total                | 10.28       | 14         | 136        |  |
| <b>Breast</b>        |              |               | <u>N</u>                | on-Hodgkin's         | s Lymphoma  | •          |            |  |
| Male                 | 1.46         | 2             | NC*                     | Male                 | 20.62       | 27         | 131        |  |
| Female               | 184.13       | 195           | 106                     | Female               | 21.17       | 25         | 118        |  |
| Total                | 185.59       | 197           | 106                     | Total                | 41.79       | 52         | 124        |  |
| <u>Cervix Uteri</u>  |              |               | Oral Cavity and Pharynx |                      |             |            |            |  |
|                      |              |               |                         | Male                 | 18.30       | 20         | 109        |  |
| Female               | 11.77        | 13            | 110                     | Female               | 9.39        | 10         | 106        |  |
|                      |              |               |                         | Total                | 27.69       | 30         | 108        |  |
| Colon / Rectun       | <u>1</u>     |               | <u>O</u>                | <u>vary</u>          |             |            |            |  |
| Male                 | 73.22        | 69            | 94                      |                      |             |            |            |  |
| Female               | 80.91        | 85            | 105                     | Female               | 22.17       | 19         | 86         |  |
| Total                | 154.13       | 154           | 100                     |                      |             |            |            |  |
| <b>Esophagus</b>     |              |               | <u>Pa</u>               | ancreas              |             |            |            |  |
| Male                 | 9.24         | 9             | 97                      | Male                 | 10.04       | 13         | 129        |  |
| Female               | 4.01         | 5             | 125                     | Female               | 12.67       | 16         | 126        |  |
| Total                | 13.24        | 14            | 106                     | Total                | 22.71       | 29         | 128        |  |
| Hodgkin's Dis        | ease         |               | <u>P</u> 1              | <u>rostate</u>       |             |            |            |  |

69 of 84

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

| Male                   | 4.48           | 4            | NC*                                  | Male              | 162.51  | 143  | 88     |  |
|------------------------|----------------|--------------|--------------------------------------|-------------------|---------|------|--------|--|
| Female                 | 3.96           | 4            | NC*                                  |                   |         |      |        |  |
| Total                  | 8.44           | 8            | 95                                   |                   |         |      |        |  |
| Kidney and Re          | enal Pelvis    |              | <u>St</u>                            | <u>omach</u>      |         |      |        |  |
| Male                   | 15.81          | 19           | 120                                  | Male              | 12.17   | 18   | 148    |  |
| Female                 | 11.02          | 13           | 118                                  | Female            | 8.86    | 14   | 158    |  |
| Total                  | 26.83          | 32           | 119                                  | Total             | 21.04   | 32   | 152 #+ |  |
| <u>Larynx</u>          |                |              | <u>Te</u>                            | <u>estis</u>      |         |      |        |  |
| Male                   | 9.89           | 11           | 111                                  | Male              | 6.81    | 4    | NC*    |  |
| Female                 | 3.06           | 2            | NC*                                  |                   |         |      |        |  |
| Total                  | 12.95          | 13           | 100                                  |                   |         |      |        |  |
| <b>Leukemia</b>        | <u>Thyroid</u> |              |                                      |                   |         |      |        |  |
| Male                   | 10.92          | 20           | 183 #+                               | Male              | 2.73    | 0    | NC*    |  |
| Female                 | 9.50           | 11           | 116                                  | Female            | 8.21    | 3    | NC*    |  |
| Total                  | 20.41          | 31           | 152 #+                               | Total             | 10.94   | 3    | NC*    |  |
| <b>Liver and Intra</b> | ahepatic Bile  | <b>Ducts</b> | <u>Uteri, Corpus and Uterus, NOS</u> |                   |         |      |        |  |
| Male                   | 4.47           | 8            | 179                                  |                   |         |      |        |  |
| Female                 | 2.40           | 2            | NC*                                  | Female            | 34.31   | 27   | 79     |  |
| Total                  | 6.87           | 10           | 146                                  |                   |         |      |        |  |
| Lung and Bronchus      |                |              |                                      | All Sites / Types |         |      |        |  |
| Male                   | 88.69          | 115          | 130 ~+                               | Male              | 546.29  | 606  | 111 #+ |  |
| Female                 | 71.80          | 84           | 117                                  | Female            | 582.98  | 608  | 104    |  |
| Total                  | 160.49         | 199          | 124 ~+                               | Total             | 1129.27 | 1214 | 108 #+ |  |
|                        |                |              |                                      |                   |         |      |        |  |

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

#### **FAIRHAVEN**

Cancer Incidence by Sex, 1990 - 1995

**Expected and Observed Case Counts, with Standardized Incidence Ratios** 

Exp Obs SIR Exp Obs SIR

Bladder, Urinary Melanoma of Skin

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} \le 0.05$  level

<sup>~</sup> indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

| Male                             | 14.65          | 15            | 102        | Male           | 7.09        | 3          | NC*    |  |  |  |  |
|----------------------------------|----------------|---------------|------------|----------------|-------------|------------|--------|--|--|--|--|
| Female                           | 5.98           | 3             | NC*        | Female         | 6.08        | 8          | 132    |  |  |  |  |
| Total                            | 20.63          | 18            | 87         | Total          | 13.17       | 11         | 84     |  |  |  |  |
| <b>Brain and Cent</b>            | tral Nervous S | <u>System</u> | <u>M</u>   | ultiple Mye    | <u>loma</u> |            |        |  |  |  |  |
| Male                             | 4.61           | 6             | 130        | Male           | 2.63        | 4          | NC*    |  |  |  |  |
| Female                           | 4.75           | 2             | NC*        | Female         | 2.66        | 0          | NC*    |  |  |  |  |
| Total                            | 9.36           | 8             | 85         | Total          | 5.28        | 4          | NC*    |  |  |  |  |
| <b>Breast</b>                    |                |               | <u>N</u>   | on-Hodgkin     | 's Lymphom  | <u>a_</u>  |        |  |  |  |  |
| Male                             | 0.76           | 0             | NC*        | Male           | 10.28       | 9          | 88     |  |  |  |  |
| Female                           | 89.66          | 86            | 96         | Female         | 10.35       | 15         | 145    |  |  |  |  |
| Total                            | 90.42          | 86            | 95         | Total          | 20.63       | 24         | 116    |  |  |  |  |
| Cervix Uteri                     |                |               | <u>O</u> : | ral Cavity a   | nd Pharynx  |            |        |  |  |  |  |
|                                  |                |               |            | Male           | 9.39        | 11         | 117    |  |  |  |  |
| Female                           | 5.27           | 4             | NC*        | Female         | 4.62        | 5          | 108    |  |  |  |  |
|                                  |                |               |            | Total          | 14.01       | 16         | 114    |  |  |  |  |
| Colon / Rectum                   | <u>L</u>       |               | <u>O</u>   | <u>vary</u>    |             |            |        |  |  |  |  |
| Male                             | 38.91          | 32            | 82         |                |             |            |        |  |  |  |  |
| Female                           | 40.36          | 45            | 111        | Female         | 10.66       | 15         | 141    |  |  |  |  |
| Total                            | 79.27          | 77            | 97         |                |             |            |        |  |  |  |  |
| <u>Esophagus</u> <u>Pancreas</u> |                |               |            |                |             |            |        |  |  |  |  |
| Male                             | 4.87           | 9             | 185        | Male           | 5.32        | 10         | 188    |  |  |  |  |
| Female                           | 2.01           | 3             | NC*        | Female         | 6.34        | 12         | 189    |  |  |  |  |
| Total                            | 6.88           | 12            | 174        | Total          | 11.66       | 22         | 189 ~+ |  |  |  |  |
| Hodgkin's Disc                   | ease_          |               | <u>Pr</u>  | <u>rostate</u> |             |            |        |  |  |  |  |
| Male                             | 1.96           | 0             | NC*        | Male           | 88.57       | 61         | 69 ~-  |  |  |  |  |
| Female                           | 1.69           | 1             | NC*        |                |             |            |        |  |  |  |  |
| Total                            | 3.65           | 1             | NC*        |                |             |            |        |  |  |  |  |
| Kidney and Re                    | nal Pelvis     |               | <u>St</u>  | <u>omach</u>   |             |            |        |  |  |  |  |
| Male                             | 8.26           | 11            | 133        | Male           | 6.38        | 8          | 125    |  |  |  |  |
| Female                           | 5.45           | 7             | 128        | Female         | 4.40        | 7          | 159    |  |  |  |  |
| Total                            | 13.72          | 18            | 131        | Total          | 10.78       | 15         | 139    |  |  |  |  |
| <u>Larynx</u>                    |                |               | <u>T</u>   | <u>estis</u>   |             |            |        |  |  |  |  |
| Male                             | 5.22           | 3             | NC*        | Male           | 2.69        | 4          | NC*    |  |  |  |  |
| Female                           | 1.53           | 1             | NC*        |                |             |            |        |  |  |  |  |
| Total                            | 6.75           | 4             | NC*        |                |             |            |        |  |  |  |  |
| <b>Leukemia</b>                  |                |               | <u>Tl</u>  | <u>nyroid</u>  |             |            |        |  |  |  |  |
| Male                             | 5.57           | 7             | 126        | Male           | 1.25        | 0          | NC*    |  |  |  |  |
| Female                           | 4.58           | 7             | 153        | Female         | 3.60        | 1          | NC*    |  |  |  |  |
| Total                            | 10.15          | 14            | 138        | Total          | 4.85        | 1          | NC*    |  |  |  |  |
| <b>Liver and Intra</b>           | hepatic Bile I | <u>Ducts</u>  | <u>U</u> 1 | teri, Corpus   | and Uterus, | <b>NOS</b> |        |  |  |  |  |
| Male                             | 2.35           | 2             | NC*        |                |             |            |        |  |  |  |  |
| Female                           | 1.19           | 0             | NC*        | Female         | 16.98       | 18         | 106    |  |  |  |  |
| Total                            | 3.54           | 2             | NC*        |                |             |            |        |  |  |  |  |
| <b>Lung and Bron</b>             | <u>chus</u>    |               | <u>A</u> ] | ll Sites / Ty  | <u>oes</u>  |            |        |  |  |  |  |
|                                  |                |               |            | _              |             |            |        |  |  |  |  |

| Male   | 47.50 | 49 | 103 | Male   | 287.97 | 260 | 90  |
|--------|-------|----|-----|--------|--------|-----|-----|
| Female | 35.89 | 40 | 111 | Female | 285.37 | 307 | 108 |
| Total  | 83.39 | 89 | 107 | Total  | 573.34 | 567 | 99  |

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

#### FALL RIVER

## Cancer Incidence by Sex, 1990 - 1995

#### **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|                      | Exp          | <u>Obs</u>             | SIR                      |                     | Exp         | <u>Obs</u> | SIR   |  |
|----------------------|--------------|------------------------|--------------------------|---------------------|-------------|------------|-------|--|
| Bladder, Urina       | <u>iry</u>   |                        | $\underline{\mathbf{M}}$ | lelanoma of         | <u>Skin</u> |            |       |  |
| Male                 | 76.12        | 108                    | 142 ^+                   | Male                | 36.92       | 19         | 51 ~- |  |
| Female               | 33.43        | 35                     | 105                      | Female              | 33.71       | 20         | 59 #- |  |
| Total                | 109.56       | 143                    | 131 ~+                   | Total               | 70.63       | 39         | 55 ^- |  |
| <b>Brain and Cen</b> | tral Nervous | <u>System</u>          | <u>M</u>                 | <u>lultiple Mye</u> | <u>loma</u> |            |       |  |
| Male                 | 24.43        | 29                     | 119                      | Male                | 13.61       | 9          | 66    |  |
| Female               | 26.39        | 29                     | 110                      | Female              | 14.70       | 14         | 95    |  |
| Total                | 50.82        | 58                     | 114                      | Total               | 28.31       | 23         | 81    |  |
| <b>Breast</b>        |              | Non-Hodgkin's Lymphoma |                          |                     |             |            |       |  |
| Male                 | 3.96         | 1                      | NC*                      | Male                | 54.01       | 52         | 96    |  |
| Female               | 490.05       | 392                    | 80 ^-                    | Female              | 57.65       | 45         | 78    |  |
| Total                | 494.00       | 393                    | 80 ^-                    | Total               | 111.66      | 97         | 87    |  |
| Cervix Uteri         |              |                        | <u>O</u>                 | ral Cavity a        | nd Pharynx  |            |       |  |
|                      |              |                        |                          | Male                | 48.10       | 62         | 129   |  |
| Female               | 29.41        | 23                     | 78                       | Female              | 25.38       | 25         | 99    |  |
|                      |              |                        |                          | Total               | 73.47       | 87         | 118   |  |
| Colon / Rectun       | <u>n</u> _   |                        | <u>O</u>                 | <u>vary</u>         |             |            |       |  |
| Male                 | 201.85       | 198                    | 98                       |                     |             |            |       |  |
| Female               | 226.47       | 210                    | 93                       | Female              | 58.38       | 52         | 89    |  |
| Total                | 428.32       | 408                    | 95                       |                     |             |            |       |  |
| <b>Esophagus</b>     |              |                        | <u>Pa</u>                | ancreas             |             |            |       |  |

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} <= 0.05$  level

 $<sup>\</sup>sim$  indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

| Male                | 24.97         | 23             | 92              | Male                 | 27.41         | 28   | 102    |  |  |
|---------------------|---------------|----------------|-----------------|----------------------|---------------|------|--------|--|--|
| Female              | 11.24         | 12             | 107             | Female               | 35.24         | 30   | 85     |  |  |
| Total               | 36.20         | 35             | 97              | Total                | 62.65         | 58   | 93     |  |  |
| Hodgkin's Di        | <u>sease</u>  |                | <b>Prostate</b> |                      |               |      |        |  |  |
| Male                | 10.86         | 10             | 92              | Male                 | 456.49        | 413  | 90 #-  |  |  |
| Female              | 9.82          | 11             | 112             |                      |               |      |        |  |  |
| Total               | 20.68         | 21             | 102             |                      |               |      |        |  |  |
| Kidney and R        | enal Pelvis   | <u>Stomach</u> |                 |                      |               |      |        |  |  |
| Male                | 42.52         | 36             | 85              | Male                 | 33.25         | 62   | 186 ^+ |  |  |
| Female              | 29.92         | 32             | 107             | Female               | 24.86         | 28   | 113    |  |  |
| Total               | 72.44         | 68             | 94              | Total                | 58.11         | 90   | 155 ^+ |  |  |
| <u>Larynx</u>       |               |                | <u>T</u>        | <u>estis</u>         |               |      |        |  |  |
| Male                | 26.60         | 43             | 162 ~+          | Male                 | 15.26         | 12   | 79     |  |  |
| Female              | 8.20          | 6              | 73              |                      |               |      |        |  |  |
| Total               | 34.80         | 49             | 141 #+          |                      |               |      |        |  |  |
| <b>Leukemia</b>     |               |                | <u>Tl</u>       | <u>nyroid</u>        |               |      |        |  |  |
| Male                | 29.53         | 40             | 135             | Male                 | 6.66          | 3    | NC*    |  |  |
| Female              | 25.95         | 30             | 116             | Female               | 20.34         | 15   | 74     |  |  |
| Total               | 55.47         | 70             | 126             | Total                | 26.99         | 18   | 67     |  |  |
| Liver and Inti      | ahepatic Bile | Ducts          | <u>U</u> 1      | teri, Corpus         | s and Uterus. | NOS  |        |  |  |
| Male                | 12.12         | 12             | 99              |                      |               |      |        |  |  |
| Female              | 6.62          | 5              | 76              | Female               | 91.83         | 87   | 95     |  |  |
| Total               | 18.74         | 17             | 91              |                      |               |      |        |  |  |
| <b>Lung and Bro</b> | <u>nchus</u>  |                | <u>A</u> ]      | <u>ll Sites / Ty</u> | <u>pes</u>    |      |        |  |  |
| Male                | 243.43        | 267            | 110             | Male                 | 1491.71       | 1539 | 103    |  |  |
| Female              | 194.44        | 161            | 83 #-           | Female               | 1573.54       | 1396 | 89 ^-  |  |  |
| Total               | 437.88        | 428            | 98              | Total                | 3065.25       | 2935 | 96 #-  |  |  |
|                     |               |                |                 |                      |               |      |        |  |  |

**Obs** = observed case count

SIR = standardized incidence ratio [ (Obs / Exp) X 100]

## **FALMOUTH**

Cancer Incidence by Sex, 1990 - 1995

73 of 84

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} <= 0.05$  level

<sup>~</sup> indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

# **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|                      | Exp                | <u>Obs</u>    | <u>SIR</u>               |                      | Exp         | <u>Obs</u> | <u>SIR</u> |  |
|----------------------|--------------------|---------------|--------------------------|----------------------|-------------|------------|------------|--|
| Bladder, Urina       | <u>ry</u>          |               | $\underline{\mathbf{M}}$ | <u>lelanoma of</u>   | <u>Skin</u> |            |            |  |
| Male                 | 29.63              | 23            | 78                       | Male                 | 13.88       | 15         | 108        |  |
| Female               | 10.81              | 10            | 92                       | Female               | 11.07       | 21         | 190 #+     |  |
| Total                | 40.44              | 33            | 82                       | Total                | 24.95       | 36         | 144 #+     |  |
| <b>Brain and Cen</b> | tral Nervous       | <u>System</u> | $\underline{\mathbf{M}}$ | <u> Iultiple Mye</u> | <u>loma</u> |            |            |  |
| Male                 | 8.85               | 8             | 90                       | Male                 | 5.29        | 4          | NC*        |  |
| Female               | 8.66               | 9             | 104                      | Female               | 4.82        | 2          | NC*        |  |
| Total                | 17.51              | 17            | 97                       | Total                | 10.11       | 6          | 59         |  |
| <b>Breast</b>        |                    |               |                          | on-Hodgkin           | 's Lymphoma | _          |            |  |
| Male                 | 1.53               | 4             | NC*                      | Male                 | 20.05       | 21         | 105        |  |
| Female               | 164.52             | 178           | 108                      | Female               | 18.68       | 19         | 102        |  |
| Total                | 166.05             | 182           | 110                      | Total                | 38.73       | 40         | 103        |  |
| <u>Cervix Uteri</u>  |                    |               | Oral Cavity and Pharynx  |                      |             |            |            |  |
|                      |                    |               |                          | Male                 | 18.59       | 18         | 97         |  |
| Female               | 9.53               | 10            | 105                      | Female               | 8.49        | 12         | 141        |  |
|                      |                    |               |                          | Total                | 27.08       | 30         | 111        |  |
| Colon / Rectur       | <u>n</u>           |               | <u>o</u>                 | <u>vary</u>          |             |            |            |  |
| Male                 | 78.56              | 94            | 120                      |                      |             |            |            |  |
| Female               | 72.49              | 74            | 102                      | Female               | 19.55       | 17         | 87         |  |
| Total                | 151.04             | 168           | 111                      |                      |             |            |            |  |
| <b>Esophagus</b>     |                    |               | <u>Pa</u>                | ancreas              |             |            |            |  |
| Male                 | 9.78               | 10            | 102                      | Male                 | 10.66       | 15         | 141        |  |
| Female               | 3.62               | 4             | NC*                      | Female               | 11.42       | 17         | 149        |  |
| Total                | 13.40              | 14            | 104                      | Total                | 22.09       | 32         | 145        |  |
| Hodgkin's Dis        | <u>sease</u>       |               | <u>P</u> 1               | <u>rostate</u>       |             |            |            |  |
| Male                 | 3.50               | 2             | NC*                      | Male                 | 178.92      | 251        | 140 ^+     |  |
| Female               | 2.97               | 4             | NC*                      |                      |             |            |            |  |
| Total                | 6.46               | 6             | 93                       |                      |             |            |            |  |
| Kidney and R         | <u>enal Pelvis</u> |               |                          | tomach_              |             |            |            |  |
| Male                 | 16.39              | 29            | 177 ~+                   | Male                 | 12.89       | 24         | 186 ~+     |  |
| Female               | 9.94               | 11            | 111                      | Female               | 7.89        | 8          | 101        |  |
| Total                | 26.33              | 40            | 152 #+                   | Total                | 20.79       | 32         | 154 #+     |  |
| <u>Larynx</u>        |                    |               |                          | <u>estis</u>         |             |            |            |  |
| Male                 | 10.44              | 15            | 144                      | Male                 | 4.54        | 3          | NC*        |  |
| Female               | 2.86               | 3             | NC*                      |                      |             |            |            |  |
| Total                | 13.30              | 18            | 135                      |                      |             |            |            |  |
| <u>Leukemia</u>      |                    |               |                          | <u>hyroid</u>        |             |            |            |  |
| Male                 | 10.92              | 14            | 128                      | Male                 | 2.30        | 1          | NC*        |  |
| Female               | 8.25               | 8             | 97                       | Female               | 6.46        | 8          | 124        |  |
| Total                | 19.17              | 22            | 115                      | Total                | 8.77        | 9          | 103        |  |

| <b>Liver and Intrahepatic Bile Ducts</b> |              |     | <u>Uteri, Corpus and Uterus, NOS</u> |        |         |      |        |
|--|--------------|-----|--------------------------------------|--------|---------|------|--------|
| Male                                     | 4.68         | 5   | 107                                  |        |         |      |        |
| Female                                   | 2.15         | 3   | NC*                                  | Female | 31.38   | 40   | 127    |
| Total                                    | 6.82         | 8   | 117                                  |        |         |      |        |
| <b>Lung and Bron</b>                     | <u>ichus</u> |     | All Sites / Types                    |        |         |      |        |
| Male                                     | 95.19        | 106 | 111                                  | Male   | 575.41  | 703  | 122 ^+ |
| Female                                   | 65.63        | 90  | 137 ~+                               | Female | 519.72  | 587  | 113 ~+ |
| Total                                    | 160.81       | 196 | 122 ~+                               | Total  | 1095.13 | 1290 | 118 ^+ |
|  |              |     |                                      |        |         |      |        |

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

## **FITCHBURG**

## Cancer Incidence by Sex, 1990 - 1995

### **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|                      | <b>Exp</b>     | <u>Obs</u>    | SIR                    |                      | Exp         | <u>Obs</u> | SIR    |  |
|----------------------|----------------|---------------|------------------------|----------------------|-------------|------------|--------|--|
| Bladder, Urina       | <u>ry</u>      |               | <u>M</u>               | <u>lelanoma of </u>  | <u>Skin</u> |            |        |  |
| Male                 | 30.69          | 29            | 95                     | Male                 | 15.38       | 6          | 39 #-  |  |
| Female               | 12.96          | 12            | 93                     | Female               | 13.59       | 6          | 44 #-  |  |
| Total                | 43.65          | 41            | 94                     | Total                | 28.96       | 12         | 41 ^-  |  |
| <b>Brain and Cen</b> | tral Nervous S | <u>System</u> | <u>M</u>               | <u>[ultiple Myel</u> | <u>loma</u> |            |        |  |
| Male                 | 10.34          | 15            | 145                    | Male                 | 5.49        | 2          | NC*    |  |
| Female               | 10.58          | 8             | 76                     | Female               | 5.68        | 0          | NC*    |  |
| Total                | 20.92          | 23            | 110                    | Total                | 11.17       | 2          | NC*    |  |
| <b>Breast</b>        |                |               | Non-Hodgkin's Lymphoma |                      |             |            |        |  |
| Male                 | 1.61           | 1             | NC*                    | Male                 | 22.59       | 24         | 106    |  |
| Female               | 191.86         | 179           | 93                     | Female               | 22.61       | 25         | 111    |  |
| Total                | 193.46         | 180           | 93                     | Total                | 45.20       | 49         | 108    |  |
| Cervix Uteri         |                |               | <u>O</u>               | ral Cavity ar        | nd Pharynx  |            |        |  |
|                      |                |               |                        | Male                 | 19.64       | 31         | 158 #+ |  |
| Female               | 12.19          | 17            | 139                    | Female               | 9.92        | 16         | 161    |  |
|                      |                |               |                        | Total                | 29.57       | 47         | 159 ~+ |  |

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} <= 0.05$  level

<sup>~</sup> indicates statistical significance at the  $p \le 0.01$  level, as well as at the  $p \le 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

| Colon / Rectur      | <u>m</u>     |                 | 9        | <u>Ovary</u>        |             |         |       |
|---------------------|--------------|-----------------|----------|---------------------|-------------|---------|-------|
| Male                | 81.27        | 73              | 90       |                     |             |         |       |
| Female              | 87.73        | 62              | 71 ~-    | Female              | 23.09       | 21      | 91    |
| Total               | 169.00       | 135             | 80 ~-    |                     |             |         |       |
| <b>Esophagus</b>    |              |                 | ]        | <u>Pancreas</u>     |             |         |       |
| Male                | 10.05        | 8               | 80       | Male                | 11.04       | 10      | 91    |
| Female              | 4.35         | 1               | NC*      | Female              | 13.60       | 12      | 88    |
| Total               | 14.40        | 9               | 63       | Total               | 24.64       | 22      | 89    |
| Hodgkin's Di        | <u>sease</u> |                 | ]        |                     |             |         |       |
| Male                | 4.95         | 3               | NC*      | Male                | 181.29      | 108     | 60 ^- |
| Female              | 4.25         | 2               | NC*      |                     |             |         |       |
| Total               | 9.20         | 5               | 54       |                     |             |         |       |
| Kidney and R        | enal Pelvis  |                 | <u> </u> | <b>Stomach</b>      |             |         |       |
| Male                | 17.26        | 11              | 64       | Male                | 13.48       | 10      | 74    |
| Female              | 11.64        | 9               | 77       | Female              | 9.67        | 4       | NC*   |
| Total               | 28.90        | 20              | 69       | Total               | 23.15       | 14      | 60    |
| <u>Larynx</u>       |              |                 |          | <u> </u>            |             |         |       |
| Male                | 10.69        | 13              | 122      | Male                | 7.31        | 6       | 82    |
| Female              | 3.16         | 1               | NC*      |                     |             |         |       |
| Total               | 13.85        | 14              | 101      |                     |             |         |       |
| <u>Leukemia</u>     |              |                 | ,<br>-   | <u> Thyroid</u>     |             |         |       |
| Male                | 12.27        | 8               | 65       | Male                | 2.93        | 2       | NC*   |
| Female              | 10.41        | 8               | 77       | Female              | 8.57        | 7       | 82    |
| Total               | 22.68        | 16              | 71       | Total               | 11.50       | 9       | 78    |
| Liver and Inti      | <del>-</del> | <u>le Ducts</u> | _        | <u>Uteri, Corpu</u> | s and Uteru | is, NOS |       |
| Male                | 4.91         | 6               | 122      |                     |             |         |       |
| Female              | 2.58         | 5               | 194      | Female              | 35.55       | 34      | 96    |
| Total               | 7.50         | 11              | 147      |                     |             |         |       |
| <b>Lung and Bro</b> |              |                 | _        | All Sites / Ty      |             |         |       |
| Male                | 97.40        | 101             | 104      | Male                | 603.51      | 494     | 82 ^- |
| Female              | 74.75        | 52              | 70 ~-    | Female              | 615.67      | 524     | 85 ^- |
| Total               | 172.15       | 153             | 89       | Total               | 1219.18     | 1018    | 83 ^- |

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} <= 0.05$  level

<sup>~</sup> indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

# **FLORIDA**

# Cancer Incidence by Sex, 1990 - 1995

# **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|                         | Exp      | <u>Obs</u>              | SIR                      |                      | <b>Exp</b>      | <u>Obs</u> | SIR |  |  |
|-------------------------|----------|-------------------------|--------------------------|----------------------|-----------------|------------|-----|--|--|
| Bladder, Urinary        |          |                         |                          | <u>lelanoma of S</u> |                 |            |     |  |  |
| Male                    | 0.52     | 0                       | NC*                      | Male                 | 0.29            | 1          | NC* |  |  |
| Female                  | 0.17     | 0                       | NC*                      | Female               | 0.21            | 0          | NC* |  |  |
| Total                   | 0.69     | 0                       | NC*                      | Total                | 0.51            | 1          | NC* |  |  |
| <b>Brain and Centra</b> |          | <u>System</u>           | $\underline{\mathbf{M}}$ | <u>lultiple Myel</u> | <u>oma</u>      |            |     |  |  |
| Male                    | 0.20     | 0                       | NC*                      | Male                 | 0.10            | 0          | NC* |  |  |
| Female                  | 0.16     | 1                       | NC*                      | Female               | 0.08            | 0          | NC* |  |  |
| Total                   | 0.36     | 1                       | NC*                      | Total                | 0.17            | 0          | NC* |  |  |
| <b>Breast</b>           |          |                         | <u>N</u>                 | <u>on-Hodgkin's</u>  | <u>Lymphoma</u> | <u>1</u>   |     |  |  |
| Male                    | 0.03     | 0                       | NC*                      | Male                 | 0.41            | 0          | NC* |  |  |
| Female                  | 2.92     | 0                       | NC*                      | Female               | 0.31            | 0          | NC* |  |  |
| Total                   | 2.95     | 0                       | NC*                      | Total                | 0.72            | 0          | NC* |  |  |
| Cervix Uteri            |          | Oral Cavity and Pharynx |                          |                      |                 |            |     |  |  |
|                         |          |                         |                          | Male                 | 0.39            | 0          | NC* |  |  |
| Female                  | 0.20     | 0                       | NC*                      | Female               | 0.15            | 0          | NC* |  |  |
|                         |          |                         |                          | Total                | 0.53            | 0          | NC* |  |  |
| Colon / Rectum          |          |                         | <u>O</u>                 | <u>vary</u>          |                 |            |     |  |  |
| Male                    | 1.39     | 0                       | NC*                      |                      |                 |            |     |  |  |
| Female                  | 1.09     | 0                       | NC*                      | Female               | 0.36            | 0          | NC* |  |  |
| Total                   | 2.48     | 0                       | NC*                      |                      |                 |            |     |  |  |
| <b>Esophagus</b>        |          |                         | <u>Pa</u>                | ancreas_             |                 |            |     |  |  |
| Male                    | 0.19     | 0                       | NC*                      | Male                 | 0.20            | 0          | NC* |  |  |
| Female                  | 0.05     | 0                       | NC*                      | Female               | 0.17            | 0          | NC* |  |  |
| Total                   | 0.24     | 0                       | NC*                      | Total                | 0.37            | 0          | NC* |  |  |
| Hodgkin's Diseas        | <u>e</u> |                         | <u>P</u> 1               | <u>rostate</u>       |                 |            |     |  |  |
| Male                    | 0.09     | 0                       | NC*                      | Male                 | 3.00            | 1          | NC* |  |  |
| Female                  | 0.07     | 0                       | NC*                      |                      |                 |            |     |  |  |
| Total                   | 0.16     | 0                       | NC*                      |                      |                 |            |     |  |  |
| Kidney and Rena         | l Pelvis |                         | St                       | omach                |                 |            |     |  |  |
| Male                    | 0.32     | 0                       | NC*                      | Male                 | 0.23            | 0          | NC* |  |  |
| Female                  | 0.17     | 0                       | NC*                      | Female               | 0.12            | 1          | NC* |  |  |
| Total                   | 0.49     | 0                       | NC*                      | Total                | 0.35            | 1          | NC* |  |  |
| <u>Larynx</u>           |          |                         | <u>T</u>                 | <u>estis</u>         |                 |            |     |  |  |
| Male                    | 0.21     | 0                       | NC*                      | <br>Male             | 0.14            | 0          | NC* |  |  |
| Female                  | 0.05     | 0                       | NC*                      |                      |                 |            |     |  |  |

| Total               | 0.26             | 0           | NC*        |                            |             |      |     |
|---------------------|------------------|-------------|------------|----------------------------|-------------|------|-----|
| <b>Leukemia</b>     |                  |             | <u>Tl</u>  | <u>ayroid</u>              |             |      |     |
| Male                | 0.22             | 0           | NC*        | Male                       | 0.06        | 0    | NC* |
| Female              | 0.15             | 0           | NC*        | Female                     | 0.14        | 0    | NC* |
| Total               | 0.37             | 0           | NC*        | Total                      | 0.20        | 0    | NC* |
| Liver and Int       | rahepatic Bile D | <u>ucts</u> | <u>U</u> 1 | t <mark>eri, Corpus</mark> | and Uterus, | NOS_ |     |
| Male                | 0.09             | 0           | NC*        |                            |             |      |     |
| Female              | 0.03             | 0           | NC*        | Female                     | 0.55        | 0    | NC* |
| Total               | 0.12             | 0           | NC*        |                            |             |      |     |
| <b>Lung and Bro</b> | onchus_          |             | <u>A</u> ] | ll Sites / Tyr             | <u>oes</u>  |      |     |
| Male                | 1.75             | 0           | NC*        | Male                       | 10.59       | 2    | NC* |
| Female              | 1.07             | 0           | NC*        | Female                     | 8.84        | 2    | NC* |
| Total               | 2.82             | 0           | NC*        | Total                      | 19.43       | 4    | NC* |

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the  $\mathbf{p} <= 0.05$  level
- ~ indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level

### **FOXBOROUGH**

## Cancer Incidence by Sex, 1990 - 1995

## **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|                      | $\mathbf{Exp}$ | <u>Obs</u>    | <u>SIR</u>             |        | <b>Exp</b> | <u>Obs</u> | <u>SIR</u> |  |  |
|----------------------|----------------|---------------|------------------------|--------|------------|------------|------------|--|--|
| Bladder, Urina       | <u>ary</u>     |               | <u>M</u>               |        |            |            |            |  |  |
| Male                 | 10.72          | 10            | 93                     | Male   | 5.92       | 15         | 254 ~+     |  |  |
| Female               | 3.66           | 7             | 191                    | Female | 4.63       | 8          | 173        |  |  |
| Total                | 14.38          | 17            | 118                    | Total  | 10.54      | 23         | 218 ~+     |  |  |
| <b>Brain and Cen</b> | tral Nervous S | <u>System</u> | <u>M</u>               |        |            |            |            |  |  |
| Male                 | 4.00           | 1             | NC*                    | Male   | 1.96       | 3          | NC*        |  |  |
| Female               | 3.51           | 4             | NC*                    | Female | 1.66       | 3          | NC*        |  |  |
| Total                | 7.51           | 5             | 67                     | Total  | 3.62       | 6          | 166        |  |  |
| <b>Breast</b>        |                |               | Non-Hodgkin's Lymphoma |        |            |            |            |  |  |
| Male                 | 0.59           | 1             | NC*                    | Male   | 8.39       | 11         | 131        |  |  |
| Female               | 63.79          | 85            | 133 #+                 | Female | 6.77       | 7          | 103        |  |  |

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

| T-4-1               | C1 20         | 96           | 124 4.     | T-4-1          | 15 15        | 10   | 110    |
|---------------------|---------------|--------------|------------|----------------|--------------|------|--------|
| Total               | 64.38         | 86           | 134 #+     | Total          | 15.15        | 18   | 119    |
| <u>Cervix Uteri</u> |               |              | <u>O</u> 1 | •              | nd Pharynx   | 7    | 00     |
| г 1                 | 4.25          | 4            | MαΨ        | Male           | 7.95         | 7    | 88     |
| Female              | 4.35          | 4            | NC*        | Female         | 3.19         | 7    | 219    |
| G 1 / 1 / 1 / 1     |               |              | 0          | Total          | 11.14        | 14   | 126    |
| Colon / Rectum      |               | 2.6          |            | <u>vary</u>    |              |      |        |
| Male                | 28.48         | 26           | 91         |                | <b>5</b> .05 | _    | 0.0    |
| Female              | 24.08         | 30           | 125        | Female         | 7.85         | 7    | 89     |
| Total               | 52.56         | 56           | 107        |                |              |      |        |
| <b>Esophagus</b>    |               |              |            | <u>ancreas</u> |              |      |        |
| Male                | 3.87          | 5            | 129        | Male           | 4.06         | 1    | NC*    |
| Female              | 1.20          | 0            | NC*        | Female         | 3.84         | 2    | NC*    |
| Total               | 5.07          | 5            | 99         | Total          | 7.90         | 3    | NC*    |
| Hodgkin's Disc      | <u>ease</u>   |              |            | <u>rostate</u> |              |      |        |
| Male                | 1.86          | 1            | NC*        | Male           | 63.33        | 68   | 107    |
| Female              | 1.46          | 1            | NC*        |                |              |      |        |
| Total               | 3.32          | 2            | NC*        |                |              |      |        |
| Kidney and Re       | enal Pelvis   |              | <u>St</u>  | <u>omach</u>   |              |      |        |
| Male                | 6.65          | 3            | NC*        | Male           | 4.74         | 4    | NC*    |
| Female              | 3.66          | 8            | 219        | Female         | 2.63         | 6    | 228    |
| Total               | 10.31         | 11           | 107        | Total          | 7.37         | 10   | 136    |
| <u>Larynx</u>       |               |              | <u>T</u>   | <u>estis</u>   |              |      |        |
| Male                | 4.26          | 3            | NC*        | Male           | 2.76         | 3    | NC*    |
| Female              | 1.10          | 0            | NC*        |                |              |      |        |
| Total               | 5.35          | 3            | NC*        |                |              |      |        |
| <b>Leukemia</b>     |               |              | <u>Tl</u>  | <u>hyroid</u>  |              |      |        |
| Male                | 4.48          | 4            | NC*        | Male           | 1.16         | 0    | NC*    |
| Female              | 3.18          | 7            | 220        | Female         | 3.06         | 3    | NC*    |
| Total               | 7.66          | 11           | 144        | Total          | 4.22         | 3    | NC*    |
| Liver and Intra     | ahepatic Bile | <b>Ducts</b> | <u>U</u> 1 | teri, Corpus   | and Uterus   | NOS_ |        |
| Male                | 1.84          | 0            | NC*        |                |              |      |        |
| Female              | 0.75          | 0            | NC*        | Female         | 11.96        | 13   | 109    |
| Total               | 2.60          | 0            | NC*        |                |              |      |        |
| Lung and Bron       |               |              | Al         | ll Sites / Ty  | pes          |      |        |
| Male                | 36.39         | 30           | 82         | Male           | 218.96       | 217  | 99     |
| Female              | 23.71         | 43           | 181 ^+     | Female         | 193.84       | 261  | 135 ^+ |
| Total               | 60.10         | 73           | 121        | Total          | 412.80       | 478  | 116 ~+ |
| 1 0 1               | 22.20         | , 5          |            | _ 0 ****       |              |      |        |

**Obs** = observed case count

SIR = standardized incidence ratio [ (Obs / Exp) X 100]

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the  $\mathbf{p} \le 0.05$  level
- $\sim$  indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level

## **FRAMINGHAM**

# Cancer Incidence by Sex, 1990 - 1995

# **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|                      | Exp                 | <u>Obs</u>    | <u>SIR</u>               |                      | <b>Exp</b>  | <u>Obs</u> | SIR    |  |
|----------------------|---------------------|---------------|--------------------------|----------------------|-------------|------------|--------|--|
| Bladder, Urina       | <u>ry</u>           |               | $\underline{\mathbf{M}}$ | <u>lelanoma of</u>   | <u>Skin</u> |            |        |  |
| Male                 | 44.00               | 49            | 111                      | Male                 | 24.25       | 38         | 157 #+ |  |
| Female               | 18.80               | 19            | 101                      | Female               | 21.94       | 37         | 169 ~+ |  |
| Total                | 62.80               | 68            | 108                      | Total                | 46.19       | 75         | 162 ^+ |  |
| <b>Brain and Cen</b> | <u>tral Nervous</u> | <b>System</b> | $\underline{\mathbf{M}}$ | <u> Iultiple Mye</u> | <u>loma</u> |            |        |  |
| Male                 | 16.28               | 22            | 135                      | Male                 | 8.00        | 13         | 163    |  |
| Female               | 16.36               | 19            | 116                      | Female               | 8.30        | 5          | 60     |  |
| Total                | 32.64               | 41            | 126                      | Total                | 16.30       | 18         | 110    |  |
| <u>Breast</u>        |                     |               | Non-Hodgkin's Lymphoma   |                      |             |            |        |  |
| Male                 | 2.39                | 6             | 251                      | Male                 | 34.71       | 35         | 101    |  |
| Female               | 301.28              | 325           | 108                      | Female               | 33.70       | 34         | 101    |  |
| Total                | 303.67              | 331           | 109                      | Total                | 68.42       | 69         | 101    |  |
| <u>Cervix Uteri</u>  |                     |               | <u>o</u>                 | ral Cavity a         | nd Pharynx  |            |        |  |
|                      |                     |               |                          | Male                 | 31.80       | 33         | 104    |  |
| Female               | 20.42               | 10            | 49 #-                    | Female               | 15.26       | 15         | 98     |  |
|                      |                     |               |                          | Total                | 47.06       | 48         | 102    |  |
| Colon / Rectun       | <u>1</u>            |               | <u>O</u>                 | <u>vary</u>          |             |            |        |  |
| Male                 | 116.81              | 107           | 92                       |                      |             |            |        |  |
| Female               | 125.76              | 117           | 93                       | Female               | 36.74       | 41         | 112    |  |
| Total                | 242.57              | 224           | 92                       |                      |             |            |        |  |
| <b>Esophagus</b>     |                     |               | <u>Pa</u>                | <u>ancreas</u>       |             |            |        |  |
| Male                 | 15.51               | 8             | 52                       | Male                 | 16.48       | 15         | 91     |  |
| Female               | 6.21                | 7             | 113                      | Female               | 19.59       | 26         | 133    |  |
| Total                | 21.72               | 15            | 69                       | Total                | 36.07       | 41         | 114    |  |
| <b>Hodgkin's Dis</b> | <u>ease</u>         |               | <u>P</u> 1               | <u>rostate</u>       |             |            |        |  |
| Male                 | 7.98                | 7             | 88                       | Male                 | 258.09      | 261        | 101    |  |
| Female               | 6.91                | 6             | 87                       |                      |             |            |        |  |
| Total                | 14.88               | 13            | 87                       |                      |             |            |        |  |
| Kidney and Re        | enal Pelvis         |               | <u>St</u>                | tomach_              |             |            |        |  |
| Male                 | 26.76               | 35            | 131                      | Male                 | 19.49       | 15         | 77     |  |
| Female               | 17.46               | 16            | 92                       | Female               | 13.94       | 23         | 165 #+ |  |

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

| Tr.4-1              | 44.00          | <i>E</i> 1 | 115        | Tr.4.1        | 22.42      | 20   | 111   |
|---------------------|----------------|------------|------------|---------------|------------|------|-------|
| Total               | 44.22          | 51         | 115        | Total         | 33.43      | 38   | 114   |
| <u>Larynx</u>       |                |            | <u>To</u>  | <u>estis</u>  |            |      |       |
| Male                | 16.93          | 9          | 53         | Male          | 12.35      | 14   | 113   |
| Female              | 4.98           | 6          | 121        |               |            |      |       |
| Total               | 21.91          | 15         | 68         |               |            |      |       |
| <b>Leukemia</b>     |                |            | <u>Tl</u>  | <u>hyroid</u> |            |      |       |
| Male                | 18.25          | 24         | 131        | Male          | 4.88       | 5    | 102   |
| Female              | 15.47          | 14         | 91         | Female        | 14.39      | 15   | 104   |
| Total               | 33.72          | 38         | 113        | Total         | 19.27      | 20   | 104   |
| Liver and Int       | rahepatic Bile | Ducts      | <u>U</u> 1 | and Uterus,   | <b>NOS</b> |      |       |
| Male                | 7.46           | 6          | 80         |               |            |      |       |
| Female              | 3.75           | 5          | 133        | Female        | 55.49      | 39   | 70 #- |
| Total               | 11.21          | 11         | 98         |               |            |      |       |
| <b>Lung and Bro</b> | <u>nchus</u>   |            | <u>A</u> ] | ll Sites / Ty | pes        |      |       |
| Male                | 146.55         | 144        | 98         | Male          | 893.11     | 908  | 102   |
| Female              | 111.92         | 99         | 88         | Female        | 938.03     | 942  | 100   |
| Total               | 258.46         | 243        | 94         | Total         | 1831.13    | 1850 | 101   |
|                     |                |            |            |               |            |      |       |

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

### **FRANKLIN**

## Cancer Incidence by Sex, 1990 - 1995

## **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|                     | $\mathbf{\underline{Exp}}$ | <u>Obs</u>       | <u>SIR</u>       |        | Exp   | <u>Obs</u> | <u>SIR</u> |  |  |
|---------------------|----------------------------|------------------|------------------|--------|-------|------------|------------|--|--|
| Bladder, Urin       | <u>ary</u>                 | Melanoma of Skin |                  |        |       |            |            |  |  |
| Male                | 11.72                      | 10               | 85               | Male   | 7.27  | 10         | 138        |  |  |
| Female              | 4.53                       | 6                | 132              | Female | 6.28  | 7          | 111        |  |  |
| Total               | 16.25                      | 16               | 98               | Total  | 13.56 | 17         | 125        |  |  |
| <b>Brain and Ce</b> | ntral Nervous S            | <u>System</u>    | Multiple Myeloma |        |       |            |            |  |  |
| Male                | 5.27                       | 6                | 114              | Male   | 2.16  | 4          | NC*        |  |  |
| Female              | 4.78                       | 3                | NC*              | Female | 2.04  | 1          | NC*        |  |  |

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} <= 0.05$  level

 $<sup>\</sup>sim$  indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

| Total  | 10.05   | 9   | 90  | Total  | 4.20  | 5   | 119                                      |  |  |
|--|---|---|---|--|---|---|--|--|--|
| <b>Breast</b>  |   | Non-Hodgkin's Lymphoma  |   |  |   |   |  |  |  |
| Male   | 0.66  | 2   | NC*   | Male   | 10.44   | 9   | 86                                       |  |  |
| Female   | 81.52   | 75  | 92  | Female   | 8.69  | 13  | 150                                      |  |  |
| Total  | 82.19   | 77  | 94  | Total  | 19.13   | 22  | 115                                      |  |  |
| Cervix Uteri   | Oral Cavity and Pharynx   |   |   |  |   |   |  |  |  |
|  |   |   |   | Male   | 9.41  | 2   | NC*                                      |  |  |
| Female   | 6.18  | 1   | NC*   | Female   | 4.04  | 3   | NC*                                      |  |  |
|  |   |   |   | Total  | 13.45   | 5   | 37 #-                                    |  |  |
| Colon / Rectun   | <u>n</u>  |   | <u>O</u>  | <u>vary</u>  |   |   |  |  |  |
| Male   | 31.17   | 31  | 99  |  |   |   |  |  |  |
| Female   | 29.83   | 22  | 74  | Female   | 10.28   | 11  | 107                                      |  |  |
| Total  | 61.00   | 53  | 87  |  |   |   |  |  |  |
| <b>Esophagus</b>   |   |   | <u>Pa</u>   | ncreas   |   |   |  |  |  |
| Male   | 4.35  | 6   | 138   | Male   | 4.55  | 3   | NC*                                      |  |  |
| Female   | 1.47  | 1   | NC*   | Female   | 4.72  | 3   | NC*                                      |  |  |
| Total  | 5.82  | 7   | 120   | Total  | 9.27  | 6   | 65                                       |  |  |
| Hodgkin's Disease Prostate   |   |   |   |  |   |   |  |  |  |
| Male   | 2.88  | 1   | NC*   | Male   | 67.77   | 80  | 118                                      |  |  |
| Female   | 2.28  | 4   | NC*   |  |   |   |  |  |  |
| Total  | 5.16  | 5   | 97  |  |   |   |  |  |  |
| Kidney and Renal Pelvis  |   |   |   | <u>omach</u>   |   |   |  |  |  |
|  |   | 1.0   | 120   | N / -1 -   | 5.26  | 3   | NC*                                      |  |  |
| Male   | 7.75  | 10  | 129   | Male   | 3.20  | 3   | NC.                                      |  |  |
| Male<br>Female   | 7.75<br>4.63  | 3   | NC*   | Female   | 3.20  | 8   | 243 #+                                   |  |  |
|  |   |   |   |  |   |   |  |  |  |
| Female   | 4.63  | 3   | NC*<br>105  | Female   | 3.30  | 8   | 243 #+                                   |  |  |
| Female<br>Total  | 4.63  | 3   | NC*<br>105  | Female<br>Total  | 3.30  | 8   | 243 #+                                   |  |  |
| Female<br>Total<br><b>Larynx</b>   | 4.63<br>12.38   | 3<br>13   | NC*<br>105<br><u>Te</u>                                   | Female<br>Total<br>estis   | 3.30<br>8.56  | 8<br>11                                   | 243 #+<br>129                            |  |  |
| Female<br>Total<br><u>Larynx</u><br>Male   | 4.63<br>12.38<br>4.85   | 3<br>13<br>6  | NC*<br>105<br><u>Te</u><br>124                            | Female<br>Total<br>estis   | 3.30<br>8.56  | 8<br>11                                   | 243 #+<br>129                            |  |  |
| Female Total Larynx Male Female  | 4.63<br>12.38<br>4.85<br>1.34   | 3<br>13<br>6<br>3   | NC*<br>105<br><u>To</u><br>124<br>NC*<br>145              | Female<br>Total<br>estis   | 3.30<br>8.56  | 8<br>11                                   | 243 #+<br>129                            |  |  |
| Female Total Larynx Male Female Total  | 4.63<br>12.38<br>4.85<br>1.34   | 3<br>13<br>6<br>3   | NC*<br>105<br><u>To</u><br>124<br>NC*<br>145              | Female<br>Total<br>estis<br>Male                                     | 3.30<br>8.56  | 8<br>11                                   | 243 #+<br>129                            |  |  |
| Female Total Larynx Male Female Total Leukemia   | 4.63<br>12.38<br>4.85<br>1.34<br>6.19   | 3<br>13<br>6<br>3<br>9  | NC*<br>105<br>124<br>NC*<br>145                           | Female Total estis Male  | 3.30<br>8.56<br>4.57  | 8<br>11<br>2                              | 243 #+<br>129<br>NC*                     |  |  |
| Female Total Larynx Male Female Total Leukemia Male  | 4.63<br>12.38<br>4.85<br>1.34<br>6.19<br>5.63   | 3<br>13<br>6<br>3<br>9  | NC*<br>105<br>124<br>NC*<br>145<br>142                    | Female Total estis Male  nyroid Male                                 | 3.30<br>8.56<br>4.57  | 8<br>11<br>2                              | 243 #+<br>129<br>NC*                     |  |  |
| Female Total  Larynx  Male Female Total  Leukemia  Male Female   | 4.63<br>12.38<br>4.85<br>1.34<br>6.19<br>5.63<br>4.38<br>10.01                          | 3<br>13<br>6<br>3<br>9<br>8<br>3<br>11                                | NC* 105  Te 124 NC* 145  Tl 142 NC* 110                   | Female Total estis Male  Male Male Female Total                      | 3.30<br>8.56<br>4.57<br>1.64<br>4.51  | 8<br>11<br>2<br>2<br>4<br>6               | 243 #+<br>129<br>NC*<br>NC*              |  |  |
| Female Total Larynx Male Female Total Leukemia Male Female Total   | 4.63<br>12.38<br>4.85<br>1.34<br>6.19<br>5.63<br>4.38<br>10.01                          | 3<br>13<br>6<br>3<br>9<br>8<br>3<br>11                                | NC* 105  Te 124 NC* 145  Tl 142 NC* 110                   | Female Total estis Male  Male Male Female Total                      | 3.30<br>8.56<br>4.57<br>1.64<br>4.51<br>6.15  | 8<br>11<br>2<br>2<br>4<br>6               | 243 #+<br>129<br>NC*<br>NC*              |  |  |
| Female Total  Larynx  Male Female Total  Leukemia Male Female Total  Liver and Intre   | 4.63 12.38  4.85 1.34 6.19  5.63 4.38 10.01  cahepatic Bile                             | 3<br>13<br>6<br>3<br>9<br>8<br>3<br>11<br><b>Ducts</b>                | NC* 105  124 NC* 145  142 NC* 110                         | Female Total estis Male  Male Male Female Total                      | 3.30<br>8.56<br>4.57<br>1.64<br>4.51<br>6.15  | 8<br>11<br>2<br>2<br>4<br>6               | 243 #+<br>129<br>NC*<br>NC*              |  |  |
| Female Total  Larynx Male Female Total  Leukemia Male Female Total  Liver and Introducts   | 4.63 12.38  4.85 1.34 6.19  5.63 4.38 10.01 cahepatic Bile 1 2.13                       | 3<br>13<br>6<br>3<br>9<br>8<br>3<br>11<br><b>Ducts</b><br>0           | NC* 105  124 NC* 145  142 NC* 110  Ut NC*                 | Female Total estis Male  Male Male Female Total teri, Corpus         | 3.30<br>8.56<br>4.57<br>1.64<br>4.51<br>6.15<br><b>and Uterus,</b>                                  | 8<br>11<br>2<br>2<br>4<br>6<br><b>NOS</b> | 243 #+<br>129<br>NC*<br>NC*<br>NC*<br>98 |  |  |
| Female Total  Larynx  Male Female Total  Leukemia Male Female Total  Liver and Introduce  Male Female  | 4.63 12.38  4.85 1.34 6.19  5.63 4.38 10.01  cahepatic Bile 1 2.13 0.96 3.08            | 3<br>13<br>6<br>3<br>9<br>8<br>3<br>11<br><b>Ducts</b><br>0<br>2      | NC* 105  124 NC* 145  142 NC* 110  VC* NC* NC* NC*        | Female Total estis Male  Male Male Female Total teri, Corpus         | 3.30<br>8.56<br>4.57<br>1.64<br>4.51<br>6.15<br>5 and Uterus,                                       | 8<br>11<br>2<br>2<br>4<br>6<br><b>NOS</b> | 243 #+<br>129<br>NC*<br>NC*<br>NC*<br>98 |  |  |
| Female Total  Larynx  Male Female Total  Leukemia Male Female Total  Liver and Intr Male Female Female Total   | 4.63 12.38  4.85 1.34 6.19  5.63 4.38 10.01  cahepatic Bile 1 2.13 0.96 3.08            | 3<br>13<br>6<br>3<br>9<br>8<br>3<br>11<br><b>Ducts</b><br>0<br>2      | NC* 105  124 NC* 145  142 NC* 110  VC* NC* NC* NC*        | Female Total estis Male  Male Male Female Total teri, Corpus         | 3.30<br>8.56<br>4.57<br>1.64<br>4.51<br>6.15<br>5 and Uterus,                                       | 8<br>11<br>2<br>2<br>4<br>6<br><b>NOS</b> | 243 #+<br>129<br>NC*<br>NC*<br>NC*<br>98 |  |  |
| Female Total  Larynx  Male Female Total  Leukemia Male Female Total  Liver and Introde  Male Female Total  Liver and Introde  Female Female Female Female Female Total | 4.63 12.38  4.85 1.34 6.19  5.63 4.38 10.01 cahepatic Bile 1 2.13 0.96 3.08             | 3<br>13<br>6<br>3<br>9<br>8<br>3<br>11<br><b>Ducts</b><br>0<br>2<br>2 | NC* 105  124 NC* 145  142 NC* 110  NC* NC* NC* NC*        | Female Total estis Male  Male Female Total teri, Corpus Female       | 3.30<br>8.56<br>4.57<br>1.64<br>4.51<br>6.15<br><b>and Uterus,</b><br>14.87                         | 8 11 2 4 6 NOS                            | 243 #+<br>129<br>NC*<br>NC*<br>NC*<br>98 |  |  |
| Female Total  Larynx  Male Female Total  Leukemia Male Female Total  Liver and Intr Male Female Total  Liver and Intr Male Female Total  Lung and Bron                 | 4.63 12.38  4.85 1.34 6.19  5.63 4.38 10.01 cahepatic Bile 1 2.13 0.96 3.08 nchus 40.44 | 3 13 6 3 9 8 3 11  Ducts 0 2 2 48                                     | NC* 105  124 NC* 145  142 NC* 110  VI NC* NC* NC* NC* NC* | Female Total estis Male  Male  Male Female Total teri, Corpus Female | 3.30<br>8.56<br>4.57<br>1.64<br>4.51<br>6.15<br><b>and Uterus,</b><br>14.87<br><b>pes</b><br>248.81 | 8 11 2  2 4 6  NOS  21                    | 243 #+<br>129<br>NC*<br>NC*<br>NC*<br>98 |  |  |

**Obs** = observed case count

SIR = standardized incidence ratio [ (Obs / Exp) X 100]

- \* = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the  $\mathbf{p} \le 0.05$  level
- ~ indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level
- ^ indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

### **FREETOWN**

## Cancer Incidence by Sex, 1990 - 1995

### **Expected and Observed Case Counts, with Standardized Incidence Ratios**

|   | <b>Exp</b>             | <u>Obs</u>              | <u>SIR</u>      |                     | <b>Exp</b>  | <u>Obs</u> | SIR   |  |
|---|------------------------|-------------------------|-----------------|---------------------|-------------|------------|-------|--|
| Bladder, Urina                          | Melanoma of Skin       |                         |                 |                     |             |            |       |  |
| Male                                    | 4.94                   | 2                       | NC*             | Male                | 2.97        | 3          | NC*   |  |
| Female                                  | 1.57                   | 3                       | NC*             | Female              | 2.34        | 2          | NC*   |  |
| Total                                   | 6.51                   | 5                       | 77              | Total               | 5.31        | 5          | 94    |  |
| <b>Brain and Central Nervous System</b> |                        |                         | <u>M</u>        | <u>lultiple Mye</u> | <u>loma</u> |            |       |  |
| Male                                    | 2.08                   | 4                       | NC*             | Male                | 0.91        | 0          | NC*   |  |
| Female                                  | 1.77                   | 3                       | NC*             | Female              | 0.73        | 0          | NC*   |  |
| Total                                   | 3.86                   | 7                       | 182             | Total               | 1.64        | 0          | NC*   |  |
| <b>Breast</b>                           | Non-Hodgkin's Lymphoma |                         |                 |                     |             |            |       |  |
| Male                                    | 0.28                   | 0                       | NC*             | Male                | 4.20        | 3          | NC*   |  |
| Female                                  | 30.76                  | 31                      | 101             | Female              | 3.10        | 0          | NC*   |  |
| Total                                   | 31.04                  | 31                      | 100             | Total               | 7.30        | 3          | NC*   |  |
| Cervix Uteri                            |                        | Oral Cavity and Pharynx |                 |                     |             |            |       |  |
|   |                        |                         |                 | Male                | 3.96        | 3          | NC*   |  |
| Female                                  | 2.32                   | 1                       | NC*             | Female              | 1.50        | 0          | NC*   |  |
|   |                        |                         |                 | Total               | 5.46        | 3          | NC*   |  |
| Colon / Rectum                          |                        |                         | <u>Ovary</u>    |                     |             |            |       |  |
| Male                                    | 13.13                  | 15                      | 114             |                     |             |            |       |  |
| Female                                  | 10.11                  | 14                      | 138             | Female              | 3.89        | 2          | NC*   |  |
| Total                                   | 23.25                  | 29                      | 125             |                     |             |            |       |  |
| <b>Esophagus</b>                        |                        |                         | <u>Pa</u>       | ancreas             |             |            |       |  |
| Male                                    | 1.86                   | 1                       | NC*             | Male                | 1.91        | 4          | NC*   |  |
| Female                                  | 0.50                   | 1                       | NC*             | Female              | 1.65        | 1          | NC*   |  |
| Total                                   | 2.36                   | 2                       | NC*             | Total               | 3.57        | 5          | 140   |  |
| Hodgkin's Disease                       |                        |                         | <b>Prostate</b> |                     |             |            |       |  |
| Male                                    | 1.05                   | 0                       | NC*             | Male                | 28.52       | 17         | 60 #- |  |

| Female                 | 0.82  | 1             | NC*        |               |            |     |     |
|------------------------|---|---------------|------------|---------------|------------|-----|-----|
| Total                  | 1.87  | 1             | NC*        |               |            |     |     |
| Kidney and Re          | nal Pelvis  |               | <u>St</u>  | <u>omach</u>  |            |     |     |
| Male                   | 3.25  | 2             | NC*        | Male          | 2.21       | 2   | NC* |
| Female                 | 1.72  | 0             | NC*        | Female        | 1.10       | 0   | NC* |
| Total                  | 4.97  | 2             | NC*        | Total         | 3.30       | 2   | NC* |
| <u>Larynx</u>          |   | <u>Testis</u> |            |               |            |     |     |
| Male                   | 2.06  | 2             | NC*        | Male          | 1.62       | 1   | NC* |
| Female                 | 0.53  | 0             | NC*        |               |            |     |     |
| Total                  | 2.59  | 2             | NC*        |               |            |     |     |
| <u>Leukemia</u>        |   |               | <u>Tl</u>  | <u>nyroid</u> |            |     |     |
| Male                   | 2.25  | 7             | 311 #+     | Male          | 0.63       | 1   | NC* |
| Female                 | 1.54  | 3             | NC*        | Female        | 1.67       | 0   | NC* |
| Total                  | 3.79  | 10            | 264 #+     | Total         | 2.30       | 1   | NC* |
| <b>Liver and Intra</b> | d Intrahepatic Bile Ducts Uteri, Corpus and Uterus, N |               |            | NOS           |            |     |     |
| Male                   | 0.89  | 1             | NC*        |               |            |     |     |
| Female                 | 0.34  | 0             | NC*        | Female        | 5.73       | 1   | NC* |
| Total                  | 1.23  | 1             | NC*        |               |            |     |     |
| <b>Lung and Bron</b>   | <u>chus</u>   |               | <u>A</u> ] | ll Sites / Ty | <u>pes</u> |     |     |
| Male                   | 17.14   | 19            | 111        | Male          | 103.52     | 94  | 91  |
| Female                 | 11.05   | 10            | 91         | Female        | 90.97      | 75  | 82  |
| Total                  | 28.18   | 29            | 103        | Total         | 194.49     | 169 | 87  |
|                        |   |               |            |               |            |     |     |

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

SIR = standardized incidence ratio [ (Obs / Exp) X 100]

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} \le 0.05$  level

<sup>~</sup> indicates statistical significance at the p <= 0.01 level, as well as at the p <= 0.05 level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels